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Thesis Summary 
The antipsychotic clozapine is uniquely effective in the management of treatment-
resistant schizophrenia (TRS), but its use is limited by its potential to induce 
agranulocytosis. A substantial proportion of patients discontinue clozapine treatment, 
which carries a poor prognosis, and only 30-60% of patients with TRS will respond to 
clozapine.  
The causes of clozapine-associated agranulocytosis, and of its precursor neutropenia, are 
largely unknown although genetic factors contribute. To examine the genetic susceptibility 
to clozapine-associated neutropenia, I conducted a multifaceted genetic analysis in the 
largest combined sample studied to date. Using GWAS, I identified a novel genome-wide 
significant association with rs149104283 (OR = 4.32, P = 1.79x10-8), a SNP intronic to 
transcripts of SLCO1B3 and SLCO1B7, members of a family of hepatic transporter genes 
involved in drug uptake. Furthermore, I replicated a previously reported association 
between neutropenia and a variant in HLA-DQB1 (OR = 15.6, P = 0.015). 
I investigated clozapine discontinuation and clinical response in a two-year retrospective 
cohort study of 316 patients with TRS receiving their first course of clozapine. By studying 
the reasons for discontinuations due to a patient decision, I found that adverse drug 
reactions accounted for over half of clozapine discontinuations. High levels of deprivation 
in the neighbourhood where the patient lived were associated with increased risk of 
clozapine discontinuation (HR = 2.12, 95% CI 1.30-3.47). Female gender (HR = 0.63, 95% CI 
0.41-0.96) and clinical improvement after one month of treatment (HR = 0.56, 95% CI 0.44-
0.71) were significantly associated with a good response to clozapine. However, I found 
that up to six months of treatment may be required to determine non-response.  
This thesis implicates variants that may increase susceptibility to clozapine-associated 
neutropenia and contributes to our current understanding of the causes of clozapine 
discontinuation and treatment response.   
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Structure of Thesis 
This thesis is divided into six chapters. Chapter 1 provides an overview of schizophrenia 
and the use of clozapine in its management. The focus then turns to the literature base of 
clozapine-associated agranulocytosis and neutropenia, all-cause discontinuation, and 
clinical response to clozapine. Chapters 2, 4 and 5 are presented as results chapters, each 
with their own introduction, method, results and discussion sections. Chapter 3 provides 
details of methods relevant for both Chapters 4 and 5. Finally, Chapter 6 provides an 
overall discussion of the principal findings of the thesis in the context of the existing 
literature, the strengths and weaknesses of the studies, and provides indications for future 
research.  
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 Chapter 1
Background Literature 
1.1. Introduction 
The aim of this thesis is to investigate treatment response and the adverse effects of 
clozapine, a uniquely effective antipsychotic medication in the management of treatment-
resistant schizophrenia. Specifically, the thesis aims are to (i) identify genetic risk variants 
associated with clozapine-induced agranulocytosis and neutropenia, (ii) investigate the 
clinical risk factors, reasons and timing of clozapine discontinuation, and (iii) identify 
clinical predictors of clozapine response. The identification of predictor variables 
associated with these different outcomes of clozapine treatment may be valuable in 
assisting clinicians in determining if clozapine is likely to be beneficial. This introductory 
chapter will provide an overview of schizophrenia, treatment-resistant schizophrenia, and 
the use of clozapine in the management of these conditions. The focus will then turn to 
the literature base of clozapine-associated agranulocytosis and neutropenia, all-cause 
discontinuation, and clinical response to clozapine. Finally, the limitations of the current 
research will be discussed and the aims of the thesis outlined.  
1.2. Schizophrenia 
Schizophrenia is a severe psychiatric syndrome characterised by positive symptoms, such 
as delusions and hallucinations, negative symptoms and cognitive deficits. Although the 
illness course of schizophrenia is highly heterogeneous, it is frequently life-long and 
debilitating (Tandon et al., 2008). Consequently, schizophrenia is one of the leading causes 
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of disability worldwide (Rossler et al., 2005; World Health Organisation, 2008). The 
associated economic burden to society is extremely high, from both direct healthcare and 
non-healthcare related costs such as unemployment, reduced workplace productivity, 
family care-giving and premature mortality (Knapp et al., 2004; Wu et al., 2005). In 
England the estimated cost of schizophrenia per year to society and the public sector is 
£11.8 billion and £7.2 billion, respectively (The Schizophrenia Commission, 2012). People 
with schizophrenia have a reduced life expectancy of approximately 15-20 years compared 
to the general population, driven by both increased rates of suicide and a wide range of 
comorbid somatic conditions (Saha et al., 2007; McGrath et al., 2008). Worryingly, this 
mortality gap is widening over time (Saha et al., 2007; Walker et al., 2015).  
Schizophrenia occurs across diverse cultures and populations worldwide. A large 
systematic meta-analysis of epidemiological studies indicates that the lifetime prevalence 
of schizophrenia is 4.0 per 1,000 people and the median incidence is 15.2 per 100,000 
people per year (McGrath et al., 2008). Although there are no sex differences in the 
prevalence (Perala et al., 2007; McGrath et al., 2008), the incidence is higher in males, with 
a male:female incidence rate ratio of 1.4:1 (Aleman et al., 2003; McGrath et al., 2008; Abel 
et al., 2010). Prevalence and incidence rates also vary based on ethnicity, seasonality of 
birth, urbanicity and latitude (McGrath et al., 2008; Tandon et al., 2008). The onset of 
schizophrenia is usually during adolescence or early adulthood and the onset in males is 
three to four years earlier than females, who have a second peak around age 50 (Hafner et 
al., 1993). 
Schizophrenia has only been considered as a unique syndrome or disorder for a little over 
a century and its classification has been based on the observation that certain symptoms 
occur together. Our current conceptualisation of schizophrenia has derived principally 
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from the clinical concepts described by Kraepelin, Bleuler and Schneider (Tandon et al., 
2009). In 1899, German psychiatrist Emil Kraepelin described a discrete mental illness 
called ‘dementia praecox’ (early dementia), characterised by an onset in early adulthood, a 
chronic and deteriorating course, and the lack of depression or mania, which he called 
manic depressive insanity (Kraepelin, 1971). The term schizophrenia was coined in 1911 by 
a Swiss psychiatrist called Eugen Bleuler (Bleuler, 1950), derived from the Greek words 
‘schizo’ (split) and ‘phren’ (mind), intended to describe a loosening of association rather 
than a split personality, which is a common misconception. He proposed an alternative 
term to dementia praecox to reflect the fact that the disease can occur in later life and 
mental deterioration is not always present (Moskowitz & Heim, 2011). Bleuler was the first 
to distinguish the positive and negative symptoms of schizophrenia (Bleuler, 1950). In 
1959, German psychiatrist Kurt Schneider described 11 ‘first-rank’ symptoms that were 
particularly characteristic of schizophrenia, for example bizarre delusions or two or more 
voices conversing with each other (Schneider, 1959). However, it has become apparent 
that the diagnostic value of first-rank symptoms in schizophrenia is unclear and thus they 
are no longer solely sufficient for a diagnosis in the latest classifications (Moskowitz & 
Heim, 2011; Soares-Weiser et al., 2015). Aspects of the clinical concepts described by 
Kraepelin, Bleuler and Schneider are incorporated in the International Statistical 
Classification of Diseases and Related Health Problems (ICD-10) (World Health 
Organization, 1992) and the Diagnostic and Statistical Manual of Mental Disorders (DSM-V) 
(American Psychiatric Association, 2013) classifications of schizophrenia. Table 1.1 details 
the DSM-V criteria for schizophrenia (American Psychiatric Association, 2013). The 
classification of schizophrenia has changed over time and has been the subject of 
significant debate, particularly regarding whether schizophrenia and bipolar disorder are 
distributed across a dimensional spectrum.  
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Table 1.1. Diagnostic and Statistical Manual of Mental Disorders (DSM-V) classification for 
schizophrenia (American Psychiatric Association, 2013). 
DSM-V diagnostic criteria for schizophrenia 
Criterion A. Characteristic symptoms 
Two or more of the following, each present for a significant portion of time during a one-
month period (or less if successfully treated). At least one of these should include 1-3. 
1. Delusions 
2. Hallucinations 
3. Disorganised speech 
4. Grossly disorganised or catatonic behaviour 
5. Negative symptoms (affective flattening, alogia, or avolition) 
Criterion B. Social/occupational dysfunction 
For a significant portion of the time since the onset of the disturbance, one or more major 
areas of functioning, such as work, interpersonal relations, or self-care, are markedly below 
the level achieved prior to the onset (or when onset is in childhood or adolescence, failure to 
achieve expected level of interpersonal, academic, or occupational achievement).  
Criterion C. Duration 
Continuous signs of the disturbance persist for at least six months. This six-month period 
must include at least one month of symptoms (or less so if successfully treated) that meet 
Criterion A and may include periods of prodromal or residual symptoms. During these 
prodromal or residual periods, the signs of the disturbance may be manifested by only 
negative symptoms or by two or more symptoms listed in Criterion A present in an 
attenuated form (e.g., odd beliefs, unusual perceptual experiences). 
Criterion D. Schizoaffective and major mood disorder exclusion 
Schizoaffective disorder and depressive or bipolar disorder with psychotic features have been 
ruled out because either (1) no major depressive or manic episodes have occurred 
concurrently with the active phase symptoms; or (2) if mood episodes have occurred during 
active-phase symptoms, their total duration is brief relative to the active and residual 
periods. 
Criterion E. Substance/general mood condition exclusion 
The disturbance is not attributed to the direct physiological effects of a substance (e.g., a 
drug of abuse, a medication) or other medical condition. 
Criterion F. Relationship to Global Developmental Delay or Autism Spectrum Disorder 
If there is a history of autism spectrum disorder, the additional diagnoses of schizophrenia is 
made only if prominent delusions or hallucinations are also present for at least one-month (or 
less if successfully treated). 
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1.2.1 Symptoms of schizophrenia 
The clinical features of schizophrenia are variable between affected individuals, but are 
likely to be a mixture of positive, negative and cognitive symptoms.  
Positive symptoms 
The positive symptoms of schizophrenia are characterised by distortions of thinking and 
perception, named ‘positive’ because they are ‘in addition’ to normal experiences. 
Hallucinations are false perceptions in the absence of an appropriate stimulus and can 
take any sensory modality including auditory, visual, tactile, gustatory and olfactory, 
although auditory hallucinations, usually in the form of hearing voices, are the most 
common (Tandon et al., 2009). These voices may talk directly to the individual, perhaps 
stating derogatory remarks or issue commands, but can also talk in third person (American 
Psychiatric Association, 2013). 
Delusions are firmly held beliefs that cannot be substantiated with evidence and are not 
part of the individual’s culture. The specific content of delusions can vary widely, but 
delusions of persecution are the most common whereby the individual may believe that 
they are being followed, spied on, or conspired against. Other delusions may include 
beliefs that comments, gestures or text is specifically directed at them (delusions of 
reference), that they are someone of great importance (delusions of grandiose), or may be 
related to religion. Bizarre delusions are delusions that are clearly implausible, such as 
delusions of control (Tandon et al., 2009). 
Disorganised thinking or formal thought disorder, relates to unusual or dysfunctional ways 
of thinking, primarily detected through speech (Tandon et al., 2009). The person may slip 
off track (derailment), give obliquely related answers to questions (tangentiality), or in 
extreme examples be incomprehensible (American Psychiatric Association, 2013). 
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Disorganised behaviour frequently co-occurs with formal thought disorder and may 
manifest as unpredictable agitation, inappropriate sexual behaviour or dressing in a very 
unusual way (for example winter clothing on a hot day).  
Negative symptoms 
The negative symptoms of schizophrenia are characterised by a loss of affective or 
behavioural functions that are present among healthy individuals. Common negative 
symptoms include a blunting of emotional expressiveness either facially or through body 
language (affective flattening), a decreased production or fluency of speech (alogia), and 
the reduced motivation or ability to carry out goal-directed activities (avolition) (American 
Psychiatric Association, 2013). These symptoms can be harder to recognise as they are 
part of a continuum of normal behaviour and can occur as a result of other factors, such as 
medication side effects or depression (Kirkpatrick et al., 2006). Nonetheless, negative 
symptoms are resistant to current treatments and are a debilitating component of 
schizophrenia (Tandon et al., 2009). 
Motor symptoms 
Patients with schizophrenia may show abnormalities in psychomotor activity, manifested 
as either excessive unstimulated motor activity or as a marked decrease in reactivity to the 
environment, in its extreme form catatonia (Tandon et al., 2009). Psychomotor slowing is 
common in schizophrenia (Morrens et al., 2007) and neuromotor disturbances have been 
found in up to a quarter of first episode treatment-naive patients with schizophrenia 
(Cortese et al., 2005). Catatonic symptoms are now more common in mood disorders than 
schizophrenia and are thus no longer considered a core feature of schizophrenia (Taylor & 
Fink, 2003). 
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Cognitive deficits 
Although cognitive deficits are a core feature of schizophrenia, they are not currently part 
of the diagnostic classification due to the lack of diagnostic specificity (Tandon et al., 
2009). Cognitive deficits contribute significantly to the functional disability in 
schizophrenia, impacting employment, independent living and general quality of life 
(Bowie et al., 2008). People with schizophrenia perform on average up to two standard 
deviations below the general population on cognitive tasks (Keefe & Harvey, 2012) and 
nearly all patients with schizophrenia have cognitive deficits to some degree (Heinrichs & 
Zakzanis, 1998). Even if the cognitive ability of an individual with schizophrenia is not 
severe enough to be ‘impaired’, studies have shown that their performance is below what 
would be expected based on their premorbid functioning (Keefe et al., 2005). The 
cognitive deficit in schizophrenia is of a generalised nature and thus includes many 
important aspects of cognition (Dickinson et al., 2008).  
The clinical course of cognition in schizophrenia is still unclear. Many studies have 
consistently shown that cognitive impairment precedes the onset of schizophrenia (Bilder 
et al., 2006). There appears to be a cognitive decline around the onset of psychotic 
symptoms, relative stability thereafter, and there is mixed evidence regarding the impact 
of pharmacologic treatment on cognition in schizophrenia (Keefe & Harvey, 2012). A 
considerable challenge in this field has been the wide variability of assessments, making 
comparisons between studies difficult. To combat this issue the Measurement and 
Treatment Research to Improve Cognition in Schizophrenia (MATRICS) consensus cognitive 
battery was developed to provide a standardised outcome measure for the key cognitive 
domains related to schizophrenia: speed of processing, attention, working memory, verbal 
learning, visual learning, reasoning and problem solving, and social cognition (Nuechterlein 
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et al., 2008). The significant interest in cognition over the last 10 years has led to valuable 
insights, such as evidence indicating that the deficits are related to genetic susceptibility to 
schizophrenia (Lencz et al., 2014). 
Comorbid symptoms 
There is an increased prevalence of anxiety, depression and substance-abuse disorders in 
people with schizophrenia (Buckley et al., 2009). The overall lifetime prevalence of anxiety 
disorders in schizophrenia is between 30-85%, with post-traumatic stress disorder, panic 
disorder, and obsessive-compulsive disorder being the most common (Pokos & Castle, 
2006). Approximately 50% of patients with schizophrenia will manifest affective symptoms 
at some point (Siris, 2000), and 47% will have a lifetime diagnosis of comorbid substance 
abuse (Buckley et al., 2009). These comorbid psychiatric disorders are associated with 
poorer outcomes and complicate the clinical picture in schizophrenia (Buckley et al., 2009). 
Their relationship to schizophrenia (whether they are related or separate conditions) and 
the underlying causes are still poorly understood.  
People with schizophrenia are also at high risk of multiple physical comorbidities, which 
contribute to premature mortality. In particular, there is an increased prevalence of 
cardiovascular disease, type II diabetes, obesity, HIV infection, hepatitis, and smoking-
related lung disease compared to the general population (Dixon et al., 2000; Leucht et al., 
2007a; Smith et al., 2013). Numerous factors are likely to contribute to these increased 
rates. Large proportions of people with schizophrenia smoke cigarettes and have 
substance abuse disorders (Leucht et al., 2007a). Negative symptoms and cognitive deficits 
can lead to a lack of exercise and poor diet (McCreadie & Scottish Schizophrenia Lifestyle 
Group, 2003), and may mean that individuals are less motivated to seek treatment for 
9 
 
physical illness. Lastly, side effects of antipsychotic medication such as weight gain are 
likely to have a negative impact on physical health (Leucht et al., 2007a).  
1.2.2 Aetiology of schizophrenia 
The exact causes of schizophrenia are still unclear. We know that schizophrenia is highly 
heritable and heritability has been estimated at approximately 80% (Sullivan et al., 2003). 
Family, twin and adoption studies have demonstrated that the degree of risk of 
schizophrenia increases with greater genetic relatedness (Lichtenstein et al., 2009; Plomin 
et al., 2013). However, the aetiology of schizophrenia is complex and multifactorial, likely a 
result of numerous environmental and genetic causes.  
Environmental 
Epidemiological studies have implicated a number of environmental influences that 
increase the risk of schizophrenia: obstetric complications, prenatal nutritional deficiency, 
winter births, childhood trauma, urbanicity, immigration and cannabis use. There is strong 
evidence that obstetric complications increase the risk of schizophrenia in later life. In a 
Finnish general population birth cohort of 11,017 people, being born early (<37 weeks) 
and a low birth weight were associated with an increased risk of schizophrenia (Jones et 
al., 1998). In a similar Swedish study, schizophrenia was associated with multiparity, 
maternal bleeding during pregnancy, and birth in late winter (Hultman et al., 1999). A 
systematic meta-analysis concluded that the well-replicated obstetric risks for 
schizophrenia include (i) complications in pregnancy (preeclampsia, diabetes or bleeding in 
pregnancy), (ii) abnormal foetal growth and development (low birth weight, congenital 
malformation) and (iii) complications with delivery (asphyxia, uterine atony and 
emergency caesarean section) (Cannon et al., 2002).  
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Two key studies have shown that prenatal exposure to famine increased rates of 
schizophrenia in later life, indicating that prenatal nutrition may play a role in 
schizophrenia. Being conceived during the height of the Dutch Hunger Winter famine of 
1944/1945, a result of a Nazi blockade, resulted in a 2-fold increased risk for schizophrenia 
(Susser et al., 1996). Furthermore, births that occurred during the Chinese famine of 1959-
1961 were also associated with a 2-fold risk of developing schizophrenia in later life 
compared to births before or after the famine (St Clair et al., 2005). The mechanism by 
which famine increases risk of schizophrenia is currently unclear, but hypothesis include 
prenatal folate deficiency, which is related to neural tube defects (St Clair et al., 2005), or 
epigenetic changes (Heijmans et al., 2008).  
Adversity and trauma in childhood is associated with a 3-fold increased risk for 
schizophrenia in later life (Varese et al., 2012). Childhood adversity is a heterogeneous 
concept for physical, sexual or emotional abuse, neglect, death or separation from a 
parent, and bullying. Childhood adversity may also affect the persistence of psychotic 
symptoms (Trotta et al., 2015). However, it is possible that the association between 
childhood adversity and schizophrenia is mediated by child-related cognitive and affective 
difficulties (Fisher et al., 2013).  
Individuals with schizophrenia are more likely to be born during the winter or spring 
compared to the general population (Davies et al., 2003). A large meta-analysis of studies 
from both Northern and Southern hemisphere countries found a 5-15% excess of births in 
winter months in schizophrenia (Torrey et al., 1997), which could be a result of increased 
rates of infections, vitamin D deficiencies, or other winter-related factors (Davies et al., 
2003; McGrath et al., 2010). The incidence of schizophrenia is 2-fold higher in urban 
compared to rural environments, although this difference is not reflected in prevalence 
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estimates (McGrath et al., 2008; Vassos et al., 2012). Explanations for this association 
include an increased exposure to infections, pollutants, poor diet, social environment and 
selected migration (Vassos et al., 2012). 
Increased rates of schizophrenia have been reported for migrant and ethnic minority 
groups (McGrath et al., 2008). A systematic meta-analysis reported that the relative risk of 
developing schizophrenia among first- and second-generation migrants was 2.7 and 4.5, 
respectively, and that the effect was greater for migrants from developing countries 
(Cantor-Graae & Selten, 2005). The Aetiology and Ethnicity in Schizophrenia and Other 
Psychoses (AESOP) study found that the incidence of first-episode psychosis in the African-
Caribbean (IRR = 9.1) and Black African (IRR = 5.8) populations in the UK was remarkably 
high (Fearon et al., 2006) and African Americans born in the US were found to have a 3-
fold increased risk of schizophrenia (Bresnahan et al., 2007). There are additional factors 
to migration per se that may account for the increased risk of schizophrenia in ethnic 
minority groups. For example, the association has been partly explained by factors related 
to socioeconomic disadvantage: unemployment, lone parent status, low perceived social 
support and poverty (indicated by lack of car ownership) (Brugha et al., 2004). Further 
investigations regarding the nature of these relationships may provide valuable insights 
into the aetiology of schizophrenia. 
Cannabis use has been associated with an increased risk of psychosis (Andreasson et al., 
1987; Zammit et al., 2002) and this risk is particularly evident for those who use cannabis 
during adolescence (Arseneault et al., 2002). Furthermore, a recent meta-analysis 
identified a dose related effect; regular and ever users were 2.1 and 1.4 times more likely 
to develop schizophrenia, respectively (Moore et al., 2007). This association is not 
explained by the use of other psychoactive drugs, personality traits or pre-existing 
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psychotic symptoms (Andreasson et al., 1987; Arseneault et al., 2002; Moore et al., 2007). 
People with schizophrenia are more likely to smoke tobacco compared to the rest of the 
population (de Leon & Diaz, 2005), thought to be because of self-medication, or to relieve 
distress. Although it is difficult to determine the direction of causality, a recent meta-
analysis found that daily tobacco use was associated with an increased risk of psychosis 
and an earlier age at onset of psychotic illness, suggesting that there may a causal link 
(Gurillo et al., 2015).  
Genetic 
It has become clear that the genetic architecture of schizophrenia involves cumulative 
effects of common alleles of small effect and rare variants of relatively large effect, both of 
which are distributed across many genes at numerous loci (Rees et al., 2015). Due to a 
number of well powered studies and consortia there have recently been major advances in 
the understanding of the genetic aetiology of schizophrenia (Ripke et al., 2011; 
Schizophrenia Working Group of the Psychiatric Genomics Consortium, 2014; Rees et al., 
2015). The most recent contributions have come from common single nucleotide 
polymorphisms (SNPs), rare copy number variation (CNV), rare single nucleotide variants 
(SNVs), and de novo mutations.  
GWAS studies investigate the contribution of common (present in more than 1% of the 
population) single nucleotide polymorphisms (SNPs) to disease. The SNPs used in GWAS 
are an informative backbone of tag SNPs that capture most of the common genetic 
variation in the genome and have made large-scale whole-genome genotyping affordable 
(Visscher et al., 2012). GWAS is a hypothesis-free approach and has been successful in 
identifying numerous risk loci for schizophrenia. Individually, these SNPs have a small 
effect but they have been demonstrated to have cumulative effects, a polygenic 
13 
 
component involving thousands of common alleles (International Schizophrenia 
Consortium et al., 2009). Recent advances have come from analyses conducted by the 
Schizophrenia Working Group of the Psychiatric Genomics Consortium (PGC) (Ripke et al., 
2011; Schizophrenia Working Group of the Psychiatric Genomics Consortium, 2014). The 
PGC was created to combine data from multiple international research groups and thus 
maximise sample size. The latest GWAS analysis of 36,989 schizophrenia cases and 
113,075 controls identified 128 independent associations from 108 distinct loci that were 
associated at the genome-wide significance level (GWS) of P < 5 x 10-8, which corresponds 
to a Bonferroni multiple testing correction for 1 million SNPs in linkage equilibrium 
(Schizophrenia Working Group of the Psychiatric Genomics Consortium, 2014). The most 
significant associations were in the major histocompatibility complex (MHC) on the short 
arm of chromosome 6 (Schizophrenia Working Group of the Psychiatric Genomics 
Consortium, 2014). Additional GWS loci included genes previously hypothesised to be 
involved in schizophrenia, such as the dopamine D2 receptor gene DRD2, the target of 
antipsychotic drugs. Other findings included genes involved in glutamatergic 
neurotransmission and synaptic plasticity (GRM2, GRIN2A, SRR, GRIA1) and voltage-gated 
calcium channels (CACNA1C, CACNB2 and CACNA1I) (Schizophrenia Working Group of the 
Psychiatric Genomics Consortium, 2014). It has become apparent that many of these 
common risk alleles for schizophrenia also convey risk for other neuropsychiatric disorders 
(Cross-Disorder Group of the Psychiatric Genomics Consortium, 2013a, 2013b). 
Specifically, there is a high genetic overlap with bipolar disorder, a moderate overlap with 
major depressive disorder and a small but significant overlap with autism spectrum 
disorders (ASD) (Cross-Disorder Group of the Psychiatric Genomics Consortium, 2013a). 
Furthermore, polygenic risk scores for schizophrenia have also been associated with lower 
cognitive ability (Lencz et al., 2014).  
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The SNPs identified by GWAS are likely to be associated with other variants in the genome 
through linkage disequilibrium (LD). Thus, complimentary studies to GWAS are required to 
identify causal variants and to determine the possible direct or indirect functional effect 
variants may have on the risk of schizophrenia (Visscher et al., 2012). Liability threshold 
models, in comparison to observed models, are used to show that once genetic risk 
surpasses a threshold, schizophrenia will develop. One estimate using all imputed SNPs 
explains approximately a quarter to a third of the variation in liability to schizophrenia (Lee 
et al., 2012c; Rees et al., 2015). When restricted to a subset of SNPs in relative linkage 
equilibrium only 7% of the variation on the liability scale to schizophrenia is explained 
(Schizophrenia Working Group of the Psychiatric Genomics Consortium, 2014). Differences 
in liability across methods are likely explained by the different number of SNPs that are 
included within the model, making direct comparisons challenging. A small amount of 
additional variation can be explained by rare (present in less than 1% of the population) 
mutations, taking the form of large copy number variation (CNVs) or single nucleotide 
variation (SNVs), both of which may either be inherited or occur as de novo mutations.  
CNVs are chromosomal deletions and duplications that range in size from kilobases to 
megabases of DNA. The first CNV associated with an increased risk for schizophrenia was a 
~2.3 Mb deletion on 22q11.2, noted after high rates of schizophrenia were found in adults 
with velocardiofacial syndrome, a syndrome characterised by deletions at 22q11.2 
(Murphy et al., 1999). Collectively, individuals with schizophrenia have an increased 
genome-wide burden of rare CNVs compared with the general population (International 
Schizophrenia Consortium, 2008; Stefansson et al., 2008). Up to 15 specific CNVs have so 
far been implicated in schizophrenia risk and cumulatively they are found in approximately 
2.5% of schizophrenia cases and 0.9% of controls (Kirov et al., 2014; Rees et al., 2014). 
However, only 11 of these 15 CNVs have been robustly shown to increase the risk of 
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schizophrenia; deletions at 1q21.1, NRXN1, 3q29, 15q11.2, 15q13.3 and 22q11.2, and 
duplications at 1q21.1, 7q11.23, 15q11.2-q13.1, 16p13.1 and 16p11.2 (Kirov, 2015). These 
CNVs have a large effect on the risk for schizophrenia, with odds ratios varying between 2 
and over 50, and generally the rarer the CNV the higher the risk it poses for schizophrenia 
(Kirov, 2015). All of the CNVs robustly associated with schizophrenia also increase the risk 
for developmental delay (DD), ASD and congenital malformations (CM), but not for bipolar 
disorder (Kirov et al., 2014; Kirov, 2015). The penetrance of CNVs is higher for these 
developmental conditions than for schizophrenia (Vassos et al., 2010; Kirov et al., 2014). 
Furthermore, they are also associated with cognitive deficits in the general population 
(Stefansson et al., 2014).  
Strong selection pressures remove CNVs from the population in a few generations and 
thus the low frequencies of CNVs are maintained by a balance between negative selection 
from reduced fecundity (Bundy et al., 2011) and new de novo mutations (Kirov, 2015). In 
fact, a large proportion of the 11 replicated CNVs are not inherited and instead caused by 
de novo mutations (Kirov et al., 2012). De novo CNVs in general have been shown to occur 
more frequently and are larger in patients with schizophrenia compared to controls, 
indicating at least some of them are pathogenic (Kirov et al., 2012). There is some 
evidence to suggest that the de novo CNV mutation rate is higher among individuals with 
schizophrenia that do not have any family history of the disorder (Kirov et al., 2012). 
Furthermore, advancing paternal age at conception, which is correlated with the number 
of de novo mutations, has been associated with increased schizophrenia risk, supporting 
the hypothesis that de novo mutations contribute to risk for non-familial schizophrenia 
(Malaspina et al., 2001; Malaspina et al., 2002).  
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Many of the CNVs associated with schizophrenia span numerous genes making biological 
insights difficult. However, the genes disrupted by de novo CNVs are enriched for synaptic 
proteins, an association largely explained by N-methyl-D-aspartate receptor (NMDAR) and 
neuronal activity-regulated cytoskeleton-associated protein (ARC) complexes (Kirov et al., 
2012). A recent functional analysis of CNVs in 11,355 schizophrenia cases and 16,416 
controls found CNV enrichment among genes involved in synaptic plasticity and 
glutamatergic signalling; NMDAR, post synaptic density-95 (PSD-95, a major postsynaptic 
scaffolding protein at glutamatergic synapses) and ARC complexes (Pocklington et al., 
2015). They also found enrichment for GABAergic neurotransmission, an inhibitory 
modulator of synaptic signalling hypothesised to contribute to schizophrenia 
pathophysiology (Pocklington et al., 2015).  
Recently the contribution of rare single nucleotide variants (SNVs) to the risk of 
schizophrenia has been assessed. A large exome sequencing study did not find a general 
increased burden of rare SNVs in people with schizophrenia but did note a polygenic 
burden of very rare (less than 1 in 10,000), damaging mutations in approximately 2000 
genes that had prior evidence for being associated with schizophrenia (Purcell et al., 
2014). At the level of gene-sets, these rare damaging mutations were enriched for genes 
involved in NMDAR, ARC, fragile X mental retardation protein (FMRP)-targets and voltage-
gated calcium channels. A further study examining the exome-wide mutation rate of de 
novo SNVs and indels also did not find increased rates in schizophrenia cases (Fromer et 
al., 2014). However, the de novo SNV mutation rate was associated with low educational 
attainment and there was significant enrichment for nonsynonymous and loss-of-function 
mutations among synaptic gene sets, as well as specifically for NMDAR, ARC and FMRP-
targets. (Fromer et al., 2014). Studies of rare variants are likely to be underpowered and 
larger samples are needed to implicate single genes with rare variants.  
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In conclusion, genetic studies of different mutation classes and allele frequencies in 
schizophrenia have converged on common biological pathways, such as post-synaptic 
proteins, providing robust support that these genes are disrupted in schizophrenia.  
1.2.3 Neurochemical pathophysiology of schizophrenia 
Dysregulation of the neurotransmitters dopamine and glutamate are the two primary 
neurochemical hypotheses of schizophrenia. Neurotransmitters enable transmission of 
signals from one neuron to another across synapses in the brain. The dopamine hypothesis 
of schizophrenia originated from the observation that antipsychotic drugs such as 
chlorpromazine were highly correlated with dopamine D2 receptor potency (Seeman et al., 
1976). In contrast, repeated use of dopamine agonists, such as amphetamine, can induce a 
psychosis that is similar to schizophrenia (Lieberman et al., 1987). Thus, it was 
hypothesised that individuals with schizophrenia had altered dopaminergic 
neurotransmission (Howes & Kapur, 2009). Post-mortem studies have found higher 
dopamine concentrations and dopamine receptor densities in the brains of people with 
schizophrenia compared to healthy controls (Davis et al., 1991). However, post-mortem 
studies may have been biased by the use of antipsychotics in study participants and were 
unable to measure other aspects of dopamine function, such as dopamine release. The 
investigation of dopamine in schizophrenia has been significantly advanced by the use of 
positron emission tomography (PET) and single-photon emission computed tomographic 
(SPECT) imaging in treatment-naive patients. A recent meta-analysis of these imaging 
studies confirmed that presynaptic dopaminergic function is significantly elevated in 
individuals with schizophrenia (Howes et al., 2012a).  
The glutamate hypothesis of schizophrenia was based on the observation in the 1950s that 
the dissociative anaesthetic phencyclidine (PCP) could induce schizophrenia-like symptoms 
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(Moghaddam & Javitt, 2012). PCP is an antagonist of N-methyl-D-aspartate receptors 
(NMDAR) (Javitt & Zukin, 1991), glutamate receptors that play an important role in 
excitatory neurotransmission and synaptic plasticity (Marsman et al., 2013). In contrast to 
amphetamine, PCP can induce the negative and cognitive as well as the positive symptoms 
of schizophrenia. Thus, it was hypothesised that glutamate dysfunction may be particularly 
relevant to chronic schizophrenia (Moghaddam & Javitt, 2012). Post-mortem studies have 
identified lower concentrations of glutamate in the cerebrospinal fluid and abnormalities 
of glutamate receptor density in the prefrontal cortex, thalamus and temporal lobe in 
patients with schizophrenia (Goff & Coyle, 2001). A recent meta-analysis of magnetic 
resonance spectroscopy (MRS) studies found lower levels of glutamate and higher levels of 
glutamine (glutamate’s metabolite) in the frontal regions of the brains of people with 
schizophrenia compared to healthy controls (Marsman et al., 2013). Furthermore, 
glutamate and glutamine levels in the frontal region decreased progressively with age, 
indicating there could be a progressive loss of synaptic activity in patients with 
schizophrenia (Marsman et al., 2013). 
1.2.4 Treatment of schizophrenia 
There is currently no cure for schizophrenia and its treatment is focused on alleviating 
symptoms and improving the individual’s quality of life. Successful treatment will most 
likely include a combination of antipsychotic drug therapy (Zhang & Malhotra, 2011; Lally 
& MacCabe, 2015), psychological interventions such as cognitive behavioural therapy 
(National Institute for Health and Care Excellence, 2009), and psychosocial and family 
support. Typical or first-generation antipsychotics (FGA) are effective in improving the 
positive symptoms of schizophrenia but often cause extrapyramidal symptoms (EPS). 
Newer atypical or second-generation antipsychotics (SGA) are less likely to cause EPS 
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(Zhang et al., 2013a). However, SGAs are associated with increased rates of weight gain, 
metabolic changes and cardiovascular related adverse effects (Leucht et al., 2009). 
Unfortunately, there have been very few new antipsychotic drug advancements in the last 
40 years. The mechanism of action of antipsychotic drugs is mediated by the dopamine 
neurotransmitter system and antagonism of the dopamine D2 receptor appears to be 
necessary for antipsychotic drug action (Kapur et al., 1999). Many patients will discontinue 
and switch antipsychotic treatments, primarily due to intolerable side effects or lack of 
efficacy (Lieberman et al., 2005). It is currently unclear which patients will respond to 
which antipsychotic and clinicians have little empirical evidence to guide drug selection. 
Furthermore, 20-30% of patients will remain symptomatic and significantly impaired 
despite antipsychotic treatment (Kane et al., 1988; Meltzer, 1997; Suzuki et al., 2012). This 
group of patients are referred to as treatment-resistant or treatment-refractory. 
1.3. Treatment-resistant schizophrenia 
Treatment-resistant schizophrenia (TRS) is one of the most disabling forms of mental 
illness (Kane et al., 1988; McEvoy et al., 2006; Leucht et al., 2009) and may manifest itself 
either as a failure to achieve remission from the initial onset of psychosis, failure to 
maintain remission, or as a gradual deterioration from successive relapses (Sheitman & 
Lieberman, 1998). It is yet to be determined whether TRS should be considered simply as a 
chronic form of schizophrenia, at the severe end of the illness spectrum, or as a 
biologically and genetically distinct subgroup (Barnes & Dursun, 2008). Patients with TRS 
present a major clinical challenge as most remain highly symptomatic, often require 
multiple hospitalisations, and experience extremely poor outcomes (Conley & Kelly, 2001; 
Kennedy et al., 2014). Consequently, care for TRS patients consumes a disproportionally 
high share of the total cost of treating schizophrenia (Conley & Kelly, 2001). Davies and 
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Drummond found that care for the 10% of patients with a long-term disabling course of 
schizophrenia accounted for 80% of total lifetime direct costs of schizophrenia within the 
UK (Davies & Drummond, 1994). Furthermore, a recent systematic review by Kennedy and 
colleagues reported that annual costs for treating TRS patients were 3-11-fold higher than 
for patients with non-TRS schizophrenia and that this cost was driven by increased rates of 
hospitalisations (Kennedy et al., 2014).  
1.3.1 Defining TRS 
The definition of TRS has varied widely, making comparisons between studies difficult 
(Suzuki et al., 2011b). Table 1.2 details the four most frequently used criteria. Kane and 
colleagues proposed the first, and most stringent, criteria in their landmark clozapine trial 
(Kane et al., 1988). Although subsequent definitions have tended to be less conservative 
(Conley & Kelly, 2001; Barnes & Dursun, 2008; Suzuki et al., 2012), they have had 
consistent themes. In general, criteria have reflected (i) a failure to respond to at least two 
antipsychotic trials of adequate duration and therapeutic dose, (ii) the current presence of 
at least moderate positive psychotic symptoms, and (iii) persistent disability in functional 
and psychosocial aspects (Barnes & Dursun, 2008). Some studies have additionally 
included a further prospective trial to confirm resistance (Suzuki et al., 2011b). 
Importantly, TRS should be distinguished from intolerance (sensitivity to pharmacological 
side-effects of a drug) or non-adherence (Conley & Kelly, 2001; Caspi et al., 2004). Because 
the NICE guidelines (National Institute for Health and Care Excellence, 2009) represent 
eligibility for clozapine, several studies have used a history of clozapine treatment as a 
proxy for TRS (Frank et al., 2015). 
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Definitions of treatment-resistant schizophrenia 
Kane et al (1988)  
Drug refractory condition: At least three periods within the preceding five years with 
conventional antipsychotics (from at least two chemical classes) at doses ≥ 1000 mg/day 
of chlorpromazine equivalents for six weeks, each without significant symptom relief, 
and failure to improve by at least 20% in total BPRS score or intolerance to a six-week 
prospective trial of haloperidol at 10 to 60 mg per day. 
Persistence of illness: No stable period of good social and/or occupational functioning 
within the last five years. 
Persistent psychotic symptoms: Item score ≥ 4 (moderate) on at least two of four 
positive symptom items on the Brief Psychiatric Rating Scale (BPRS).  
Current presence of at least moderately severe illness: Total BPRS score ≥ 45 on the 18-
item scale and a score ≥ 4 (moderate) on Clinical Global Impression (CGI).  
Conley and Kelly (2001)  
Drug refractory condition: at least two prior drug trials of 4-6 weeks duration at 400-
600mg of chlorpromazine (or equivalent) with no clinical improvement. 
Persistence of illness: more than five years with no period of good social or occupational 
functioning. 
Persistent psychotic symptoms: BPRS total score > 45 (on 18 item scale) and item score > 
4 (moderate) on at least two of four positive symptom items. 
National Institute for Health and Care Excellence (2009) 
Lack of satisfactory clinical improvement despite the sequential use of adequate doses 
of at least two different antipsychotic drugs for 6-8 weeks. At least one of the drugs 
should be a non-clozapine second-generation antipsychotic. 
Suzuki et al (2012)  
Drug refractory condition: At least two failed antipsychotic trials with different 
antipsychotics (at chlorpromazine-equivalent doses of ≥ 600 mg/day for ≥ six 
consecutive weeks) that could be retrospective or preferably include prospective failure 
to respond to one or more antipsychotic trials.  
Persistence of illness: Both a score of ≥ 4 on the CGI-Severity and a score of ≤ 49 on the 
Functional Assessment for Comprehensive Treatment of Schizophrenia (FACT-Sz) or ≤ 50 
on the Global Assessment of Functioning (GAF) scales. 
Table 1.2. Definitions of treatment-resistant schizophrenia. 
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1.3.2 Mechanisms of TRS 
Given the considerable heterogeneity in the illness course of schizophrenia, there has long 
been a search for outcome predictors and to understand the mechanisms behind poor 
clinical outcomes such as TRS. If reliable clinical, neurological or genetic predictors could 
be identified, there is the potential to tailor treatment strategies for particular patient 
subgroups (Carbon & Correll, 2014).  
Clinical 
In 1980, Huber and colleagues followed 502 patients longitudinally and concluded that it 
was not possible to predict the outcome of schizophrenia from clinical factors (Huber et 
al., 1980). However, there is now a substantial amount of research in this area and with 
particularly good evidence from first-episode studies, several reliable clinical predictors 
have been identified (Carbon & Correll, 2014). The most replicated clinical predictors of 
poor outcome in schizophrenia include; male gender, a longer duration of untreated 
psychosis, poor premorbid functioning, comorbid substance-use disorders and non-
adherence. However, very few studies have assessed TRS directly and there has been a 
wide variability in outcome measures. 
Male gender has been associated with a decreased likelihood of recovery in schizophrenia 
as well as a poor response to antipsychotic treatment, independent of confounding factors 
such as age of onset and illness severity (Robinson et al., 1999b; Usall et al., 2007; 
Rabinowitz et al., 2014; Thorup et al., 2014; Frank et al., 2015). However, this is still a 
relatively controversial finding as many studies have not replicated the association (Carbon 
& Correll, 2014). It is unclear why males are more likely to have a chronic course of illness, 
but it may be driven, at least in part, by the overrepresentation of other risk factors in 
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males such as substance abuse, non-adherence, prominent negative symptoms and poor 
social functioning (Thorup et al., 2014). 
A longer duration of untreated psychosis, the period of psychosis experienced prior to 
antipsychotic treatment, is one of the most replicated predictors of poor clinical outcome 
in schizophrenia (Marshall et al., 2005; Perkins et al., 2005). Poor premorbid functioning 
has also been consistently associated with multiple poor outcomes measures, including a 
lack of response to antipsychotics (Levine & Rabinowitz, 2010; Rabinowitz et al., 2011), 
rate of relapse (Robinson et al., 1999a), and clozapine treatment (proxy for TRS) (Caspi et 
al., 2007; Frank et al., 2015). Poor premorbid function may be a marker for greater 
neurodevelopment disturbance (Carbon & Correll, 2014). An earlier age at onset of 
schizophrenia has been associated with a poor antipsychotic response (Levine & 
Rabinowitz, 2010; Carbon & Correll, 2014) and a recent study found that patients taking 
clozapine had a significantly earlier age and insidious disease onset (Frank et al., 2015). 
However, this has not been replicated in other large studies (Amminger et al., 2011; 
Rabinowitz et al., 2014) and the effect may be mediated by a longer illness duration 
(Carbon & Correll, 2014).  
Comorbidities, especially substance-use disorders have been associated with poor clinical 
outcomes in schizophrenia and increased rates of mortality (Volkow, 2009) but it is 
currently unclear what drives this association. For example, substance use is associated 
with non-adherence, which also impacts functional outcome in schizophrenia (Ascher-
Svanum et al., 2006). Additional factors that may be associated with poor outcome in 
schizophrenia include prominent negative symptoms (Foussias & Remington, 2010; Ucok 
et al., 2011), a family history of schizophrenia (Frank et al., 2015), and a lack of early 
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antipsychotic response (Agid et al., 2003), poor cognitive functioning (Levine & Rabinowitz, 
2010).  
Neurological 
It is hypothesised that glutamate dysfunction may be particularly relevant for TRS 
(Moghaddam & Javitt, 2012), as discussed in section 1.2.2. There have been very few 
neuroimaging studies focusing specifically on patients with TRS and there are currently no 
reliable neuroimaging correlates of TRS in comparison to healthy controls (Nakajima et al., 
2015). In comparison to schizophrenia patients responsive to treatment, TRS has been 
associated with decreased thickness of dorsolateral prefrontal cortex (Zugman et al., 
2013), relatively normal striatal dopamine synthesis and elevated anterior cingulate cortex 
glutamate levels (Demjaha et al., 2014). A recent study found increased rates of minor 
physical anomalies and craniofacial features in patients with TRS, implicating a 
neurodevelopmental mechanism (Lin et al., 2015).  
Genetic 
There have been relatively few studies directly investigating the genetic aetiology of TRS. 
However, pharmacogenetic studies of the genetic variability associated with individual 
responses to drug treatments have offered insights. There have been many 
pharmacogenetic candidate studies focusing on either the neurotransmitters impacted by 
antipsychotics (dopamine and serotonin) or genes encoding the enzymes responsible for 
drug metabolism (cytochrome P450 family). There is evidence for a role in antipsychotic 
response for the -141C Ins/Del polymorphism in DRD2 (Zhang et al., 2010), the -1438G 
polymorphism in HRT2A (Ellingrod et al., 2003), and 5-HTTLPR, a degenerate repeat 
polymorphism in SLC6A4 (Dolzan et al., 2008). SLC6A4 encodes the serotonin transporter 
and 5-HTTLPR has been demonstrated to affect the rate of serotonin uptake (Dolzan et al., 
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2008; Zhang & Malhotra, 2011). The Val108Met polymorphism in COMT, which affects 
dopamine clearance, has also been associated with antipsychotic response (Zhang & 
Malhotra, 2011). A study of 74 candidate genes from the Clinical Antipsychotic Trials for 
Intervention Effectiveness (CATIE) trial in the US of 738 individuals failed to identify any 
variants that were significantly associated with discontinuation of olanzapine, quetiapine, 
risperidone, ziprasidone or perphenazine after correction for multiple testing (Need et al., 
2009). A GWAS of the same sample identified an intergenic variant on chromosome 4p15 
that predicted the effect of ziprasidone on positive symptoms only (McClay et al., 2011). 
Candidate pharmacogenetic studies of antipsychotic response have produced a number of 
false positive and false negative findings with few consistent replications. This is likely due 
to inadequate statistical power and the considerable variability in treatment response 
definitions. It has become clear from the field of schizophrenia genetics that biology-
driven candidate gene studies are unlikely to yield robust insights into disease aetiology 
(Farrell et al., 2015). Thus, large, well-powered GWAS studies are required to validate and 
extend these findings. 
More recent studies have directly investigated the genetic aetiology of TRS. In 2012, a 
study of 384 candidate markers from 46 genes failed to identify any variants significantly 
associated with TRS (Teo et al., 2012). However, a study of 74 candidate genes in 89 
patients treated with clozapine (and thus TRS) and 190 schizophrenia patients, found that 
variants within BDNF, including the Val66Met (rs6265) polymorphism, were associated 
with TRS (Zhang et al., 2013b). BDNF interacts with multiple neurotransmitters, including 
dopamine and serotonin, may lead to reduced synaptic plasticity, and has been previously 
associated with therapeutic response in schizophrenia (Krebs et al., 2000). A significant 
association between TRS and DISC1 was reported in a further candidate study (Mouaffak 
et al., 2011), although this was not replicated in a study of Japanese patients (Hotta et al., 
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2011). No significant associations have been reported from candidate gene studies 
specifically relating to serotoninergic genes and TRS (Ji et al., 2008a; Ji et al., 2008b). A 
GWAS in 79 TRS patients and 95 non-TRS schizophrenia patients failed to identify any 
variants significantly associated with TRS (Li & Meltzer, 2014). Furthermore, a GWAS in 
795 Han Chinese TRS patients and 806 healthy controls also failed to identify any 
significant variants (Liou et al., 2012). However, suggestive variants from these two GWAS 
included the 7p12.2 region (Li & Meltzer, 2014) and intronic variants in NFKB1, RIPK4 and 
SLAMF1 (Liou et al., 2012). A study by Frank and colleagues found that the polygenic risk 
score for schizophrenia was increased in 434 patients treated with clozapine in 
comparison to 370 patients with no history of clozapine treatment (Frank et al., 2015) but 
this finding was not replicated in another study (Martin & Mowry, 2015), which found an 
increased burden of genome-wide rare copy number duplications in 277 patients with TRS 
compared to 385 individuals with schizophrenia (Martin & Mowry, 2015). In conclusion, 
there are no robustly replicated risk loci for TRS. Studies to date have been underpowered 
as a result of small sample sizes and the variability in TRS definition has limited the 
comparability between studies. 
1.3.3 Treatment of TRS 
Clozapine is the only medication with robust effectiveness for patients with TRS (Kane et 
al., 1988; McEvoy et al., 2006; Leucht et al., 2009). Given its potential to induce severe 
adverse effects, particularly agranulocytosis, it is recommended that the drug is offered 
after failure to respond to two adequate antipsychotic trials (National Institute for Health 
and Care Excellence, 2009). Other pharmacological interventions for TRS include the use of 
high dose antipsychotic medication, although there is little empirical evidence to suggest 
that this has any advantage over standard dosage (Royal College of Psychiatrists, 2014). 
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There is a lack of convincing evidence of efficacy for other strategies such as the 
concomitant use of two or more antipsychotics, which is used despite the increased risk of 
side effects (Caspi et al., 2004; Correll et al., 2009). There is some evidence for adjunctive 
use of lithium and anticonvulsants for the treatment of TRS (Conley & Kelly, 2001). 
Psychological and psychosocial interventions such as cognitive behavioural therapy (CBT), 
a good therapeutic alliance with the patient, and providing support to patients and carers 
are also critical to the treatment of TRS (Barnes & Dursun, 2008; Burns et al., 2014). 
1.4. Clozapine 
The Swiss pharmaceutical company Sandoz identified clozapine in 1959. Other 
antipsychotics in use at the time, such as chlorpromazine, caused extrapyramidal 
symptoms (EPS) (Crilly, 2007). Because clozapine did not cause EPS, it was labelled as 
having an ‘atypical’ profile. Ironically, this limited clozapine’s acceptance because of the 
assumption that antipsychotics needed to cause EPS in order to effectively treat psychotic 
symptoms (Hippius, 1999). Following encouraging clinical trials in the early 1970s (Stille & 
Hippius, 1971), it was introduced in Switzerland and Austria in 1972, in West Germany in 
1974 and in Finland in 1975. Within four months of clozapine being marketed in Finland, a 
report was published of 18 patients developing severe haematological disorders, 9 of 
whom died (Idanpaan-Heikkila et al., 1975). In addition, there were 12 other cases 
reported from other countries (Griffith & Saameli, 1975). The majority of cases had 
developed agranulocytosis, a deficiency of infection-fighting white blood cells called 
neutrophils that renders the person vulnerable to infections (Amsler et al., 1977). This 
alarming accumulation of severe adverse reactions led to clozapine being voluntarily 
withdrawn by Sandoz and, for the most part, it fell out of favour for more than a decade. 
However, some countries continued to use clozapine under the condition of weekly blood 
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monitoring to aid early detection of agranulocytosis (Hippius, 1999). A turning point in 
clozapine’s history came from two clinical trials in the United States of America (USA). The 
first demonstrated its therapeutic superiority over chlorpromazine for the treatment of 
schizophrenia (Claghorn et al., 1987) and the second demonstrated its therapeutic 
superiority over chlorpromazine for the treatment of TRS (Kane et al., 1988). 
Consequently, in 1990, the Food and Drug Administration (FDA) in the USA approved 
clozapine for use in patients with TRS, under the condition of mandatory blood monitoring 
via a safety system, and it was reintroduced in other countries around the same time. 
Clozapine is now well proven to have superior beneficial effects in patients with TRS. This 
section discusses the pharmacology, metabolism, efficacy and current use of clozapine. 
1.4.1 Pharmacology 
Clozapine is a dibenzodiazepine with a unique pharmacological profile. It has affinities 
toward dopamine, serotonin, α adrenergic, muscarinic and histamine receptors (Selent et 
al., 2008). Clozapine is classified as an atypical antipsychotic because it has a lower affinity 
for D2 receptors than seen with conventional antipsychotics and a higher affinity for 5-HT2A 
receptors than for D2 receptors (Meltzer, 1989; Meltzer et al., 1989b). However, the 
mechanism that causes clozapine’s superior efficacy is still unclear. 
Dopamine 
Consistent with all antipsychotics, clozapine is a D2 antagonist. At therapeutic doses 
clozapine has a lower affinity for D2 receptor occupancy (20-67%) than conventional 
antipsychotics (70-90%) (Nordstrom et al., 1995) or for several other atypicals such as 
risperidone and olanzapine (Kapur et al., 1999). Clozapine’s low D2 occupancy is 
responsible for the absence of EPS (Kapur & Seeman, 2001), which are caused by an excess 
of D2 receptor occupancies. Clozapine has a rapid dissociation from D2 receptors and is 
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thus called a ‘fast-Off-D2’ antipsychotic (Seeman, 2014). Clozapine was found to occupy 
72% of the D2 receptors in the human striatum two hours after administration, followed by 
a quick reduction to less than 30% by 24 hours (Seeman, 2002). Similar to quetiapine, 
clozapine binds briefly to the D2 receptor, triggering a suppression of psychotic symptoms, 
while allowing endogenous dopamine to displace the loosely bound drug (Seeman, 2014). 
After dissociating, clozapine allows normal dopamine neurotransmission, which keeps 
prolactin levels normal and also spares cognition (Seeman, 2002). This was thought to 
explain clozapine’s reduced effects on EPS, but this does not explain the same effects in 
other antipsychotics lacking the fast-Off-D2 profile (e.g. aripiprazole, ziprasidone) (Horacek 
et al., 2006).  
Clozapine shows a higher affinity for D4 compared to D2 receptors (Guan & Sunahara, 
1991; Horacek et al., 2006). However, because pure D4 antagonists have not shown any 
independent antipsychotic effect (Kramer et al., 1997), D4 is mainly considered to have a 
supplementary effect to D2 receptor antagonism. Although clozapine is a D1 antagonist, 
there is limited support the role for D1 receptors in antipsychotic drug efficacy (Karlsson et 
al., 1995). 
Serotonin 
Clozapine has a high affinity for the serotonin 5-HT2A receptor (Meltzer, 1999) and studies 
indicate that 96% of 5-HT2A receptors are occupied at daily doses of 300-600 mg (Kapur et 
al., 1999). It was thought that this action was responsible for the absence of EPS, but this 
has since been refuted (Kapur & Seeman, 2001; Seeman, 2014). Clozapine is also a 5-HT1A 
agonist, and 5-HT2B, 5-HT2C, 5-HT6 and 5-HT7 antagonists. It is currently thought that rather 
than having an independent effect, it is likely that the effect on serotonergic receptors 
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works in combination with D2 receptors to cause the therapeutic effect of clozapine 
(Horacek et al., 2006). 
Other neurotransmitters  
Clozapine is an antagonist of α1- and α2-adrenoceptors (Brosda et al., 2014). Many 
antipsychotic drugs also possess α1-adrenoceptor blocking properties. Although a clinical 
trial of the pure α1-adrenoceptor antagonist prazosin found no direct antipsychotic effect 
(Hommer et al., 1984), one study reported that prazosin enhanced the effect of 
antipsychotic drugs (Svensson, 2003). In contrast to other antipsychotic drugs, clozapine 
has a high affinity for α2-adrenoceptor antagonism. α2-adrenoceptor blocking is 
hypothesised to act by augmenting prefrontal dopaminergic functioning, and has received 
some recent interest (Svensson, 2003; Brosda et al., 2014). Clozapine also impacts 
histamine receptors (Humbert-Claude et al., 2012) and is a marked agonist of muscarinic 
acetylcholine M1 – M5 receptors (Bymaster et al., 2003).  
1.4.2 Metabolism 
Orally administered drugs such as clozapine are absorbed by the digestive system and 
carried via the hepatic portal vein into the liver where it is metabolised before reaching 
the rest of the body. Clozapine is 90-95% absorbed when administered orally but due to 
the first pass metabolism effect, it has only moderate (60-70%) bioavailability, which is not 
affected by food (Wenthur & Lindsley, 2013). The peak concentration of clozapine occurs 
approximately 2.5 hours after oral dosing. The mean elimination half-life is 8 hours after a 
single 75mg dose and 12 hours after achieving steady state dose of 100mg twice daily. 
Clozapine is approximately 97% bound to serum proteins. Clozapine is extensively 
metabolised in the liver by the cytochrome P450 (CYP450) system and only trace amount 
of unchanged drug are detected in the urine and faeces. Clozapine is metabolised into two 
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major stable metabolites norclozapine (N-desmethylclozapine, NDMC) and clozapine N-
oxide, and is bioactivated into a reactive metabolite (Pirmohamed et al., 1995). 
Norclozapine is the major metabolite and is pharmacologically active (Li et al., 2005). The 
reactive metabolite, thought to be a nitrenium ion, has been linked to agranulocytosis (Liu 
& Uetrecht, 1995; Maggs et al., 1995; Pirmohamed & Park, 1997). The CYP450 enzyme 1A2 
(CYP1A2) is primarily responsible for clozapine metabolism, and agents that induce 
CYP1A2 such as cigarettes reduce clozapine levels (van der Weide et al., 2003) whereas 
agents that inhibit CYP1A2 such as caffeine increase clozapine levels (Bertilsson et al., 
1994). There are also additional contributions of CYP2D6, CYP3A4 and CYP2C19 to 
clozapine metabolism (Urichuk et al., 2008). Approximately 50% of the administered dose 
is excreted as metabolites in the urine and 30% in the faeces. Excretion of N-oxide and 
norclozapine is dependant on the activity of P-glycoprotein, a transmembrane transporter 
expressed in the liver and kidneys, coded by the ABCB1/MDR1 gene. There is evidence 
that ABCB1 polymorphisms affect serum clozapine levels (Consoli et al., 2009; Krivoy et al., 
2015). These factors contribute to wide inter-individual differences in metabolism and 
thus monitoring of plasma clozapine levels during treatment can be used to assess 
metabolism and adjust dosage (Wenthur & Lindsley, 2013).  
1.4.3 Efficacy of clozapine 
The efficacy of clozapine on positive, negative and cognitive symptoms of schizophrenia, 
as well as other outcomes such as mortality, suicide and aggression has been extensively 
studied. 
Positive and negative symptoms 
An early landmark clinical trial indicated the superior efficacy of clozapine over 
chlorpromazine, a typical antipsychotic, for patients that had an inadequate response to 
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conventional antipsychotics (Claghorn et al., 1987; Kane et al., 1988). Subsequent to the 
reintroduction of clozapine, there have been a significant number of randomised 
controlled trials investigating the efficacy of clozapine treatment. Several meta-analyses of 
these studies have demonstrated clozapine’s superiority over typical antipsychotics in 
terms of improvement in overall psychopathology for patients with TRS and reduced 
extrapyramidal side effects (Chakos et al., 2001; Davis et al., 2003; Essali et al., 2009). 
Furthermore, clozapine has increased efficacy over atypical antipsychotics in patients with 
TRS (Wahlbeck et al., 2000; Davis et al., 2003). Considerable support was provided by 
three large non-commercial trials. The Clinical Antipsychotic Trials for Intervention 
Effectiveness (CATIE) in the USA assigned patients that had discontinued a previous 
antipsychotic, primarily due to inadequate response, to either clozapine or another 
atypical antipsychotic (olanzapine, quetiapine or risperidone) (McEvoy et al., 2006). The 
primary outcome of the CATIE study was time to discontinuation, chosen to encapsulate 
multiple kinds of drug failure and also to represent real-world practice. The decision to 
discontinue a treatment represents a synthesis of clinician and patient judgements 
balancing efficaciousness against tolerability of adverse effects. The CATIE trial found that 
time to discontinuation of clozapine was significantly longer than other atypical 
antipsychotics; the median time to clozapine discontinuation was 10 months, twice the 
time from olanzapine, the next best (McEvoy et al., 2006). Clozapine has been consistently 
associated with a prolonged time to discontinuation in other studies (Rosenheck et al., 
2000; Kane et al., 2001; Kroken et al., 2014). The UK Cost Utility of the Latest Antipsychotic 
Drugs in Schizophrenia Study (CUtLASS) found clozapine to be superior in a clinical trial of 
clozapine vs. other atypical antipsychotics in 136 patients with TRS (Lewis et al., 2006). 
Lastly, the Schizophrenia Outpatient Health Outcome (SOHO) study found that clozapine 
and olanzapine were associated with a lower risk of relapse compared to other atypical 
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antipsychotics (Haro & Salvador-Carulla, 2006). Although there is substantial evidence 
regarding clozapine’s superiority in overall psychopathology, it has generally not been 
associated with greater improvements in quality of life scales compared to other 
antipsychotics (Rosenheck et al., 1997; Lewis et al., 2006).  
Early clinical trials suggested that clozapine could be more effective for treating negative 
symptoms than chlorpromazine (Kane et al., 1988). However, no superior effects were 
found in trials comparing clozapine with haloperidol (Buchanan et al., 1998; Kane et al., 
2001) and other studies have found no effect after controlling for the impact on positive 
symptoms (Lieberman et al., 1994b; Rosenheck et al., 1999a). A recent review concluded 
that clozapine does not have an independent effect on negative symptoms (Arango et al., 
2013).  
There is some evidence to suggest that clozapine is also more effective than haloperidol 
(Kane et al., 2001) and risperidone (Azorin et al., 2001) in patients with non-TRS. A recent 
meta-analysis by Leucht and colleagues of 15 antipsychotic drugs, which excluded patients 
with TRS, found that clozapine was significantly more effective than placebo, and had the 
largest effect size of all the antipsychotics (Leucht et al., 2013). However, there is no 
evidence for the increased efficacy of clozapine in first-episode patients (Girgis et al., 
2011).  
Cognitive symptoms 
Although initial studies suggested clozapine had superior efficacy in improving cognition 
(Buchanan et al., 1994), there does not appear to be any clear advantage over other 
atypical antipsychotics (Bilder et al., 2002). There have been mixed results for specific 
effects of antipsychotics on cognition and no one drug appears to have a superior profile 
(Woodward et al., 2005; Nielsen et al., 2015). Meta-analyses indicate that there may be a 
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superior effect of clozapine specifically on verbal fluency (Meltzer & McGurk, 1999; 
Woodward et al., 2005; Nielsen et al., 2015). Furthermore, a recent study demonstrated 
that the ratio of serum clozapine and norclozapine (its major metabolite) was significantly 
correlated with working memory (Rajji et al., 2015).  
Mortality and suicide 
Clozapine has been associated with decreased rates of all-cause mortality and suicidality. 
Meltzer & Okayli reported markedly reduced suicidality among 88 neuroleptic-resistant 
patients treated with clozapine for six months to seven years (Meltzer & Okayli, 1995) and 
further support came from the International Suicide Prevention Trial (InterSePT), a large 
prospective randomised study in patients with schizophrenia at high risk of suicide, which 
found that clozapine was superior to olanzapine in reducing key measures of suicidality 
(Meltzer et al., 2003a). Clozapine has also been associated with a reduced risk of mortality 
from suicide (Reid et al., 1998; Tiihonen et al., 2009; Ringback Weitoft et al., 2014). Walker 
and colleagues, using the Clozaril National Registry to identify 67,000 current and former 
clozapine users in the United States, found that mortality from suicide was markedly 
decreased in current compared to past clozapine users (Walker et al., 1997). Although 
another study failed to replicate this association in veterans (Sernyak et al., 2001), a large 
meta-analysis concluded that clozapine substantially lowered the overall risk of suicidal 
behaviours and mortality from suicide in comparison to other treatments (Hennen & 
Baldessarini, 2005). 
There is evidence indicating that clozapine decreases rates of mortality in general, not 
solely those attributable to suicide. A nationwide register study in Finland (FIN11) with an 
11-year follow-up found that long-term exposure to any antipsychotic treatment was 
associated with lower mortality and that clozapine had the lowest mortality risk (Tiihonen 
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et al., 2009). Although this study has received some methodological criticism (De Hert et 
al., 2010), the results have been replicated by another Finnish registry study (Kiviniemi et 
al., 2013). It is possible that the reduction in suicidality and mortality in clozapine patients 
was due to increased clinical contact from the mandatory haematological monitoring. 
However, Hayes and colleagues, in a large naturalistic cohort study, found a strong 
association between clozapine and lower mortality rates, which persisted after controlling 
for the frequency of clinical contact (Hayes et al., 2015). Furthermore, there was evidence 
that clozapine reduced the risk of mortality due to natural as well as unnatural causes 
(Hayes et al., 2015).  
Aggression 
There is emerging evidence that clozapine is effective in reducing violent and aggressive 
behaviour in patients with schizophrenia, and particularly in those with TRS (Frogley et al., 
2012; Victoroff et al., 2014). Evidence has come from randomised-controlled trials, 
crossover trials, retrospective and prospective studies, and these effects have been found 
to be independent of general antipsychotic and sedative effects (Frogley et al., 2012).  
Economics 
Many studies investigating the cost-effectiveness of clozapine treatment in patients with 
TRS have used mirror-image designs; comparing the period of time prior to and after the 
onset of clozapine. These studies have consistently found reduced costs in the two years 
after the onset of clozapine compared to the two years before (Honigfeld & Patin, 1990; 
Meltzer et al., 1993; Aitchison & Kerwin, 1997; Hayhurst et al., 2002). This cost saving 
appeared to be driven by reduced hospitalisations (Meltzer et al., 1993). There are only a 
limited number of studies comparing the benefits of clozapine with other atypical 
antipsychotics (Rosenheck et al., 1997). The CUtLASS study found that clozapine treatment 
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was associated with increased costs after one year in comparison to other atypical 
antipsychotics, although the difference was not statistically significant (Lewis et al., 2006). 
Davis and colleagues also found that clozapine was more expensive than other atypical 
antipsychotics within the first year (Davies et al., 2008). However, these increased costs 
appear to be driven by the inpatient admission required for commencing clozapine. Long-
term studies are required to assess the cost-effectiveness of clozapine, as the long-term 
benefits may offset the cost of initial hospitalisation and this has yet to be studied. 
1.4.4 Side effects of clozapine 
Although clozapine is the most effective antipsychotic in the management of TRS, its use 
has been limited by the potential for adverse effects (Meltzer, 2012). The FDA requires 
clozapine to carry serious warnings for agranulocytosis, seizures, myocarditis, other 
adverse cardiovascular and respiratory effects, and increased mortality in elderly patients 
with dementia-related psychosis. These adverse effects are rare but potentially fatal. The 
risk of agranulocytosis is discussed in section 1.5. The risk of potentially fatal myocarditis 
or cardiomyopathy is between 0.015% and 0.188% of those treated with clozapine (Merrill 
et al., 2005). Another serious risk is clozapine’s potential to cause marked weight gain, 
type II diabetes and diabetes ketoacidosis (Tang et al., 2008; Meltzer, 2012). Clozapine and 
olanzapine are the most likely antipsychotics to cause clinically significant weight gain and 
metabolic dysfunction (Newcomer, 2005; Leucht et al., 2013). Other common side effects 
of clozapine include drowsiness and sedation, dizziness, tachycardia, constipation and 
hypersalivation (Waserman & Criollo, 2000; Essali et al., 2009). 
1.4.5 Clozapine utilisation 
The National Institute of Clinical Excellence (NICE) guidance states that clinicians should 
‘offer clozapine to people with schizophrenia whose illness has not responded adequately 
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to treatment despite the sequential use of adequate doses of at least two different 
antipsychotic drugs’ (National Institute for Health and Care Excellence, 2009). Despite this 
guidance, and considering clozapine is the only licenced drug for TRS, clozapine is widely 
underutilised (Stroup et al., 2009; Joober & Boksa, 2010; Royal College of Psychiatrists, 
2012). The UK National Audit of Schizophrenia in 2012 found that 43% of patients eligible 
for clozapine in the UK have not yet been considered for a trial (Royal College of 
Psychiatrists, 2012). The under prescription of clozapine has also been documented in 
other countries (Koen et al., 2008), particularly in the US (Stroup et al., 2009), although its 
use is very high in China (Tang et al., 2008). In patients that do receive clozapine, there is a 
delay to treatment. In New Zealand, Wheeler and colleagues reported an average duration 
of illness of 9.7 years before patients were started on clozapine (Wheeler, 2008). In 2003, 
Taylor and colleagues found a theoretical delay of five years from eligibility to first 
clozapine treatment in the UK (Taylor et al., 2003). An update found this delay to still be an 
average of four years (Howes et al., 2012b).  
There are many reasons for the underutilisation of clozapine. Of particular importance is 
the attitude and experience of the prescribing psychiatrist (Patel, 2012; Tungaraza & 
Farooq, 2015). In a survey of psychiatrist’s attitudes, Nielsen and colleagues found that 
64% of psychiatrists in Denmark would rather prescribe two antipsychotics than use 
clozapine and 66% thought that patients treated with clozapine were less satisfied 
compared to those treated with other atypical antipsychotics (Nielsen et al., 2010). 
Wheeler and colleagues found that audit and feedback improved clozapine prescription in 
New Zealand (Wheeler et al., 2009a), suggesting targeting clinician attitudes may be an 
effective intervention in improving clozapine prescription. In a recent UK online survey of 
243 consultant psychiatrists, Tungaraza and colleagues found that the major concerns of 
psychiatrists that limited clozapine prescription were in regards to side effects and 
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concerns over patient’s reluctance for blood monitoring (Tungaraza & Farooq, 2015). 
However, a survey of patient’s attitudes found that although patients disliked the blood 
monitoring, 87% felt that the advantages of clozapine outweighed the disadvantages and 
only 1.6% wanted to discontinue due to this reason (Taylor et al., 2000). Other studies 
have also found that concerns over side effects are a major contributor to the widespread 
underutilisation of clozapine (Atkin et al., 1996; Henderson et al., 2000), particularly in 
regards to the risk of agranulocytosis.  
1.5. Clozapine-induced agranulocytosis and neutropenia 
Neutropenia is the reduction of white blood cells called neutrophils to levels below 1500 
cells/mm3 of blood. Agranulocytosis is a more severe form where the neutrophil levels fall 
below 500 cells/mm3. Neutrophils are the most abundant type (50-70%) of white blood 
cells (leukocytes) and play a fundamental role in the immune system. Thus, the decrease 
or disappearance of neutrophils renders the person susceptible to infection due to a 
suppressed immune system. Neutrophils are formed from stem cells in the bone marrow 
over a period of approximately five days and have a short circulating half-life in the blood 
of 6-8 hours, after which cells die by apoptosis (Summers et al., 2010). The principal 
regulator of neutrophil production is granulocyte colony stimulating factor (G-CSF). 
Agranulocytosis and neutropenia can be caused by a number of factors, including 
exogenous agents such as chemotherapy, but also vitamin deficiency, leukaemia, 
autoimmune diseases, and bacterial and viral infections such as human immunodeficiency 
virus (HIV) (Flanagan & Dunk, 2008). The main clinical manifestations of agranulocytosis 
are secondary to infection and may include fever, fatigue, weakness, cough, sore throat 
and pneumonia (Flanagan & Dunk, 2008). Neutropenia was first recognised as a side effect 
of antipsychotic medication when it was observed in association with chlorpromazine in 
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the 1950s and has now been associated with many antipsychotics, although clozapine is 
the only one with mandatory haematological monitoring. 
To facilitate the early detection of agranulocytosis, clozapine treatment is accompanied by 
regular and, in many countries including the UK, mandatory haematological monitoring. 
This burden of monitoring limits the acceptability of the drug to patients, and poses an 
additional obstacle to clinician recommendation and use in clinical practice (Patel, 2012). If 
neutropenia or agranulocytosis is identified, clozapine treatment is discontinued and 
usually haematological parameters will subsequently normalise. However, some may 
require treatment with G-CSF to stimulate neutrophil production.  
The monitoring systems put in place for clozapine have been successful in reducing the 
prevalence of clozapine-induced agranulocytosis (CIA) and associated fatality rates 
(Schulte, 2006). Studies utilising the centralised clozapine monitoring system in the UK and 
US have found the cumulative prevalence of CIA and neutropenia in those taking clozapine 
to be approximately 0.8% and 2.9%, respectively (Alvir et al., 1993; Atkin et al., 1996; 
Munro et al., 1999). Furthermore, the prevalence of fatal CIA is now very low. In the UK, 
fatal CIA occurred in 0.016% to 0.03% of patients treated with clozapine (Atkin et al., 1996; 
Munro et al., 1999). In the US, the case fatality rate of CIA was estimated between 4.2-
16%, depending on whether the individual was treated with G-CSF (Schulte, 2006). 
The peak incidence of both CIA and neutropenia is in the first 6-18 weeks of clozapine 
treatment (Atkin et al., 1996; Munro et al., 1999). There is a reduced incidence after six 
months of treatment (Alvir et al., 1993). After the first year, the incidence of 
agranulocytosis decreases to rates similar to other medications, such as chlorpromazine, 
that do not require haematological monitoring (Atkin et al., 1996; Schulte, 2006). These 
findings led to a relaxation in haematological monitoring and current European guidelines 
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are for weekly blood tests in first 18 weeks of treatment, fortnightly up to one year and 
then monthly thereafter. 
1.5.1 Aetiology 
The mechanism by which clozapine causes agranulocytosis and neutropenia has been 
extensively studied but is still not well understood (Pirmohamed & Park, 1997; Flanagan & 
Dunk, 2008). CIA is not due to an extension of known pharmacological effects of clozapine. 
Clozapine or its stable metabolites (norclozapine or clozapine N-oxide) are not directly 
cytotoxic to neutrophils and do not interfere with the turnover of bone marrow precursor 
cells at therapeutic drug concentrations (Gerson et al., 1994; Pirmohamed & Park, 1997). 
However, there is evidence indicating that CIA and neutropenia are caused by the 
activation of clozapine or a stable metabolite of clozapine to a chemically reactive 
nitrenium ion (Liu & Uetrecht, 1995; Maggs et al., 1995; Pirmohamed & Park, 1997). The 
nitrenium ion has been shown to cause dose-dependent apoptosis to neutrophils at 
therapeutic levels of clozapine (Williams et al., 2000; Pessina et al., 2006) as well as toxicity 
to stromal cells, the precursors of neutrophils in bone marrow (Pereira & Dean, 2006). 
Neutrophils themselves can generate hypochlorous acid via the nicotinamide adenine 
dinucleotide phosphate (NADPH)/ myeloperoxidase (MPO) pathway, which is capable of 
oxidizing clozapine to reactive metabolites that covalently bind to neutrophils (Uetrecht, 
1989; Liu & Uetrecht, 1995; Gardner et al., 1998). The covalent binding of these reactive 
metabolites could in turn lead to agranulocytosis or neutropenia via direct toxicity or by 
initiating an immune mechanism, or both. An immune mechanism, perhaps initiated by 
presence of nitrenium ions, has been suggested since CIA occurs more quickly and is more 
severe upon rechallenge of clozapine; features typical of Type B (idiosyncratic) adverse 
drug reactions (Dunk et al., 2006; Flanagan & Dunk, 2008). Genetic association studies 
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have implicated variants in HLA-B and HLA-DQB1 with CIA (Goldstein et al., 2014), 
supporting the likelihood of an immune-mediated mechanism.  
The reason why only 0.8% of individuals treated with clozapine are affected by 
agranulocytosis has not been fully elucidated (Pirmohamed & Park, 1997). There has been 
substantial interest in the identification of factors predictive of an increased susceptibility 
for CIA that in turn have provided aetiological insights. Conceivably, a sensitive and reliable 
predictor could be used as a screening procedure to identify patients vulnerable to CIA. 
For those at low risk, there could be a reduced need of regular monitoring, thereby 
broadening those that could be treated with clozapine. This section describes the 
demographic, pharmacokinetic and genetic factors that have been associated with CIA and 
neutropenia. 
Demographic 
Large epidemiological studies utilising data from clozapine registers in the UK and US have 
indicated that there may be different aetiological mechanisms for neutropenia and 
agranulocytosis (Flanagan & Dunk, 2008). Evidence from these studies suggest that the risk 
of CIA increases with age, by approximately 53% per decade, whereas the risk of 
neutropenia decreases with age (Alvir et al., 1993; Munro et al., 1999). Alvir and 
colleagues reported higher rates of CIA among women in the US (Alvir et al., 1993). In the 
UK, patients of Asian ancestry were 2.4 times more likely to develop CIA in comparison to 
those of European ancestry whereas risk of neutropenia was 77% higher in patients of 
African-Caribbean ethnicity (Munro et al., 1999). The increased risk of neutropenia in 
patients of African-Caribbean ethnicity may have been driven by an average lower baseline 
white blood cell (WBC) count, which independently predicted neutropenia but not 
agranulocytosis (Munro et al., 1999). By utilising clozapine registry data, these studies 
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have benefited from large sample sizes. However, the information recorded on drug 
registries is limited, and not subjected to verification. Furthermore, the sample will be 
biased towards patients that have remained on the treatment long-term and thus may not 
be generalisable to a cohort of patients starting clozapine. 
Dosage and pharmacokinetics 
Clozapine dosage has not been associated with agranulocytosis or neutropenia in 
observational studies (Atkin et al., 1996; Munro et al., 1999). Furthermore, there is no 
evidence to suggest an association with plasma concentrations of clozapine and/or its 
major metabolites (Hasegawa et al., 1994; Centorrino et al., 1995; Combs et al., 1997; 
Mauri et al., 1998; Oyewumi et al., 2002). However, previous studies have either failed to 
include patients with abnormally low neutrophil levels (Centorrino et al., 1995; Combs et 
al., 1997; Mauri et al., 1998; Oyewumi et al., 2002) or control for treatment duration or 
dosage (Hasegawa et al., 1994; Centorrino et al., 1995). Lastly, considering the marked 
inter-individual variation in clozapine plasma levels (Olesen et al., 1995), studies have been 
conducted in small samples (Hasegawa et al., 1994). 
Genetic 
The possibility of a genetic component to CIA was implicated from an early stage because 
the incidence in Finland was 20 times higher than other countries such as Austria, 
Switzerland and West Germany where the drug was widely used (Griffith & Saameli, 1975). 
Furthermore, there have been reports of concordant manifestations of CIA in monozygotic 
twins (Horacek et al., 2001; Anil Yagcioglu et al., 2011). Two early studies suggested that a 
direct familial gene was unlikely to be responsible for CIA. In 1977, De La Chapelle and 
colleagues found no evidence of significant parental consanguinity or genetic kinship in a 
six-generation pedigree analysis (de la Chapelle et al., 1977) and Amsler and colleagues 
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also failed to identify a genetic factor that could have been responsible for agranulocytosis 
in the Finnish patients (Amsler et al., 1977).  
The majority of genetic association studies have focused on candidate genes involved in 
immune response from the human leukocyte antigen (HLA) region, although some studies 
have investigated the role of non-HLA genes (Opgen-Rhein & Dettling, 2008; Chowdhury et 
al., 2011). The first genome-wide association study (GWAS) study was recently reported, 
providing considerable support for the role of HLA genes (Goldstein et al., 2014). This 
section describes previous studies implicating (i) HLA genes, (ii) non-HLA genes in the 
MHC, and (iii) non-MHC genes in CIA.  
HLA genes 
HLA genes are located in the major histocompatibility complex (MHC) on chromosome 6 
(6p21.31-32). MHC genes are divided into three groups: class I, class II and class III. HLA 
genes HLA-A, -B and –C are MHC-class I genes and HLA-DR, -DP, and –DQ are class II genes. 
Given HLA genes encode proteins that are responsible for regulating the immune system, 
it was reasonable to investigate associations between polymorphisms in these genes and 
CIA (Chowdhury et al., 2011). In 1990, Lieberman and colleagues conducted the first case 
control study of CIA in 6 cases and 25 clozapine-treated controls. They performed HLA 
typing because of an observed association in their sample between Ashkenazi Jewish 
ancestry and CIA and found that HLA-B38 was present in 86% of cases versus 20% of 
controls. Furthermore, a three-allele haplotype known to occur frequently in the 
Ashkenazi Jewish population, HLA-B38/DR4/DQw3, was present in all 5 of the Ashkenazi 
Jewish cases and only 12% of controls of the same ancestry (Lieberman et al., 1990). This is 
a marked overrepresentation of this haplotype, which is present in approximately 10-12% 
of people with Ashkenazi Jewish ancestry in the US and in 0.4-0.8% of people with 
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European ancestry. The association of HLA-B38 and the HLA-B38/DR4/DQw3 haplotype 
was also significant in further studies from the same research group after the inclusion of 
31 additional Jewish and non-Jewish CIA cases, although the original cases were not 
excluded (Yunis et al., 1992; Yunis et al., 1995). Furthermore, typing of class II alleles 
revealed a significant overrepresentation of HLA-DRB1*0402, -DQB1*0302 and -
DQA1*0301 and an underrepresentation of -DRB1*011 and -DQB1*0301 antigens in CIA 
patients of Ashkenazi Jewish ancestry (Yunis et al., 1995). Significant associations of HLA-
DR*02, -DQB1*0502 and –DQA1*0102 were observed in patients with non-Jewish 
European ancestry (Yunis et al., 1995).  
Valevski and colleagues provided independent replication for the association of HLA-B38, 
which was present in 72% (8/11) of CIA cases and 12% (6/50) of controls, both of Israeli 
Jewish ancestry (Valevski et al., 1998). However, none of the 5 CIA cases of Jewish ancestry 
in a study by Amar and colleagues carried the HLA-B38 antigen (Amar et al., 1998) and 
Dettling and colleagues failed to find an association in 31 German CIA cases and 77 
controls (Dettling & Cascorbi, 2001; Dettling et al., 2001). 
Amar and colleagues found that HLA-DQB1*0201 was present in all 5 CIA cases and 54% 
(7/13) of controls (Amar et al., 1998). Dettling and Cascorbi also found that HLA-
DQB1*0201 was more common in CIA cases (43%, 13/30) than controls (26%, 25/77), 
although the difference was not statistically significant (Dettling & Cascorbi, 2001). In 
addition, significant associations at HLA-DQB1*0502, -DRB1*0202, -DRB3*0202 and -Cw7 
were found (Dettling & Cascorbi, 2001; Dettling et al., 2001). In an extended sample size of 
42 CIA cases, Dettling and colleagues found significant associations at two Cw7-related 
haplotypes (HLA-Cw7/B18 and -Cw7/B39), a further two-locus haplotype (HLA-
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DRB5*0201/DRB4*000) and three three-locus haplotypes (HLA-Cw7/B18/DRB5*000, -
Cw7/B39/DRB5*000 and -Cw7/B44/DRB5*000) (Dettling et al., 2007). 
In a Finnish sample of 26 CIA cases and 19 controls, Lahdelma and colleagues found that 
HLA-A1 was present in 12% of CIA cases, 58% of clozapine-treated controls and 20% of 
healthy controls and thus could be considered a marker for successful treatment and low 
risk of agranulocytosis (Lahdelma et al., 2001). A large study conducted by Claas and 
colleagues in 1992 failed to find any association of HLA-A, -B, -C, -DR or –DQ markers in 
103 CIA cases and 95 controls (Claas et al., 1992). However, this study has been criticised 
on methodological grounds because very little clinical information was given about the 
samples and cases were pooled across different European populations (Dettling et al., 
2001).  
In 2011, Athanasiou and colleagues looked for association with 74 candidate genes in 33 
CIA cases and 54 controls from the US, Russia and South Africa and found significant 
associations for variants within five genes: HLA-DQB1, HLA-C, HLA-DRD1, NTSR1 and 
CSF2RB (Athanasiou et al., 2011). Using a previously reported replication sample of 49 CIA 
cases and 79 controls (Dettling & Cascorbi, 2001; Dettling et al., 2001; Dettling et al., 
2007), they found a significant association with HLA-DQB1 6672G>C (OR=16.9), that was 
present in 21.5% of the combined cases and 1.6% of combined controls (Athanasiou et al., 
2011). The sensitivity and specificity of HLA-DQB1 6672G>C in the combined sample was 
21.5 and 98.4, respectively. On the basis of this study, HLA-DQB1 6672G>C was marketed 
as a genetic predictive test but the low sensitivity limited its clinical utility and it has now 
been withdrawn due to the low uptake (Chowdhury et al., 2011).  
Considerable support for the role of HLA genes in CIA came from a recently published 
study by the Clozapine-Induced Agranulocytosis Consortium (CIAC) (Goldstein et al., 2014). 
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They conducted a comprehensive genetic study including a genome-wide association 
study (GWAS), whole exome sequencing, copy number variation, and imputed HLA alleles 
in up to 163 cases with clozapine-induced neutropenia, 249 clozapine-exposed controls 
without neutropenia and 7970 unexposed controls. They found that two amino acid 
polymorphisms in the MHC were independently and significantly associated with CIA; HLA-
DQB1 (126Q) and HLA-B (158T) (Goldstein et al., 2014). However, it should be noted this 
sample is not independent of earlier studies. 
Non-HLA genes in MHC 
One research group investigated whether non-HLA genes in the MHC region contributed 
to the genetic risk of CIA. They hypothesised that the association of different HLA types in 
Ashkenazi Jewish and non-Jewish CIA patients could be caused by the linkage 
disequilibrium of a common genetic marker (Turbay et al., 1997). The role of heat shock 
protein 70 (HSP-70) genes, located within the class III region of the MHC, were examined 
due to their role in immune system regulation (Corzo et al., 1995). Variants within HSP70-1 
and HSP70-2 were found to be in linkage disequilibrium with HLA class I and class II 
markers that had been previously associated with CIA in both Ashkenazi Jewish and non-
Jewish patients (Corzo et al., 1994). The clozapine control group had an excess number of 
HSP70-1 C and HSP70-2 8.5kb variants compared to CIA patients, suggesting they may 
have a protective role (Corzo et al., 1995). Furthermore, tumor necrosis factor (TNF) 
microsatellites are in linkage disequilibrium with HLA-B and –DR variants (GarciaMerino et 
al., 1996), and they found that TNF b4 and d3 microsatellite alleles were overrepresented 
in both Ashkenazi Jewish and non-Jewish patients with CIA, whereas the d5 microsatellite 
was underrepresented (Turbay et al., 1997). However, these findings are yet to be 
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replicated in an independent sample and there is no evidence to suggest that these genes 
account for the association of HLA genes with CIA. 
Non-MHC genes 
Non-immune mediated hypotheses have prompted other candidate gene studies. Based 
on the hypothesis that a defective oxidative mechanism is the cause of CIA, Ostrousky and 
colleagues investigated the candidate gene dihydronicotinamide riboside (NRH) quinone 
oxidoreductase 2 (NQO2), located on chromosome 6p25 (Ostrousky et al., 2003). They 
found a significant association of polymorphisms in NQO2 in 18 CIA cases and 80 
clozapine-treated controls. NQO2 has been implicated in the detoxification of chemicals 
and protection of cells against drug-induced oxidative and electrophilic stress (Long & 
Jaiswal, 2000). Ostrousky and colleagues suggested that NQO2 is involved in the 
detoxification of clozapine metabolites and if this detoxification is not sufficiently 
effective, the reactive metabolites of clozapine could accumulate in neutrophils leading to 
apoptosis (Ostrousky et al., 2003). However, these findings are yet to be replicated in an 
independent sample.  
Because neutrophils can generate hypochlorous acid via the NADPH/MPO pathway, which 
is capable of oxidizing clozapine to reactive metabolites, there have been studies 
investigating the role of polymorphisms that alter MPO and NADPH activity (Dettling et al., 
2000; Mosyagin et al., 2004). Dettling and colleagues found no association of G-463A, a 
polymorphism in MPO that has been shown to decrease MPO activity, in 31 CIA cases and 
77 controls (Dettling et al., 2000). However, Mosyagin and colleagues found that AA 
carriers of this variant were significantly overrepresented in CIA cases (Mosyagin et al., 
2004). No significant associations were found for C242T and A640G polymorphisms within 
NADPH subunit CYBA (Mosyagin et al., 2004). Recently, Lobach and Uetrecht 
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demonstrated that the binding of clozapine to neutrophils was decreased 2-fold in MPO 
knockout mice and 6-7 fold in gp91 knockout (NADPH oxidase null) mice (Lobach & 
Uetrecht, 2014). 
To assess the hypothesis that genetic variants of leukocyte Fcγ receptors modulate the risk 
for CIA, Mosyagin and colleagues compared the frequency of polymorphisms in FcγRIIa, 
FcγRIIIa FcγRIIIb in 48 patients with CIA and 75 controls (Mosyagin et al., 2005). However, 
the lack of association between CIA and Fcγ receptor polymorphisms indicates that these 
receptors are unlikely to play a major role in CIA (Mosyagin et al., 2005). Lastly, Dettling 
and colleagues found no evidence of a role of polymorphisms in CYP2D6, a gene involved 
in clozapine metabolism (Dettling et al., 2000). 
In 2013, a whole exome sequencing study of 24 Finnish cases with neutropenia and 24 age 
and sex matched controls did not identify any variants that were significantly associated 
after correction for multiple testing, although the sample size was small (Tiwari et al., 
2014). 
 In conclusion, previous studies indicate that the genetic aetiology of CIA and neutropenia 
is complex and is likely to involve several genes. The rare incidence of CIA has limited the 
availability of suitable patients and thus studies have small sample sizes. Furthermore, 
most studies have been conducted by four or five research groups and there is a 
considerable overlap between study samples (Zhang & Malhotra, 2013). Nevertheless, HLA 
markers in association with CIA have emerged as a consistent finding across studies. A 
comprehensive genetic analysis in a well-powered independent sample is required to 
further investigate the role of genetics in CIA and neutropenia. 
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1.6. Discontinuation of clozapine 
There are numerous reasons why clozapine treatment is discontinued, other than the 
occurrence of agranulocytosis or neutropenia. The rates of discontinuation of clozapine 
are lower than for other antipsychotics; the SOHO study of 7186 adult outpatients found 
that clozapine (20.5%) and olanzapine (23%) had the lowest rates of discontinuation after 
12 months of treatment and quetiapine (48.6) and amisulpride (41.8) had the highest 
(Haro et al., 2006). However, a substantial number of patients will still cease clozapine 
treatment, often causing a rapid deterioration in psychotic symptoms (Seppala et al., 
2005; Atkinson et al., 2007). Clozapine cessation has been associated with increased rates 
of compulsory treatment, hospitalisation, and poorer functioning in living and vocational 
activities in comparison to those that continue (Wheeler et al., 2009b). Atkinson and 
colleagues found that global functioning significantly worsened after clozapine 
discontinuation and the number of inpatient days increased by an average of 45.7 in the 
year following clozapine discontinuation compared to the previous year (Atkinson et al., 
2007).  
The rates of clozapine discontinuation reported by previous studies range from 20-54% in 
study durations from 6 months to 15 years (Moeller et al., 1995; Laker et al., 1998; 
Ciapparelli et al., 2000; Hayhurst et al., 2002; Ciapparelli et al., 2003; MacGillivray et al., 
2003; Whiskey, 2003; Krivoy et al., 2011; Davis et al., 2014). In a 15-year naturalistic 
retrospective study, 24% of all patients starting clozapine had discontinued after 1 year, 
32% by 2 years and 50% by 7 years of treatment (Davis et al., 2014). Studies indicate that 
20-34% of patients will discontinue within the first year of treatment (Munro et al., 1999; 
Haro et al., 2006) and 35-44% will discontinue within two years (Laker et al., 1998; 
Ciapparelli et al., 2000; Hayhurst et al., 2002). Rates reported in studies with longer 
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durations suggest that 45% will discontinue with 3 years (MacGillivray et al., 2003) and 
54% within 4 years of clozapine onset (Ciapparelli et al., 2003). Discontinuations are most 
likely within the first year of treatment; two studies reported that 66% (Pai & Vella, 2012) 
and 78% (Krivoy et al., 2011) of total discontinuation events occurred during the first year. 
However, Ciapparelli and colleagues in a four-year naturalistic study found that only 33% 
of discontinuation events occurred during the first year of treatment and 65% within 18 
months (Ciapparelli et al., 2003). Davis and colleagues concluded that the highest risk for 
discontinuation was between 3 and 6 months from the start of treatment (Davis et al., 
2014). 
Considering the favourable outcomes of clozapine treatment and poor prognosis for those 
that discontinue, efforts have been made to understand the causes of discontinuation and 
to identify patients that may be at increased risk.  
1.6.1 Reasons for discontinuation 
Several retrospective studies have identified non-adherence, patient decision, adverse 
effects, death and inadequate response as reasons for discontinuation of clozapine 
(Ciapparelli et al., 2000; Ciapparelli et al., 2003; Atkinson et al., 2007; Taylor et al., 2009; 
Krivoy et al., 2011; Pai & Vella, 2012; Davis et al., 2014; Mustafa et al., 2015). 
Non-adherence and patient decision 
There have been inconsistent approaches to the way that patient decision and non-
adherence have been classified in previous studies. Some studies have assigned patient 
decision and non-adherence as mutually exclusive causes (Pai & Vella, 2012) and others 
have assigned them together (Taylor et al., 2009; Krivoy et al., 2011; Davis et al., 2014). In 
a study of 151 discontinued patients, Pai and Vella found that patient decision accounted 
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for 40% of discontinuations and non-compliance for 36% (Pai & Vella, 2012). Other studies 
that have considered these reasons together (called non-adherence or non-compliance) 
have consistently found non-adherence to be the single most common reason for 
discontinuation (Leppig et al., 1989; Krivoy et al., 2011). In 2009, Taylor and colleagues 
compared the reasons for discontinuation of clozapine with a matched cohort of patients 
discontinuing risperidone injection, and found that non-adherence accounted for 48% of 
discontinuations (Taylor et al., 2009). Other rates of discontinuations due to non-
adherence range from 31-55% (Ciapparelli et al., 2003; Atkinson et al., 2007; Krivoy et al., 
2011; Davis et al., 2014; Mustafa et al., 2015). However, although non-adherence and 
patient decision have been identified as major reasons for discontinuation of clozapine, 
there has been no exploration of reasons behind this choice. 
Adverse effects 
Adverse drug reactions (ADRs) or intolerable side effects attributed to clozapine are a 
common cause of discontinuation. Previous studies indicate that 25-35% of 
discontinuations are due to ADRs (Atkinson et al., 2007; Taylor et al., 2009; Krivoy et al., 
2011; Davis et al., 2014; Mustafa et al., 2015), although there have been reports of lower 
frequencies; 17% (Pai & Vella, 2012) and 9% (Ciapparelli et al., 2003). However, the role of 
ADRs may have been underestimated due to discontinuations secondary to ADRs being 
attributed to non-adherence or patient decision. 
Haematological side effects, particularly neutropenia, are the most common ADRs cited as 
a reason to discontinue clozapine (Pai & Vella, 2012; Davis et al., 2014; Mustafa et al., 
2015). There is a wide range of other reasons reported, but common causes involve 
cardiovascular (hypotension, tachycardia), central nervous system (seizures, somnolence) 
and fever (Pai & Vella, 2012; Davis et al., 2014; Mustafa et al., 2015). A recent review by 
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Nielsen and colleagues concluded that a number of these cited side effects do not 
necessarily warrant discontinuation (Nielsen et al., 2013). Although agranulocytosis should 
always lead to prompt discontinuation, previous research has shown that in many cases 
neutropenia is transient or not related to clozapine, and 70-80% can be reinstated on 
clozapine (Manu et al., 2012; Meyer et al., 2015). Furthermore, in some patients benign 
ethnic neutropenia (BEN) may be present, particularly in those of African and Middle 
Eastern descent (Rajagopal, 2005). Those with BEN have low baseline neutrophil levels and 
many can be successfully reinstated with adjusted monitoring thresholds (Nielsen et al., 
2013). In regards to cardiovascular adverse effects, myocarditis and cardiomyopathy 
should cause immediate discontinuation (Manu et al., 2012). However, hypotension and 
tachycardia are common side effects of clozapine that could be managed by dose 
reduction, providing that myocarditis and cardiomyopathy are excluded (Nielsen et al., 
2013). Furthermore, seizures can be managed by dose reduction or addition of 
antiepileptic medication (Nielsen et al., 2013). 
Death 
A study in 2007 by Atkinson and colleagues found that 12 out of 35 patients (35%) that 
discontinued clozapine died (Atkinson et al., 2007), which led to some concern over the 
causes of death in patients taking clozapine. Other cross-sectional studies of clozapine 
discontinuation have reported death to account for 10% (Mustafa et al., 2015) and 13% 
(Davis et al., 2014) of clozapine discontinuations. Taylor and colleagues, in a matched 
cohort of patients discontinuing risperidone injection, found that 13% of clozapine 
discontinuations were due to death, a rate that was significantly higher than those treated 
with risperidone (Taylor et al., 2009). However, patients taking clozapine are more likely to 
have a longstanding illness and greater antipsychotic exposure, thus limiting the 
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comparability of these groups. Furthermore, patients stabilised on clozapine tend to 
remain on the treatment for many years, a factor that is likely to confound results from a 
cohort of patients who discontinue treatment. Contrary to these findings, there is good 
evidence that clozapine decreases all-cause mortality (Hayes et al., 2015). Nonetheless, 
these studies emphasise the need for close monitoring of physical conditions when 
undergoing clozapine treatment (Taylor et al., 2009). 
Inadequate response 
The majority of previous studies have found that inadequate response to clozapine 
treatment is cited as a reason for only 2-3% of discontinuations (Taylor et al., 2009; Pai & 
Vella, 2012; Davis et al., 2014; Mustafa et al., 2015). In a comparison with risperidone, 
patients receiving clozapine were less likely to discontinue due to inadequate response 
(Taylor et al., 2009). However, two other studies reported larger estimates; Ciapparelli and 
colleagues reported inadequate response to account for 39% of discontinuations within 
two years and 28% within four years (Ciapparelli et al., 2000; Ciapparelli et al., 2003), and 
Krivoy and colleagues found that insufficient response accounted for 19% of 
discontinuations (Krivoy et al., 2011). This disparity may be due to the small sample size in 
these two studies, differences in the study populations and differences in the definition of 
inadequate response. Given that non-response to clozapine has been estimated between 
40-70% (Kane et al., 1988; Lieberman et al., 1994b), this result is unlikely to reflect the true 
rates of inadequate response to clozapine but rather that it is seldom recorded as the 
primary reason to discontinue treatment. 
Other reasons 
There have been other cited reasons for clozapine discontinuation. Ciapparelli and 
colleagues found that 24% of discontinuations within four years were due to an inability to 
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travel to the treatment centre for monitoring (Ciapparelli et al., 2003). Davis and 
colleagues reported that 19% of discontinuations were due to administrative reasons 
(Davis et al., 2014) and a minority of females will discontinue due to pregnancy (Ciapparelli 
et al., 2003).  
A limitation of studies assessing the reasons for clozapine discontinuation is the use of 
mutually exclusive categories. In many cases, the reasons for discontinuation will have 
been multifactorial. For example, a patient (or clinician) may be more likely to tolerate an 
ADR and be willing to persevere with clozapine if they are experiencing a good clinical 
response to clozapine, but might instead discontinue clozapine, citing adverse effects, in 
the absence of a clinical response. The decision to discontinue clozapine is likely to be a 
judgement as to the balance of the likely benefits versus harms of continuing versus 
stopping clozapine, taking into account the views of the patient and of his or her carers. 
Nonetheless, these studies have highlighted the key primary causes of discontinuation of 
clozapine.  
1.6.2 Predictors of discontinuation 
Several studies have attempted to identify patients that may be at an increased risk of 
clozapine discontinuation. An older age at clozapine initiation has been associated with 
greater rates of discontinuation (Munro et al., 1999; MacGillivray et al., 2003; Whiskey, 
2003; Krivoy et al., 2011; Davis et al., 2014), an association that is not related to length of 
illness (Krivoy et al., 2011). MacGillivray and colleagues found that people who started 
clozapine at age 50+ were four times more likely to stop taking clozapine within three 
years than people ages 17-29 years (MacGillivray et al., 2003). There is evidence to suggest 
that older age at initiation is associated with non-patient-initiated but not patient-initiated 
discontinuations (Davis et al., 2014). Black African/American ethnicity in the USA and 
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African/Caribbean ethnicity in the UK has consistently been associated with a higher rate 
of clozapine discontinuation (Moeller et al., 1995; Munro et al., 1999; Rosenheck et al., 
2000; Kelly et al., 2006; Davis et al., 2014). The increased rate of haematological side 
effects (specifically benign ethnic neutropenia) found in Black African/Caribbean patients 
(Moeller et al., 1995; Munro et al., 1999; Davis et al., 2014) has been suggested to account 
for this association. Krivoy and colleagues found an association between comorbid 
substance abuse and discontinuation of clozapine (Krivoy et al., 2011). However, this was 
not replicated by another study (Moeller et al., 1995), although the follow-up period was 
shorter. Davis and colleagues found a significant association for less symptomatic 
improvement and noted there were higher rates of discontinuation in females, although 
this was not statistically significant (Davis et al., 2014). One study found that patients with 
bipolar disorder were two times more likely to discontinue than patients with 
schizophrenia or schizoaffective disorder, despite the fact patients with bipolar disorder 
experienced a greater response to clozapine (Ciapparelli et al., 2000). Lastly, there is 
evidence to suggest that clinician experience can impact discontinuation rates. Whiskey 
and colleagues found that discontinuation rates were affected by the prescribing hospital 
and the lowest rates in their study were from a London hospital with a long history in 
prescribing clozapine (Whiskey, 2003). A lack of experience may explain why some 
patients are unnecessarily discontinued (Nielsen et al., 2010). 
In conclusion, approximately 40% of patients will discontinue clozapine within 24 months 
of initiation, which carries a poor prognosis. The most common reasons for clozapine 
discontinuation identified in previous studies are ADRS, patient decision and non-
adherence. An older age at clozapine initiation, Black African/Caribbean ethnicity and 
substance abuse have been found to increase risk of clozapine discontinuation. However, 
the majority of previous studies have not been conducted in patients receiving their first 
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trial of clozapine and thus the identified reasons for discontinuing may have been biased 
by previous clozapine trials. Furthermore, although non-adherence and patient decision 
have been identified as major reasons for discontinuation of clozapine, there has been no 
exploration of reasons behind this choice. 
1.7. Clozapine response 
Although the superior efficacy of clozapine has been consistently demonstrated, not all 
patients will respond to clozapine. This section provides an overview of studies relating to 
how response to clozapine is measured and defined, the proportion of patients that have 
been found to respond and predictors of clozapine response.  
1.7.1 Clinical rating scales used in psychiatric research 
There are several rating scales used in psychiatric research to assess response. One of the 
most widely used scales is the Brief Psychiatric Rating Scale (BPRS), which measures 18-24 
different psychiatric symptoms, depending on the version, ranging from depression to 
anxiety and hallucinations (Overall & Gorham, 1962). The Positive and Negative Syndrome 
Scale (PANSS) measures 30 different symptoms specifically related to schizophrenia, and is 
widely used in the study of antipsychotic efficacy (Kay et al., 1987). Each symptom in the 
BPRS and PANSS is rated from 1-7. The Scale for the Assessment of Negative Symptoms 
(SANS) measures negative symptoms of schizophrenia, for example affective flattening, 
alogia, apathy and anhedonia (Andreasen, 1983), and the Scale for the Assessment of 
Positive Symptoms (SAPS) measures positive symptoms of schizophrenia, for example 
hallucinations, delusions, bizarre behaviour and formal thought disorder (Andreasen, 
1984). Each symptom in the SAPS and SANS is rated from 0 to 5. The Clinical Global 
Impressions (CGI) scale is a global measure comprised of two scores (i) CGI-Severity (CGI-
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S), and (ii) CGI-Improvement (CGI-I) (Guy, 1976). CGI-S is a seven-point scale measuring the 
severity of the illness in question and CGI-I is a seven-point scale measuring the change in 
psychopathology from baseline, frequently treatment initiation. Ratings take into account 
all available information (Busner & Targum, 2007). The CGI is often selected due to the 
ease and speed of application in comparison to the BPRS or PANSS, and has been 
demonstrated to have equivalent sensitivity (Leucht & Engel, 2006). General functioning 
scales such as the Global Assessment of Functioning (GAF), based on the Global 
Assessment Scale (Endicott et al., 1976), have been less frequently used. 
Several studies have made direct comparisons between these measures (Leucht et al., 
2006). A CGI-S score of 3 (mildly ill), 4 (moderately ill) and 5 (markedly ill) approximately 
corresponds to BPRS total scores of 31, 41 and 53 (Leucht et al., 2005a), and PANSS total 
scores of 58, 75 and 95 (Leucht et al., 2005b), respectively. A CGI-I score of 3 (minimally 
improved) corresponds to a 24-30% reduction in BPRS (Leucht et al., 2005a) and a 19-28% 
reduction in PANSS (Leucht et al., 2005b). A CGI-I score of 2 (much improved) 
approximately corresponds to a 40-53% reduction in BPRS score (Leucht et al., 2005a; 
Leucht & Engel, 2006) and 40-53% reduction in PANSS (Leucht et al., 2005b), although 
another study reported a 22-29% reduction in PANSS (Rabinowitz et al., 2010).  
1.7.2 Defining clozapine response 
The lack of consensus regarding how to define response to antipsychotic treatments has 
been a significant issue for some time (Suzuki et al., 2012). Consequently, there has been 
considerable variability in the definition of clozapine response used, resulting in limited 
comparability between studies. Several studies have used the absolute response criteria 
defined in Kane and colleagues’ landmark clinical trial; a 20% decrease in BPRS total score, 
and either a post-treatment CGI-S score ≤ 3 or BPRS ≤ 35 (Kane et al., 1988). Other studies 
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have focused purely on symptom reduction, for example a ≥ 20% decrease in PANSS or 
BPRS total score (Meltzer et al., 1989a; Rosenheck et al., 1998; Umbricht et al., 2002; 
Ciapparelli et al., 2004; Usall et al., 2007; Kelly et al., 2010; Suzuki et al., 2012). Few studies 
have included GAF scores (Ciapparelli et al., 2003) or defined response specifically in terms 
of positive (SAPS) or negative (SANS) symptom reduction (Mauri et al., 2003; Meltzer et al., 
2003b). More stringent thresholds (≥ 50% decrease in BPRS total score) have been used in 
longer-term studies (Ciapparelli et al., 2004). Because of these difficulties, other 
investigations have turned to more pragmatic outcomes such as time to rehospitalisation 
(Rosenheck et al., 2011; Nielsen et al., 2012) or time to discontinuation (Lieberman et al., 
2005; Kroken et al., 2014). 
A recent review recommended a response definition of ≥20% decrease in BPRS or PANSS 
total score or a CGI-Improvement score of 2 or 1 (Suzuki et al., 2012). However, defining 
response solely based on relative change ignores the importance of baseline levels 
(Mortimer, 2007) and will favour highly symptomatic patients because they have more 
room for improvement and thus the measurable effect of clozapine will be greater 
(Rosenheck et al., 1998). This is also important considering that in many studies where 
response is defined, patients with TRS were excluded. The use of a remission criteria, 
which is the clinical goal, has also been recommended (Mortimer, 2007). Due to results 
varying considerably by the response definition chosen, presenting a range of definitions 
has been recommended to evaluate whether effects remain consistent (Leucht et al., 
2007b).  
1.7.3 Proportion responding to clozapine 
The wide variability in the proportion of patients reported to have responded to clozapine 
treatment appears to stem from, at least in part, the varying response definitions and 
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durations of treatment trial (Suzuki et al., 2012). Kane and colleagues found that 30% of 
patients with TRS responded to clozapine within six weeks (Kane et al., 1988). In a trial of 
52 weeks, Lieberman and colleagues found that 50% of TRS and 76% of treatment-
intolerant patients responded (Lieberman et al., 1994b). A long-term (48 months) 
naturalistic study found 65% of schizophrenia patients experienced a 50% reduction in 
BPRS (Ciapparelli et al., 2003). In general, other clinical trials and naturalistic studies fall 
within these reports, indicating that clozapine substantially reduces psychotic symptoms in 
30-70% of TRS patients (Kane et al., 1988; Lieberman et al., 1994b; Wahlbeck et al., 2000; 
Semiz et al., 2007).  
1.7.4 Timing of clozapine response 
There has been substantial interest in the duration of clozapine treatment required to 
evaluate response to clozapine. If such a time could be identified, patients who have not 
shown significant improvement could be regarded as non-responders and their clozapine 
treatment discontinued. If this specified time is too short, patients who would have 
eventually experienced benefit may be discontinued, and if too long, nonresponsive 
patients may continue to unnecessarily receive treatment that will not benefit them. 
Previous studies have determined that response can be detected within the first 6-8 weeks 
of treatment (Rosenheck et al., 1999b; Suzuki et al., 2011a) and that early response is 
indicative of later response: response after one week of treatment predicted response at 
five weeks (Stern et al., 1994), and in another study response after four weeks predicted 
response at 16 weeks (Semiz et al., 2007). However, other studies indicate that trials up to 
six months may be required to detect non-response (Lieberman et al., 1994b) and some 
benefits of treatment may only become apparent after long-term follow-up, particularly 
for functional and quality of life measures (Rosenheck et al., 1999b). Although there have 
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been reports that a minority of patients may experience an improvement after six months 
of treatment (Wilson, 1996), there is limited evidence regarding a delayed response 
(Carpenter et al., 1995).  
Studies investigating timing of response are often hindered by a lack of control for dose or 
clozapine plasma concentrations (Schulte, 2003). One study reported that all responders 
achieved response within 8 weeks of a dose escalation and on average 17 days after 
reaching the therapeutic dose at which clozapine response was achieved (Conley et al., 
1997). Furthermore, in new responders at weeks 8, 12, and 24, in spite of a fixed clozapine 
daily dose, mean drug plasma levels progressively increased, up to the point where clinical 
response occurred (Fabrazzo et al., 2002). In addition, clozapine non-responders had a 
mean clozapine concentration below 260 ng/mL, which was significantly lower than the 
average in responders (above 400ng/mL) (Fabrazzo et al., 2002). There is evidence to 
suggest that some patients that do not respond under a normal dose may respond if 
plasma levels are brought above 350 ng/mL (Kronig et al., 1995). 
1.7.5 Predictors of response 
Predictors of clozapine response would be valuable in assisting clinicians in determining if 
clozapine treatment is likely to be beneficial. A number of studies have attempted to 
address this question (Chung & Remington, 2005; Suzuki et al., 2011c). This section 
describes the demographic and clinical, dosage and pharmacokinetic, and genetic 
predictors of response. 
Demographic and clinical 
Despite a large number of studies, there are few reliably replicated clinical or demographic 
predictors of clozapine response. There have been conflicting findings in regards to age at 
61 
 
initiation of clozapine (Meltzer et al., 1989a; Honer et al., 1995b; Rodriguez et al., 1998; 
Rosenheck et al., 1998; Sajatovic et al., 1998; Schall et al., 1999; Hofer et al., 2003; Mauri 
et al., 2003; Semiz et al., 2007; Kelly et al., 2010), age at onset of schizophrenia (Meltzer et 
al., 1989a; Lieberman et al., 1994a; Rodriguez et al., 1998; Mauri et al., 2003; Ciapparelli et 
al., 2004; Semiz et al., 2007; Kelly et al., 2010; Nielsen et al., 2012) and duration of illness 
(Lieberman et al., 1994b; Honer et al., 1995a; Schall et al., 1999; Umbricht et al., 2002; 
Hofer et al., 2003; Mauri et al., 2003). Female gender has been associated with a good 
response, independent of age of onset and chronicity (Mauri et al., 2003; Ciapparelli et al., 
2004; Usall et al., 2007), but other studies have reported either a poor response 
(Lieberman et al., 1994a; Szymanski et al., 1996) or no effect (Hofer et al., 2003; Semiz et 
al., 2007). Furthermore, there have been mixed findings regarding a diagnosis of paranoid 
schizophrenia (Honigfeld & Patin, 1989; Meltzer et al., 1989a; Fenton & Lee, 1993; 
Lieberman et al., 1994b; Honer et al., 1995a; Rosenheck et al., 1998; Semiz et al., 2007) 
and the presence of EPS during typical antipsychotic treatment (Pickar et al., 1994; 
Umbricht et al., 2002). A naturalistic study reported that patients with bipolar disorder in 
comparison to schizoaffective disorder or schizophrenia had significantly better clinical 
response to clozapine (Ciapparelli et al., 2000; Ciapparelli et al., 2003; Ciapparelli et al., 
2004), but this has not been replicated in an independent sample. 
In contrast, findings have been consistent in regards to the level of functioning prior to 
clozapine treatment. An increasing number of hospitalisations, poor functioning and no 
history of independent living have been associated with a poor response to clozapine 
(Fenton & Lee, 1993; Honer et al., 1995a; Nielsen et al., 2012). A recent study investigating 
the impact of premorbid functioning on non-response to clozapine reported a trend for 
social withdrawal, poorer adaption to school and fewer peer relationships in childhood, 
suggesting that clozapine non-responders may represent a distinct subtype of patients 
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(Kelly et al., 2010). Findings have also been consistent in the lack of association with 
ethnicity (Lieberman et al., 1994a; Rosenheck et al., 1998; Kelly et al., 2010). One study has 
reported that smokers experienced greater therapeutic response compared to non-
smokers, despite smoking less than when receiving conventional antipsychotics (McEvoy 
et al., 1999). Interestingly, increased weight gain has been associated with good clinical 
response, independent of age, initial weight, plasma clozapine levels and level of 
psychopathology (Leadbetter et al., 1992; Meltzer et al., 2003b).  
The conflicting results of clinical and demographic predictors of clozapine response may be 
due to the considerable variability in response definitions and trial durations. 
Furthermore, most studies have been conducted in small sample sizes and thus are likely 
to be underpowered.  
Baseline symptoms 
The most consistently reported clinical baseline predictor of clozapine response is higher 
or more severe baseline symptoms as measured by the CGI, total BPRS or PANSS scores 
(Hasegawa et al., 1993; Lieberman et al., 1994b; Rosenheck et al., 1998; Ciapparelli et al., 
2000; Umbricht et al., 2002; Semiz et al., 2007; Kelly et al., 2010). Specifically, high positive 
symptoms and low negative symptoms have been associated with good response 
(Rodriguez et al., 1998; Schall et al., 1999; Umbricht et al., 2002). However, the association 
with negative symptoms is unclear; a large study investigating this question found no 
differences in response between patients with high or low levels of negative symptoms or 
in patients with or without the deficit syndrome (Rosenheck et al., 1999a). The presence of 
suicidal ideation at baseline has been associated with good response (Ciapparelli et al., 
2000). However, rather than implying that there is a superior effect of clozapine in 
patients with high positive or total symptom scores, the association may be simply 
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because highly symptomatic patients have more room for improvement (Rosenheck et al., 
1998). 
Dosage and pharmacokinetic factors 
Analyses of clinical trials have indicated that dosages over 400 mg/day and up to 600 
mg/day are required for optimal clozapine treatment (Davis & Chen, 2004; Kinon et al., 
2004). One study demonstrated a significant dose effect (100 > 300 > 600 mg/day) with 
clozapine response after 16 weeks of treatment (Simpson et al., 1999) and a large 
naturalistic study reported that lower dose predicted a shorter time to hospital admission 
(Nielsen et al., 2012). However, a study comparing clinical trials across the USA and Europe 
found that although dose was higher in the USA (444 mg versus 284 mg), estimates of 
response were similar (Fleischhacker et al., 1994). However, European studies had fewer 
adverse effects, suggesting lower doses could be more tolerable and just as effective 
(Fleischhacker et al., 1994).  
Although clozapine dose and plasma concentrations are correlated, there is a wide inter-
individual variability. Thus, the relationship between clozapine response and plasma levels 
has been more commonly assessed than dose response studies (Mauri et al., 2007). Lower 
clozapine levels have been associated with increased rates of relapse (Xiang et al., 2006) 
and a number of studies indicate that a plasma concentration of at least 350-420 ng/mL is 
required for optimal clozapine response (Perry et al., 1991; Hasegawa et al., 1993; Kronig 
et al., 1995; VanderZwaag et al., 1996; Spina et al., 2000; Llorca et al., 2002; Mauri et al., 
2007). Monitoring of plasma levels is widely utilised in the clinical management of 
clozapine treatment and thus constitutes the most utilised predictor of response. There 
are many factors that influence plasma clozapine levels including age, gender, smoking 
and metabolic factors (Haring et al., 1989; Lane et al., 1999; Kim, 2015).  
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Genetic 
A twin study indicates that there may be a genetic susceptibility to clozapine response 
(Vojvoda et al., 1996). Pharmacogenetic studies have focused largely on candidate genes 
that are either directly involved in the drug mechanism of action, such as neurotransmitter 
receptors, or affect clozapine metabolism and thus influence plasma concentrations 
(Malhotra et al., 2004).  
Neurotransmitter receptors 
Initial studies of clozapine response focused on the dopamine D4 receptor gene (DRD4) 
because of clozapine’s high affinity for D4 in comparison to D2 receptors (Van Tol et al., 
1991). Studies investigating the role of DRD4 in clozapine response have focused on a 48-
base-pair repeat polymorphism, but there have been conflicting findings (Shaikh et al., 
1993; Rao et al., 1994; Kohn et al., 1997; Cohen et al., 1999; Hwang et al., 2012). Ozdemir 
and colleagues (Özdemir et al., 1999) implicated a repeat polymorphism within the first 
intron of DRD4. However, despite the functional nature of these polymorphisms, there is 
limited evidence to support their involvement in treatment response of clozapine 
(Malhotra et al., 2004). 
The dopamine D2 receptor gene (DRD2) has been examined given its action is critical for 
antipsychotic response. Previous studies have focused on the functional polymorphism -
141C Ins/Del in the promoter region of DRD2 (Malhotra et al., 1999). Although there have 
been a number of negative reports (Arranz et al., 1998c; Hwang et al., 2005), a recent 
meta-analysis of DRD2 gene variation in antipsychotic response, including but not limited 
to clozapine, added support for the role of this variant (Zhang et al., 2010). Furthermore, 
an exploratory analysis of 12 SNPs in DRD2 found an association between the Taq1A, 
Taq1B and rs1125394 markers and clozapine response, but only for African-American 
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patients (Hwang et al., 2005). More comprehensive examination of the role of DRD2 may 
be required, but it appears this gene may be more important for other antipsychotics that 
have higher affinity for D2 receptors (Zhang et al., 2010).  
Genetic association studies of the dopamine D3 receptor gene (DRD3) have focused on a 
variant that causes a serine-to-glycine substitution at amino acid position 9 (Ser9Gly, 
rs6280) (Hwang et al., 2010). A meta-analysis by Jonsson and colleagues concluded that 
responders to traditional antipsychotics were observed to have higher Ser allele, and 
homozygote genotype (Ser/Ser or Gly/Gly) frequencies, whereas the opposite was true for 
clozapine responders (Jonsson et al., 2003). However, a recent meta-analysis focusing 
solely on clozapine studies failed to replicate this finding, although there was a trend in the 
same direction (Hwang et al., 2010).  
There are fewer studies examining the possible role of D1 and D5 dopamine receptors in 
clozapine response. Two studies have implicated variants within DRD1 (Potkin et al., 2003; 
Hwang et al., 2007) and although a two-marker haplotype in DRD5 was recently reported 
to be associated with negative symptom response to clozapine, there appears to be very 
little evidence for the role of DRD5 (Hwang et al., 2012). Individually, dopamine receptor 
genes appear to have a minor effect on response to clozapine.  
Due to clozapine’s high affinity for the serotonin 5-HT2A receptor, the role of serotonin 
genes has been investigated in numerous candidate studies. In 1995, Arranz and 
colleagues identified an association between the 102-T/C polymorphism in 5-HT2A and 
clozapine response (Arranz et al., 1995). Although there were a number of subsequent 
negative findings regarding this variant (Malhotra et al., 1996a; Masellis et al., 1998), a 
meta-analysis, including these negative studies, revealed a significant excess of 102C allele 
carriers in clozapine non-responders (Arranz et al., 1998b). Additional support came from 
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a study implicating 1438-G/A, a functional variant in the promoter region of 5-HT2A, and in 
strong linkage disequilibrium with 102-T/C (Arranz et al., 1998a). Furthermore, a less 
common polymorphism in 5-HT2A, 452-His/Tyr has been associated with response (Arranz 
et al., 1996; Arranz et al., 1998a; Arranz et al., 1998b; Masellis et al., 1998) although again 
there are conflicting findings (Malhotra et al., 1996a). Other serotonin-related genes have 
also been examined in pharmacogenetic studies of clozapine response. An association was 
initially reported between a cysteine to serine substitution at amino acid 23 (Cys23Ser) in 
5-HT2C and clozapine response (Sodhi et al., 1995) but this has not been replicated in other 
studies (Malhotra et al., 1996b; Rietschel et al., 1997; Masellis et al., 1998). Although not 
previously thought to be associated (Gutiérrez et al., 2002), recent studies have implicated 
rs1062613 in 5-HT3A in clozapine response (Souza et al., 2010). Additional variants in 
serotonin genes include 267-T/C in 5-HT6 (Yu et al., 1999; Masellis et al., 2001), 5-HT7 
(Masellis et al., 2001), as well as the serotonin transporter gene SLC6A4 (Arranz et al., 
2000a; Tsai et al., 2000; Kohlrausch et al., 2010).  
A study by Arranz and colleagues identified a combination of six polymorphisms in genes 
coding for neurotransmitter receptors that predicted 76.9% of clozapine response, with a 
sensitivity of 95% (Arranz et al., 2000b). However, this was not been replicated in an 
independent sample (Schumacher et al., 2000). Further studies are required to understand 
the genetic contribution of neurotransmitter receptor genes to clozapine drug response.  
Metabolism 
The cytochrome P450 isoform CYP1A2 is primarily responsible for clozapine metabolism. 
Thus, polymorphisms within CYP1A2 may affect clozapine response by impacting on 
clozapine plasma levels. The CYP1A2*1F (-163C>A, rs762551) polymorphism has been 
associated with a decreased response to clozapine (Ozdemir et al., 2001; Eap et al., 2004; 
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Balibey et al., 2011; de Brito et al., 2015). In a sample of 75 individuals, this polymorphism 
was not found to directly impact clozapine plasma levels (Jaquenoud Sirot et al., 2009). 
ABCB1 encodes for the transmembrane transporter P-glycoprotein and has been 
demonstrated to affect plasma clozapine levels (Consoli et al., 2009; Jaquenoud Sirot et al., 
2009). A recent study reported an association between polymorphisms in ABCB1 and 
clozapine response (Lee et al., 2012b).  
Despite a significant number of studies, there is a lack of consistent pharmacogenetic 
findings of clozapine response. This may due to small sample sizes making studies 
underpowered and the significant differences between studies in regards to sample 
characteristics and definition of clozapine response. All the studies to date take a 
candidate gene approach and thus a well-powered GWAS or comprehensive examination 
of these genes is required to further examine the role genetics in clozapine response. 
1.8. Summary and limitations of existing literature 
The clinical course of schizophrenia is highly heterogeneous and 20-30% of patients will 
remain symptomatic and significantly impaired despite antipsychotic treatment. Even 
though the superior efficacy of clozapine has been consistently demonstrated in the 
management of TRS, clozapine remains widely under-prescribed, due, at least in part, to 
the risk of haematological side effects of agranulocytosis and neutropenia. The aetiology 
of clozapine-induced agranulocytosis and neutropenia is currently unknown. The first, and 
only, genome-wide association study (GWAS) conducted by the Clozapine-Induced 
Agranulocytosis Consortium (CIAC) has provided substantial support for the role of 
genetics, specifically for HLA-DQB1 and HLA-B (Goldstein et al., 2014). However, this 
sample is not independent of earlier studies. Although there have been many candidate 
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gene studies in this field, there has been significant overlap of samples (Zhang & Malhotra, 
2013). The rare incidence of agranulocytosis has limited the availability of suitable patient 
samples and thus studies have suffered from small sample sizes. Lastly, over half of the 
individuals who develop clozapine-induced agranulocytosis or neutropenia do not have 
any of the identified risk variants. A comprehensive genetic analysis in a well-powered 
independent sample is required to further investigate the role of genetics in clozapine-
associated agranulocytosis and neutropenia. This is the subject of Chapter 2.  
A substantial proportion of patients will not tolerate clozapine, or find it sufficiently 
efficacious, leading to approximately 40% discontinuing within 24 months of initiation, 
which carries a poor prognosis. The most common reasons for clozapine discontinuation 
identified in previous studies are ADRs, patient decision and non-adherence. An older age 
at clozapine initiation, Black African/Caribbean ethnicity and substance abuse have been 
found to increase risk of clozapine discontinuation. However, the majority of previous 
studies have not been conducted in patients receiving their first trial of clozapine and thus 
the identified reasons for discontinuing may have been biased by previous clozapine trials. 
A cohort of patients initiating clozapine would be the most clinically informative study 
design to examine the reasons and timing of clozapine discontinuation. Furthermore, 
although non-adherence and patient decision have been identified as major reasons for 
discontinuation of clozapine, there has been no exploration of reasons behind this choice. 
Lastly, only one study has been conducted in the UK (Taylor et al., 2009), and given the 
differences in clozapine utilisation across health care systems, there may be limited 
generalisability of other studies to UK patients. I seek to address these limitations in 
Chapter 4. 
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Despite a significant number of studies, there is a lack of consistent findings regarding 
clinical response to clozapine. The somewhat conflicting results of clinical and 
demographic predictors may be due to the considerable variability in response definitions 
as well as trial durations, resulting in limited comparability between studies. Study 
durations tend to be short and consequently may not consider a group of patients that 
take longer to meet the response criteria, but are nonetheless responders (Meltzer et al., 
1989a). Most studies are conducted in relatively small sample sizes and clinical trial data 
may not generalise to patients receiving clozapine in standard health care settings. 
Chapter 5 aims to address these limitations. 
1.9. Aims and objectives 
The aim of this thesis is to investigate and gain novel insights of treatment response and 
the adverse effects of clozapine. To achieve this aim I used a combination of genetic and 
epidemiological approaches. My three primary objectives were: 
1. Identify genetic risk variants associated with clozapine-associated neutropenia 
and agranulocytosis (Chapter 2). To examine genetic associations with clozapine-
associated neutropenia, I conducted analyses incorporating GWAS, HLA allele 
imputation and exome array variation in an independent, homogenous, UK sample 
of 66 clozapine-associated neutropenia cases and 5583 clozapine-treated controls. 
I then combined associated variants from these analyses in a joint meta-analysis 
with data from the CIAC study (Goldstein et al., 2014), giving the largest combined 
study sample of its kind to date.  
2. Examine the risk factors, reasons and timing of clozapine discontinuation 
(Chapter 4). I aimed to assess the reasons for discontinuation of clozapine, 
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investigate the timing of these reasons, determine which ADRs lead to 
discontinuation, and characterise the patients who are at increased risk of 
discontinuing clozapine. For each of these aims, I also explored the differences 
between discontinuations resulting from a clinician-led decision and those from a 
patient decision. To achieve these aims I identified a two-year retrospective 
cohort of all patients starting their first clozapine trial over a five-year period 
(2007-2011, inclusive) in South London & Maudsley (SLaM) NHS Foundation Trust. 
3. Identify demographic and clinical predictors of clozapine response (Chapter 5). I 
aimed to identify demographic and baseline clinical predictors of clozapine 
response, assess whether early improvement is indicative of long-term response, 
and determine the duration of treatment required to detect a response. To 
achieve these aims I retrospectively administered the Clinical Global Impressions 
(CGI) scale to case notes at the start of clozapine treatment and after 1, 2, 3, 6, 9, 
12, 18 and 24 months of treatment to the two-year cohort study of patients with 
TRS receiving their first course of clozapine also used for Objective 2 (Chapter 4). 
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 Chapter 2
Clozapine-associated Neutropenia 
2.1. Summary 
The antipsychotic clozapine is uniquely effective in the management of treatment-
resistant schizophrenia, but its use is limited by its potential to induce agranulocytosis. The 
causes of this, and of its precursor neutropenia, are largely unknown although genetic 
factors are implicated. I sought risk alleles for clozapine-associated neutropenia in a 
sample of 66 cases and 5583 clozapine-treated controls who have never developed 
neutropenia, through a genome-wide association study (GWAS), imputed HLA alleles and 
exome array analysis. I then combined associated variants in a meta-analysis with data 
from the Clozapine-Induced Agranulocytosis Consortium (up to 163 cases and 7970 
controls). The GWAS meta-analysis identified a novel genome-wide significant association 
with clozapine-associated neutropenia and rs149104283 (OR = 4.32, P = 1.79x10-8), 
intronic to transcripts of SLCO1B3 and SLCO1B7, members of a family of hepatic 
transporter genes involved in drug uptake. This group of genes has been previously 
implicated in adverse drug reactions, most prominently simvastatin-induced myopathy 
and also docetaxel-induced neutropenia. Exome array analysis provided evidence for 
gene-wide association between non-synonymous variants within UBAP2 and STARD9. In 
addition, a previously reported association between neutropenia and a variant at HLA-
DQB1 was replicated in a subset of 61 clozapine-associated neutropenia cases and 305 
clozapine-treated controls (OR = 15.6, P = 0.015, positive predictive value = 35.1%). These 
findings implicate biological pathways through which clozapine may act to cause this 
serious adverse effect. 
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2.2. Introduction 
Clozapine is the only licensed medication for treatment-resistant schizophrenia (TRS), 
defined as a failure to respond to at least two antipsychotic trials of sufficient dose and 
duration. Although it is the only treatment with proven efficacy in this severely impaired 
group of patients, (Kane et al., 1988; Leucht et al., 2009) it is substantially under-
prescribed (Royal College of Psychiatrists, 2012) due, at least in part, to the risk of 
haematological side effects of agranulocytosis and neutropenia (i.e., reductions of 
neutrophils to levels below 500/mm3 or 1500/mm3 respectively). The cumulative risk of 
agranulocytosis in those taking clozapine is 0.8% and for neutropenia is 2.9% (Atkin et al., 
1996). The peak incidence for clozapine-induced blood disorders is in the first 6-18 weeks 
of treatment (Atkin et al., 1996; Munro et al., 1999). If undetected, compromised immune 
function secondary to agranulocytosis can be fatal, as happened in a series of patients 
when the drug was introduced in the 1970s, leading to its widespread withdrawal. 
Evidence of its marked effectiveness over other antipsychotics led to Federal Drug Agency 
(USA) approval in 1989 with stipulations about the need for regular blood monitoring to 
aid early detection of blood abnormalities. The monitoring system has been successful in 
reducing the prevalence of agranulocytosis and in the UK the associated fatality rates are 
now very low, estimated between 0.016% and 0.03% of patients treated with clozapine 
(Atkin et al., 1996; Munro et al., 1999). However, the requirement for blood monitoring 
limits the acceptability of the drug to patients, and poses an obstacle to its use in clinical 
practice (Patel, 2012). 
The aetiology of clozapine-induced blood disorders is currently unknown. One of the best-
supported hypotheses relates to the bioactivation of clozapine or a stable metabolite of 
clozapine to a chemically reactive nitrenium ion (Liu & Uetrecht, 1995; Maggs et al., 1995; 
73 
 
Pirmohamed & Park, 1997), which has been shown to cause dose-dependent apoptosis to 
neutrophils at therapeutic levels of clozapine (Williams et al., 2000; Pessina et al., 2006) as 
well as toxicity to stromal cells, the precursors of neutrophils in bone marrow (Pereira & 
Dean, 2006). The reason why only 0.8% of individuals treated with clozapine are affected 
by agranulocytosis has not been fully elucidated, though genetic causes contribute.  
Until recently, genetic studies of clozapine-induced agranulocytosis and neutropenia have 
largely focused on candidate genes from the Human Leukocyte Antigen (HLA) region 
involved in immune response (Opgen-Rhein & Dettling, 2008). Although there have been 
many candidate studies, the rare incidence of clozapine-induced agranulocytosis has 
limited the availability of suitable patients and thus studies have been underpowered 
(Zhang & Malhotra, 2013). Nonetheless, there have been significant recent advances. In 
2011, Athanasiou and colleagues reported a replicated association between HLA-DQB1 
6672G>C and clozapine-induced agranulocytosis (Athanasiou et al., 2011). The first 
genome-wide association study (GWAS) study conducted by the Clozapine-Induced 
Agranulocytosis Consortium (CIAC) has provided substantial evidence for the role of HLA-
DQB1 and HLA-B (Goldstein et al., 2014). However, the sample used in CIAC is not 
independent of earlier studies. A small exome sequencing study did not identify any rare, 
functional variants that were significantly associated with clozapine-induced neutropenia 
(Tiwari et al., 2014). 
2.2.1 Aims of the study 
The aim of the study was to examine the genetic susceptibility to clozapine-associated 
agranulocytosis and neutropenia. The first objective was to conduct analyses incorporating 
GWAS, imputed classical HLA alleles and amino acid polymorphisms, and exome array in 
an independent UK sample. The second objective was to combine associated variants from 
74 
 
these analyses in a joint meta-analysis with the CIAC study (Goldstein et al., 2014), giving 
the largest combined study sample of its kind to date.  
2.3. Method 
2.3.1 Sample description 
Study individuals were from CLOZUK (N=5493) and CardiffCOGS (Cognition in 
Schizophrenia, N=156) samples. All had a clinical or research diagnosis of schizophrenia. 
CLOZUK is comprised of individuals who were prescribed clozapine in the UK and have a 
clinical diagnosis of TRS (Hamshere et al., 2013; Rees et al., 2014; Schizophrenia Working 
Group of the Psychiatric Genomics Consortium, 2014). The CLOZUK study individuals were 
acquired cross-sectionally over a period of three months in collaboration with Novartis 
Pharmaceuticals, one of the drug companies that provide clozapine (Clozaril®), in 
accordance with relevant ethics permissions and the UK Human Tissue Act. All individuals 
were anonymised and only basic demographic details of age, gender, ethnicity and 
diagnosis were provided. Twelve months after sample acquisition, the research team were 
informed of those that had developed neutropenia whilst taking clozapine and where 
available, the recorded lowest neutrophil counts of these individuals were supplied. 
CardiffCOGS is a schizophrenia sample recruited from secondary mental health services in 
South Wales, UK (Carroll et al., 2011; Rees et al., 2014). As part of a comprehensive clinical 
interview, individuals were asked about lifetime clozapine use and occurrence of 
neutropenia. Clinical case notes were used to confirm neutropenia status and lowest 
recorded neutrophil levels were collected. Further detailed information of both samples 
and their ascertainment are described in an open access publication (Rees et al., 2014). 
75 
 
Clozapine-associated neutropenia cases (N=66, 58 from CLOZUK, 8 from CardiffCOGS) 
developed an absolute neutrophil count (ANC) ≤ 1500/mm3 during treatment with 
clozapine. Following the approach of recent studies, (Goldstein et al., 2014; Tiwari et al., 
2014) we assessed cases with agranulocytosis and neutropenia because the success of the 
monitoring system and pre-emptive drug withdrawal in the UK has made agranulocytosis 
extremely rare. This neutrophil count threshold is used in the UK as a trigger to 
discontinue clozapine. Controls (N=5583, 5435 CLOZUK, 148 CardiffCOGS) had received 
clozapine for a minimum of a year without developing an ANC ≤ 2000/mm3. Those who 
had a test result (1500/mm3 < ANC ≤ 2000/mm3) were excluded from all analyses (n=20). 
No differences in age or sex were observed between clozapine-associated neutropenia 
cases and controls (Table 2.1). A chi-squared test demonstrated no evidence of difference 
in gender between controls and clozapine-associated neutropenia cases (X2 = 1.59, P = 
0.208). A Mann-Whitney-Wilcoxon test (as age was not normally distributed) showed no 
differences in age between controls and clozapine-associated neutropenia cases (P = 
0.408). All individuals were of European ancestry, as determined by self-report and 
principal component analysis of GWAS data.  
 Male gender  
N (%) 
Mean age 
(range) 
Controls (N=5583) 3992 (71.5) 41.9 (16-90) 
Clozapine-associated neutropenia cases (N=66) 40 (60.6) 40.3 (20-64) 
Table 2.1. Sample characteristics. Gender and age of clozapine-associated neutropenia 
cases and clozapine-treated controls. 
2.3.2 Genotyping 
Genotyping was performed at the Broad Institute, Cambridge, MA, USA. CardiffCOGS and 
part of the CLOZUK sample (40 cases and 3573 controls) were genotyped on Illumina 
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HumanOmniExpressExome-8v1 and the remainder of the CLOZUK sample (26 cases and 
2098 controls) were genotyped on both Illumina HumanOmniExpress-12v1 and Illumina 
HumanExome BeadChip.  
2.3.3 Genome-wide association study 
Genotyping arrays provide an informative backbone of tag single nucleotide 
polymorphisms (SNPs) thus making large-scale whole-genome genotyping affordable. 
Quality control procedures and imputation were conducted at the Broad Institute using 
the Psychiatric Genomics Consortium (PGC) pipeline (Schizophrenia Working Group of the 
Psychiatric Genomics Consortium, 2014) and detailed in Appendix 1. Imputation was 
performed using IMPUTE2 (Howie et al., 2009) and a reference panel from the full 1000 
Genomes Project dataset (freeze date August 2012). Imputation was conducted on a 
combined dataset of the two arrays. 
I conducted principal component estimation using EIGENSTRAT (Price et al., 2006) to 
exclude outliers and assess population stratification (Figure 2.1 and Figure 2.2). I included 
genotyping array as well as the first three principal components as covariates to account 
for population structure. Sensitivity analyses increasing the number of principal 
components included to either 5 or 10 did not alter the results or improve statistical 
inflation values (lambda or QQ plot inspection). SNPs with allele frequencies that differed 
between genotyping arrays at P < 1 x 10-5 were excluded (Figure 2.3). These 124 SNPs 
were imputed but confirmed to be non-ambiguous. Common SNPs with high imputation 
quality were selected for analysis (INFO > 0.8, MAF > 0.01 in cases and controls). 
Association analysis was performed using logistic regression in PLINK (Purcell et al., 2007) 
and SNPs functionally annotated using the Scripps genome advisor (Erikson et al., 2014). 
PLINK was used to identify index SNPs in relative linkage equilibrium (--clump-p1 0.0001 --
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clump-p2 0.0001 --clump-r2 0.1 --clump-kb 3000) and the SNP with the highest association 
was selected as the index SNP. A genome-wide significance level (GWS) of P < 5 x 10-8 was 
used to determine significance, which corresponds to a Bonferroni multiple testing 
correction for 1 million SNPs in linkage equilibrium.  
 
Figure 2.1. Principal component analysis. Figure displays principal component 1 and 2. 
Points represent individual samples; black points represent clozapine-treated controls and 
red points represent neutropenia cases. Grey lines represent exclusions (top left corner 
included). 
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Figure 2.2. Principal component analysis of included samples. Figure displays principal 
component 1 and 2. Points represent individual samples included in GWAS analysis; black 
points represent clozapine-treated controls and red points represent neutropenia cases. 
 
Figure 2.3. SNP differences by genotyping array. QQ plot of GWAS comparing SNPs 
genotyped on HumanOmniExpressExome-8v1 and Illumina HumanOmniExpress-12v1. 
Logistic regression was conducted in PLINK to detect SNPS that performed differently 
between genotyping arrays. 124 SNPs with P < 1 x 10-5, represented by the red line, were 
excluded from GWAS analyses.  
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2.3.4 HLA analysis 
Classical HLA alleles and amino acid polymorphisms were imputed using SNP2HLA version 
1.02 (Jia et al., 2013) using BEAGLE version 3.0.4 (Browning & Browning, 2007) from 
genotyped common variants using a reference dataset of 5225 individuals from the Type 1 
Diabetes Genetics Consortium (T1DGC). I used the same procedures for SNP selection, 
analysis and covariate selection (three PCAs derived from GWAS, plus genotyping array) as 
described for the GWAS analysis above. Due to complex and extended linkage 
disequilibrium in the MHC, I did not identify index SNPs in relative linkage equilibrium. 
We additionally genotyped a candidate SNP, HLA-DQB1 6672G>C (Athanasiou et al., 2011) 
(rs113332494), in 60 cases and 305 age and sex matched controls. This SNP was genotyped 
separately as it was not imputed with sufficient quality to be reported in the GWAS or HLA 
analyses, and was a strong candidate variant (Athanasiou et al., 2011). Genotyping was 
conducted at deCODE genetics using the Centaurus (Nanogen) platform (Kutyavin et al., 
2006). Association with clozapine-associated neutropenia was tested using Fisher’s exact 
test given low minor allele counts but to ensure there were no effect of population 
stratification, I also conducted a logistic regression including three PCAs derived from 
GWAS with 5 x 108 permutations to generate empirical p-values.  
2.3.5 Exome array 
The Illumina exome array is designed to genotype uncommon-to-rare coding variants 
previously observed in whole exome sequencing studies. Exome array data were available 
for 57 cases and 4958 controls. Complex quality control procedures were conducted as 
part of a schizophrenia case control analysis and are detailed in Appendix 2. I conducted 
principal component analysis using EIGENSTRAT (Price et al., 2006) with 14,743 common 
exome array variants in relative linkage equilibrium (MAF ≥ 0.05, r2 < 0.2) to assess 
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population structure and identify outliers (Figure 2.4). Due to the relatively small case 
sample size, I did not apply a frequency filter to variants in this analysis.  
Single variant association was conducted using logistic regression in PLINK with the first 10 
principal components included as covariates. Adaptive permutations (between 10 and 1 x 
109) were used to generate empirical p-values in logistic regression analyses due to 
inflated logistic regression statistics at low allele frequencies in comparison to a Fisher’s 
Exact test or permuted p-values. PLINK was used to identify index SNPs in relative linkage 
equilibrium (--clump-p1 0.01 --clump-p2 0.01 --clump-r2 0.1 --clump-kb 3000). The SNP 
with the lowest permuted p-value (strongest association) was selected as the index SNP. 
Due to reduced reliability of genotype calling for rare variants (Goldstein et al., 2012), all 
exome array variants noted in this paper were subject to visual inspection of cluster plots.  
To test for the effects of multiple functional variants in genes, I used SKAT-O (Lee et al., 
2012a) with 2 x 106 permutations, including the first 10 principal components, for genes 
with at least two uncommon (MAF < 0.05), non-synonymous (missense, stop or splice) 
variants. The SKATBinary function within SKAT-O was utilised. Variants were allocated to 
genes according the RefSeq database. SKAT-O computes the association of a SNP set (for 
example a gene) with a phenotype of interest, and maximises power by adaptively using 
the data to optimally combine the burden test and the nonburden sequence kernel 
association test (SKAT) (Lee et al., 2012a). The burden tests assume that all variants are 
causal and affect the phenotype in the same way whereas the nonburden tests allows for 
protective, neutral and risk variant effects.  
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Figure 2.4. Principal component analysis of exome array samples. Figure displays principal 
component 1 and 2 for each individual included in exome array analysis; black points 
represent clozapine-treated controls and red points represent clozapine-associated 
neutropenia cases. 
2.3.1 Secondary analysis of neutropenia below ≤ 1000/mm3 
Given that within the field there are valid concerns that a more stringent threshold may 
produce more reliable results, we additionally conducted secondary analyses on a subset 
of the more severely affected cases with ANC ≤ 1000/mm3. We assessed the association of 
single variants with clozapine-associated neutropenia below ≤ 1000/mm3 in GWAS (N=18), 
HLA imputation (N=18), and exome array (N=16) analyses. All analyses conducted were 
consistent with methods used for clozapine-associated neutropenia as described above. 
2.3.1 Replication sample and analysis 
We obtained summary statistics for associated SNPs from a recently published study by 
the CIAC (Goldstein et al., 2014), a comprehensive genetic association study in 163 
clozapine-induced neutropenia cases (98 with ANC < 500 mm3, 61 with 500 ≤ ANC ≤ 1000 
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mm3 and 4 with ANC ≤ 1500/mm3). The CIAC study included: GWAS (161 cases with 
clozapine-induced neutropenia, 249 clozapine exposed controls without neutropenia and 
947 unexposed controls), HLA allele imputation (162 cases and 4319 unexposed controls), 
and exome array analysis (148 cases and up to 7970 unexposed controls). I combined the 
replication sample with both (i) clozapine-associated neutropenia and (ii) neutropenia ≤ 
1000/mm3 analyses. SNPs that were associated with clozapine-associated neutropenia at P 
< 1 x 10-4 from the GWAS, or P < 0.05 from the HLA variant analysis, were combined with 
the replication data in fixed-effects meta-analyses using PLINK to estimate a combined 
odds ratio weighted by the study’s inverse standard error. If an index SNP was not present 
in replication data for GWAS, a proxy SNP in strong LD (r2 ≥ 0.8) was substituted and the 
s.e. weighted (s.e.w) to account for the lack of information: s.e.w=s.e./sqrt(r2) (Green et 
al., 2013). The variants that were associated with clozapine-associated neutropenia from 
exome array analyses with P < 0.01 were combined with the replication data in a p-value 
based method in METAL (Willer et al., 2010), weighted by the square root of the total 
sample size. Due to differing analytical methods used by CIAC, it was not possible to 
combine our gene-based results in a joint analysis. CIAC used a Fisher’s exact test to assess 
the number of carriers of a functional variant whereas SKAT-O assesses the frequency of 
variants. We used different p-value replication thresholds for the HLA and exome array to 
arrive at approximately the same number of variants.   
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2.4. Results 
Figure 2.5 provides a summary of the study design and key results from the primary 
analysis assessing genetic susceptibility to clozapine-associated neutropenia. 
 
Figure 2.5. Study design and key results. To investigate the association of genetic variants 
with clozapine-associated neutropenia, we conducted (A) genome-wide association study, 
(B) Human Leukocyte Antigen (HLA) allele imputation and genotyped a candidate variant 
of interest, HLA-DQB1 6672G>C/ rs113332494, and (C) exome array single variant and 
gene-based analysis. We then took forward the associated variants from GWAS, HLA and 
exome array analyses to a combined meta-analysis with the Clozapine-Induced 
Agranulocytosis Consortium (CIAC) study. 
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2.4.1 GWAS 
Discovery analysis 
We performed a genome-wide association study of 7,559,010 genotyped and imputed 
common SNPs (QQ plot in Figure 2.6, λGC = 0.95). Two SNPs were associated with 
clozapine-associated neutropenia at the genome wide significance (GWS) level of P < 5 x 
10-8 (Manhattan Plot in Figure 2.7). rs80208670 on chromosome 13 (OR = 8.76, 95% CI: 
4.21-18.25, P = 6.51 x 10-9) is 13kb downstream of SLITRK1 and was present in 7.35% of 
cases and 1.24% of controls. rs77897117 on chromosome 1 (OR = 4.02, 95% CI: 2.46-6.57, 
P = 4.60 x 10-8) is an intergenic variant and was present in 16.39% of cases and 5.24% of 
controls. Table 2.2 lists the 10 most strongly associated SNPs in relative linkage 
equilibrium from the CLOZUK analysis. Our sample size had 80% power to detect an odds 
ratio (OR) ≥ 4 for alleles with MAF ≥ 0.10 at GWS (Figure 2.8).  
 
Figure 2.6. QQ plot for clozapine-associated neutropenia GWAS. The –log10 observed 
logistic regression p-values (y-axis) are plotted against expected p-values (x-axis). λGC = 
0.95. 
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Figure 2.7. Manhattan plot of clozapine-associated neutropenia GWAS. –log10 P-values (y-
axis) for each SNP is presented on the basis of chromosomal position (x axis). The red line 
represents the genome wide significance level (P < 5 x 10-8). 
 
Figure 2.8. Power calculation for clozapine-associated neutropenia GWAS. Power 
calculations derived from Quonto software (http://biostats.usc.edu/Quanto.html) using an 
additive disease model, 3% disease prevalence for 66 cases and 5583 controls (1:85 ratio) 
to detect GWS variant (P = 5 x 10-8) at minor allele frequencies of 0.1 (red), 0.2 (orange), 
0.3 (pink), 0.4 (blue) and 0.5 (green) for effect sizes (OR) 1-10. 
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Meta-analysis 
In total, there were 266 relatively independent (r2 < 0.1) SNPs associated with clozapine-
associated neutropenia at P < 1 x 10-4 and I sought replication of these SNPs in the CIAC 
sample. Data was available for 256 SNPs and a proxy identified for a further SNP. 
rs116552069 was used as a proxy for rs16216021 (r2 = 0.96, D’= 1, Appendix 3). Table 2.2 
details the association in CIAC for the 10 most strongly associated SNPs in the CLOZUK 
analysis. The variants that were GWS in the CLOZUK analysis, rs80208670 and rs77897117, 
were not significantly associated in CIAC (OR = 1.69, P = 0.27 and OR = 0.67, P = 0.28, 
respectively).  
Table 2.3 lists the 10 most strongly associated SNPs from the meta-analysis. One SNP on 
chromosome 12 surpassed the GWS threshold for association with clozapine-associated 
neutropenia (OR = 4.32, P = 1.79 x 10-8). rs149104283 is intronic to transcripts of SLCO1B3 
and SLCO1B7 (solute carrier organic anion transporter family, member 1B3 and member 
1B7) and was present in 7.37% of cases vs. 1.52% of controls in our sample and 4.20% of 
cases vs. 1.67% of controls in the CIAC sample.  
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    CLOZUK  CIAC  Meta-analysis   
CHR SNP Position A1 P-value OR MAF A MAF U  P-value OR MAF A MAF U  P-value OR Gene Location 
13 rs80208670 84438088 C 6.51 x 10-9 8.76 7.38 1.24  0.2728 1.69 2.32 1.37  1.56 x 10-7 4.69 SLITRK1 13kb 
downstream 
1 rs77897177 4362747 C 2.60 x 10-8 4.02 16.39 5.24  0.2796 0.67 3.86 4.83  5.74 x 10-5 2.31  Intergenic 
12 rs114615084 65752916 T 9.44 x 10-8 6.73 6.82 1.00  0.5116 0.65 0.91 1.24  1.36 x 10-5 3.90 MSRB3 Intronic 
15 rs77051678 86642215 T 1.09 x 10-7 8.16 6.37 1.11  0.4718 0.64 1.10 1.51  3.86 x 10-5 3.97  Intergenic 
2 rs4464232 30007327 C 3.08 x 10-7 3.89 12.88 3.60  0.4377 0.74 2.90 3.32  1.69 x 10-4 2.27 ALK Intronic 
13 rs73181572 45617497 A 3.89 x 10-7 5.02 8.81 1.91  0.1272 0.45 1.56 2.60  4.26 x 10-4 2.60 KIAA1704 9kb 
downstream 
6 rs117655439 122314323 C 4.15 x 10-7 5.90 8.32 1.91  0.8544 1.09 1.79 1.67  2.49 x 10-5 3.32  Intergenic 
12 rs149104283 21083862 T 4.98 x 10-7 6.20 7.37 1.52  3.61 x 10-3 2.95 4.20 1.67  1.79 x 10-8 4.32 SLCO1B3, 
SLCO1B7 
Intronic, 
intronic 
20 rs6135490 15721572 G 5.98 x 10-7 3.39 17.14 6.11  0.7832 1.07 8.81 7.13  2.40 x 10-4 1.87 MACROD2 Intronic 
6 rs117329068 164581056 T 7.22 x 10-7 7.32 5.95 1.10  0.8599 0.87 0.80 1.04  1.61 x 10-5 4.65  Intergenic 
Table 2.2. Top 10 independent SNPs from discovery (CLOZUK) GWAS analysis. Results are ordered by CLOZUK analysis P-value. Columns are: 
chromosome (CHR), variant ID (SNP), chromosomal position (Position), minor reference allele (A1), p-value, odds ratio (OR), minor allele frequency in 
cases (MAF A), and minor allele frequency in controls (MAF U) for CLOZUK and CIAC sample, p-value and odds ratio (OR) for meta-analysis, gene and 
location to/in gene.   
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    CLOZUK  CIAC  Meta-analysis   
CHR SNP Position A1 P-value OR MAF A MAF U  P-value OR MAF A MAF U  P-value OR Nearest Gene Location 
12 rs14910428
3 
21083862 T 4.98 x 10-7 6.20 7.37 1.52  3.61 x 10-3 2.95 4.20 1.67  1.79 x 10-8 4.32 SLCO1B3, 
SLCO1B7 
Intronic, 
intronic 
13 rs80208670 84438088 C 6.51 x 10-9 8.76 7.38 1.24  0.2728 1.69 2.32 1.37  1.56 x 10-7 4.69 SLITRK1 13kb 
downstream 
1 rs18459756
4 
82236406 A 2.48 x 10-5 4.03 8.99 2.82  4.99 x 10-3 2.40 5.18 2.52  8.01 x 10-7 3.06 ADGRL2 Intronic 
7 rs78900159 76968378 A 6.94 x 10-6 4.01 9.12 2.44  0.0247 1.97 5.30 2.67  2.02 x 10-6 2.79 GSAP Intronic 
10 rs16916041 63146547 T 7.40 x 10-6 2.57 21.97 9.73  0.0205 1.58 13.29 9.23  2.05 x 10-6 1.98 TMEM26 20kb 
downstream 
16 rs11649311 25226020 T 9.70 x 10-5 2.07 49.68 34.13  2.62 x 10-3 1.51 42.33 34.33  2.26 x 10-6 1.68 AQP8 2kb upstream  
17 rs11720229
7 
53769035 T 8.48 x 10-6 6.25 5.60 1.22  0.1503 2.66 1.51 0.65  5.27 x 10-6 4.97 TMEM100 28kb 
downstream 
17 rs80282661 13252073 T 1.99 x 10-6 6.15 6.29 1.21  0.2632 1.85 1.45 1.00  5.49 x 10-6 4.17 HS3ST3A1 147kb 
downstream 
1 rs18505365
9 
60704250 A 7.76 x 10-6 5.80 6.33 1.42  0.1012 2.13 2.26 1.33  8.05 x 10-6 3.80 C1orf87 165kb upstream 
14 rs78074145 40404458 C 1.13 x 10-6 4.05 11.43 3.29  0.2716 1.44 3.88 3.34  1.08 x 10-5 2.60 FXB033 503kb upstream  
Table 2.3. Top 10 SNPs from GWAS meta-analysis. Results are ordered by meta-analysis P-value. Columns are: chromosome (CHR), variant ID (SNP), 
chromosomal position (Position), minor reference allele (A1), p-value, odds ratio (OR), minor allele frequency in cases (MAF A), and minor allele 
frequency in controls (MAF U) for CLOZUK and CIAC sample, p-value and odds ratio (OR) for meta-analysis, name of nearest gene and location to/in 
gene.  
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2.4.2 HLA analysis 
Discovery analysis 
We performed an association analysis of 7,751 imputed classical HLA alleles and amino 
acid polymorphisms (QQ plot in Figure 2.9, λGC = 0.94). No polymorphism was associated 
with clozapine-associated neutropenia at GWS (P < 5 x 10-8). Table 2.4 lists the 10 most 
strongly associated SNPs from the discovery analysis. The most significant variant was 
intronic to HLA-F-AS1 (OR = 0.57, P = 0.0033) and present in 31.06% of cases and 44.13% 
of controls. 
 
Figure 2.9. QQ plot for clozapine-associated neutropenia imputed HLA analysis. λGC = 0.94. 
Meta-analysis 
Data was available within CIAC for 102 of the 139 HLA variants associated with clozapine-
associated neutropenia at P < 0.05. No imputed classical HLA allele or amino acid 
polymorphism was associated with clozapine-associated neutropenia at GWS in the 
combined meta-analysis. Table 2.5 lists the 10 most strongly associated SNPs from the 
meta-analysis.  
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    CLOZUK  CIAC  Meta-analysis   
CHR SNP Position A1 P-value OR MAF A MAF U  P-value OR MAF A MAF U  P-value OR Gene Location 
6 rs2743951 29709234 A 0.003265 0.57 31.06 44.13  0.4443 1.09 45.99 44.01  0.3870 0.92 HLA-F-AS1 Intronic 
6 rs1737069 29730730 A 0.003814 1.67 38.64 27.14  0.1476 0.83 24.07 27.60  0.5720 1.06  Intergenic 
6 rs2394160 29703262 G 0.004095 0.58 31.06 43.78  0.5795 1.07 45.07 43.66  0.3121 0.91 HLA-F, HLA-F-
AS1 
Intronic 
6 rs2523393 29705659 C 0.004095 0.58 31.06 43.78  0.5841 1.06 45.06 43.67  0.3101 0.91 HLA-F, HLA-F-
AS1 
Intronic 
6 rs2523388 29707704 T 0.004111 0.58 31.06 43.78  0.5771 1.07 45.07 43.65  0.3144 0.91 HLA-F-AS1 Intronic 
6 rs2523395 29702510 T 0.004122 0.58 31.06 43.78  0.5767 1.07 45.06 43.64  0.3145 0.91 HLA-F, HLA-F-
AS1 
Intronic 
6 rs2735052 29701564 T 0.004176 0.58 31.06 43.76  0.5795 1.07 45.06 43.66  0.3146 0.91 HLA-F, HLA-F-
AS1 
Intronic 
6 rs9258266 29725452 T 0.005186 2.50 7.58 3.10  - - - -  - - IFITM4P, 
HLA-F-AS1 
7kb/9kb 
upstream 
6 rs2070600 32151443 A 0.006986 2.02 12.88 6.85  - - - -  - - AGER Missense 
6 rs9258260 29723161 T 0.008124 1.86 16.67 9.65  0.1109 0.69 6.48 9.44  0.4705 1.13 IFITM4P, 
HLA-F-AS1 
4kb/6kb 
upstream 
Table 2.4. Top 10 imputed HLA variants from CLOZUK analysis. Results are ordered by CLOZUK analysis P-value. Columns are: chromosome (CHR), 
variant ID (SNP), chromosomal position (Position), minor reference allele (A1), p-value, odds ratio (OR), minor allele frequency in cases (MAF A), and 
minor allele frequency in controls (MAF U) for CLOZUK and CIAC sample, p-value and odds ratio (OR) for meta-analysis, gene and location to gene.   
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    CLOZUK  CIAC  Meta-analysis   
CHR SNP Position A1 P-value OR MAF A MAF U  P-value OR MAF A MAF U  P-value OR Nearest Gene Location 
6 rs1150753 32059867 C 0.0255 1.70 15.91 10.08  0.0448 1.41 12.98 10.1  0.0033 1.50 TNXB Intronic 
6 rs1269852 32080191 G 0.0252 1.70 15.91 10.08  0.0453 1.41 12.93 10.04  0.0033 1.51 TNXB, ATF6B Intronic 
6 rs3130288 32096001 A 0.0248 1.70 15.91 10.06  0.0480 1.41 12.93 10.06  0.0035 1.50 ATF6B 1kb ds 
6 rs3131618 31434621 C 0.0425 1.60 16.67 11.16  0.0761 1.35 12.93 10.51  0.0085 1.44 HCP5, PMSP, 
HCG26 
1kb ds, 1kb ds, 
4kb ups 
6 rs3131619 31434331 A 0.0471 1.59 16.67 11.25  0.1084 1.31 12.94 10.69  0.0135 1.41 HCP5, PMSP, 
HCG26 
1kb ds, 1kb ds, 
4kb ups 
6 rs3094605 31430694 G 0.0468 1.59 16.67 11.24  0.1095 1.31 12.96 10.72  0.0136 1.40 HCP5, PMSP, 
HCG26 
1kb ds, 1kb ds, 
8kb ups 
6 rs2734583 31505480 C 0.0469 1.58 16.67 11.2  0.1110 1.31 13.08 10.92  0.0137 1.40 DDX39B Intronic 
6 rs3094013 31434366 T 0.0471 1.59 16.67 11.25  0.1096 1.32 12.93 10.68  0.0137 1.41 HCP5, PMSP, 
HCG26 
1kb ds, 1kb ds, 
5kb ups 
6 rs1150754 32050758 A 0.0276 1.60 21.21 14.5  0.2014 1.22 16.05 14.05  0.0194 1.35 TNXB Intronic 
6 rs1150755 32038550 A 0.0283 1.60 21.21 14.53  0.2024 1.22 16.07 14.1  0.0199 1.34 TNXB Intronic 
Table 2.5. Top 10 variants from imputed HLA meta-analysis. Results are ordered by meta-analysis P-value. Columns are: chromosome (CHR), variant 
ID (SNP), chromosomal position (Position), minor reference allele (A1), p-value, odds ratio (OR), minor allele frequency in cases (MAF A), and minor 
allele frequency in controls (MAF U) for CLOZUK and CIAC sample, p-value and odds ratio (OR) for meta-analysis, name of nearest gene and location 
to gene.  
92 
Genotyping of HLA-DQB1 6672G>C (rs113332494) 
We additionally genotyped a candidate SNP, HLA-DQB1 6672G>C (rs113332494), in 60 
cases and 305 age and sex matched controls as it was not imputed with sufficient quality. 
We found independent support for the association of rs113332494 (OR = 15.6, 95% CI: 1.6 
- 151.4, P = 0.015), replicating previous reports of association with clozapine-induced 
agranulocytosis (Athanasiou et al., 2011). The association strengthened when considering 
only those with ANC below ≤ 1000/mm3 (OR = 38.1, 95% CI: 3.4 – 430.9, P = 0.008). For the 
associated ‘G’ allele, there were three heterozygote carriers among 60 cases, and a single 
heterozygote carrier among 305 controls. Lowest neutrophil counts were available for two 
of the three ‘G’ case carriers, both of whom had a neutrophil level < 1000/mm3 (700 and 
900). The association was tested using a Fisher’s exact test given the low minor allele 
counts but to ensure there were no effect of population stratification, I also conducted a 
logistic regression including three PCAs derived from GWAS, with 5 x 108 permutations to 
generate empirical p-values. After adjusting for GWAS PCAs, rs113332494 remained 
associated with clozapine-associated neutropenia (OR = 12.4, 95% CI: 1.12 - 137.4, P = 
0.015) and neutropenia ≤ 1000/mm3 (OR = 22.5, 95% CI: 1.01 - 502.4, P = 0.039). 
Given the candidate design, the analyses of rs13332494 were limited to samples of 
European ancestry. However, if further population-based exclusions were applied, one of 
the heterozygote carriers would be classed as an outlier. When this individual is excluded 
from the analyses, the association attenuates to OR=10.5 (95% CI 0.94-116.7, P=0.070) for 
clozapine-associated neutropenia and OR=19.7 (95% CI 1.2-321.5, P=0.097) for 
neutropenia ≤ 1000/mm3. A colleague, Antonio Pardinas, conducted admixture analyses to 
address the appropriateness of excluding this sample and wider population-based analyses 
relevant to this genetic variant and region. There was no evidence to suggest that past 
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admixture had caused a strong differentiation of the MHC region in this individual in 
comparison to other individuals with the same HLA genotype or to the wider population to 
which this individual belongs.  
2.4.1 Exome array 
Discovery analysis 
I performed an association analysis of 115,029 variants genotyped on the exome array. No 
single variant exceeded a significance threshold of P < 4.3 x 10-7, corresponding to a 
Bonferroni correction for 115,000 variants tested (QQ plot displayed in Figure 2.10, λGC = 
1.11). Table 2.6 lists the 10 most strongly associated variants from the discovery analysis. 
The most significant variant was rs140003855, a missense variant in NSUN2                         
(P = 1.23 x 10-5), present in 1.75% of cases and 0.01% of controls. 
 
Figure 2.10. QQ plot of exome array discovery analysis. The –log10 observed permuted 
logistic regression p-values (y-axis) are plotted against expected p-values (x-axis). λGC = 
1.11. 
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Meta-analysis 
A total of 1138 independent variants (r2 < 0.1) were associated with clozapine-associated 
neutropenia at P < 0.01 in the discovery analysis. Data was available for 1023 of these 
variants in CIAC. However, due to rarity of the variants in this analysis, only 279 variants 
had a computable odds ratio (OR) in both samples; it was common for the minor allele to 
be absent from either cases or controls. Although we used a p-value based method for the 
meta-analysis, the OR is required to determine the direction of effect. Thus, only these 279 
variants could be included.  
Table 2.7 lists the 10 most strongly associated variants from the exome array meta-
analysis. No variant exceeded a significance threshold of P < 4.3 x 10-7. However, of 
interest is rs1546308 (P = 1.10 x 10-6), a missense variant in SLCO1B7 and intronic to 
SLCO1B3, that is 92kb from the SNP that emerged from GWAS meta-analysis. rs1546308 is 
predicted to be benign using the SIFT algorithm (Kumar et al., 2009) and was present in 
15.8% of cases vs. 5.8% of controls in our sample and 9.3% of cases vs. 5.6% of controls in 
the CIAC sample. 
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CLOZUK  CIAC  Meta-analysis 
   
CHR Variant Position A1 P-value OR MAF A MAF U  P-value OR MAF A MAF U  P-value Gene Location Function 
5 rs140003855 6620271 T 1.23 x 10-5 287.7 1.75 0.01  1 0 0.00 0.00  - NSUN2 Exonic Missense 
2 rs75073607 55408785 T 1.39 x 10-5 16.53 4.39 0.31        CLHC1 Exonic Missense 
14 rs200759581 74062288 A 2.39 x 10-5 92.6 1.75 0.03  1 0 0.00 0.06  - ACOT4 Exonic Stop gained 
1 rs147055033 145562532 G 2.58 x 10-5 7.235 7.02 1.14        ANKRD35, 
NBPF10 
Exonic, 
intronic 
Missense 
9 rs189396476 123156869 C 2.61 x 10-5 89.69 1.75 0.04  1 0 0.00 0.11  - CDK5RAP2 
 
Exonic Missense 
12 rs138912646 42711606 T 3.94 x 10-5 9.279 5.26 0.54  0.1613 2.93 1.23 0.43  1.79 x 10-4 ZCRB1 Exonic Missense 
6 rs141802559 118635315 A 5.37 x 10-5 194.8 0.88 0.01  1 0 0.00 0.09  - SLC35F1 Exonic Missense 
12 rs79149293 8975873 G 5.66 x 10-5 11.33 4.39 0.46  0.0967 4.11 1.23 0.30  1.01 x 10-4 A2ML1 Exonic Missense 
14 rs140098306 74973443 T 6.05 x 10-5 194.1 0.88 0.01        LTBP2 Exonic Missense 
2 rs12233132 25328703 T 6.27 x 10-5 2.143 41.23 25.53        EFR3B Intronic Intronic 
Table 2.6. Top 10 variants from exome array discovery (CLOZUK) analysis. Results are ordered by CLOZUK analysis P-value. Columns are: chromosome 
(CHR), variant ID (Variant), chromosomal position (Position), minor reference allele (A1), p-value, odds ratio (OR), minor allele frequency in cases 
(MAF A), and minor allele frequency in controls (MAF U) for CLOZUK and CIAC sample, meta-analysis p-value, gene reference, location and function.   
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CLOZUK  CIAC  Meta-analysis 
   
CHR Variant Position A1 P-value OR MAF A 
MAF 
U  P-value OR 
MAF 
A 
MAF 
U  P-value Gene Location Function 
4 rs201099591 7436363 A 2.48 x 10-3 67.45 0.88 0.02  1.31 x 10-4 62.13 1.85 0.03  1.10 x 10-6 PSAPL1, 
SORCS2  
Exonic, 
Intronic  
Missense1 
7 rs17139320 63726370 G 3.96 x 10-3 2.92 7.89 2.96  2.87 x 10-4 3.214 7.41 2.67  3.70 x 10-6 ZNF679 Exonic Missense1 
8 rs201071539 145003862 A 2.19 x 10-3 - 0.88 0.00  1.69 x 10-3 82.34 1.23 0.02  1.19 x 10-5 PLEC Exonic Missense1 
19 rs2591594 9076728 A 4.66 x 10-3 0.51 19.30 31.91  3.26 x 10-3 0.56 19.75 30.89  4.52 x 10-5 MUC16 Exonic Missense2 
12 rs1546308 21176135 C 1.25 x 10-4 3.00 15.79 5.83  0.06786 1.67 9.26 5.63  9.13 x 10-5 SLCO1B7, 
SLCO1B3  
Exonic, 
Intronic  
Missense1 
1 rs12073549 17720545 T 1.60 x 10-3 2.02 23.68 13.68  0.01631 1.61 20.37 13.86  9.31 x 10-5 PADI6 Exonic Synonymous 
15 rs117116488 89390513 T 2.76 x 10-4 6.09 5.26 1.04  0.04477 3.18 2.47 0.79  9.73 x 10-5 ACAN Exonic Missense2 
12 rs79149293 8975873 G 5.66 x 10-5 11.33 4.39 0.46  0.09674 4.11 1.23 0.30  1.01 x 10-4 A2ML1 Exonic Missense3 
12 rs138912646 42711606 A 3.94 x 10-5 9.28 5.26 0.54  0.1613 2.93 1.23 0.43  1.79 x 10-4 ZCRB1, 
PPHLN1 
Exonic, 
Intronic  
Missense1 
12 rs143584336 130921539 A 1.22 x 10-4 24.33 2.68 0.13  0.1144 10.22 0.62 0.06  2.12 x 10-4 RIMBP2 Exonic Missense1 
Table 2.7. Top 10 variants from exome array meta-analysis. Results are ordered by meta-analysis P-value. Columns are: chromosome (CHR), variant 
ID (Variant), chromosomal position (Position), minor reference allele (A1), p-value, odds ratio (OR), minor allele frequency in cases (MAF A), and minor 
allele frequency in controls (MAF U) for CLOZUK and CIAC sample, and meta-analysis p-value, gene reference, location and function. Predicted 
function of non-synonymous variants (Kumar et al., 2009): 1benign, 2possibly damaging, 3probably damaging. 
97 
Gene-based analysis 
To assess the cumulative effects of rare functional variants in clozapine-associated 
neutropenia, I tested the association of 3,343 genes that had two or more uncommon 
(MAF ≤ 0.05), non-synonymous variants from the exome array using SKAT-O (QQ plot in 
Figure 2.11, λGC = 3.39). Table 2.8 displays the 10 most significantly associated genes. 
There was evidence of association for two genes that exceeded a threshold of                      
P < 2.5 x 10-6, which corresponds to a Bonferroni correction of 20,000 genes tested 
(MacArthur et al., 2014); UBAP2 on chromosome 9 (P = 1.02 x 10-7) and STARD9 on 
chromosome 15 (P = 2.85 x 10-7).  
Gene N variants MAC controls 
(n=5415) 
MAC cases 
(n=57) 
Method P-value 
UBAP2 4 37 7 QA 1.02 x 10-7 
STARD9 10 776 30 UA 2.85 x 10-7 
ITFG3 3 10 4 ER 6.57 x 10-6 
CLHC1 3 597 11 UA 9.53 x 10-6 
GRIK3 3 5 3 ER 1.92 x 10-5 
AKAP9 8 167 10 QA 2.27 x 10-5 
PAK6 5 187 10 QA 4.38 x 10-5 
SMARCAD1 4 169 8 QA 8.76 x 10-5 
LYST 8 263 13 QA 1.39 x 10-4 
ASTN2 5 382 12 QA 1.46 x 10-4 
Table 2.8. Top 10 genes associated with clozapine-associated neutropenia. Analysis 
conducted using SKAT-O to test association of cumulative effects of rare functional 
variants. Columns represent: Gene name (Gene), number of variants in analysis (N 
variants), total count of rare functional alleles within gene in controls (MAC controls), total 
count of rare functional alleles within gene in cases (MAC cases), Analysis method 
(Method; Efficient resampling (ER), Quantile adjusted moment matching (QA, No 
adjustment (UA)), and permuted p-value for gene (P-value).  
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Figure 2.11. QQ plot of gene-based SKAT-O analysis. The –log10 observed permuted SKAT-
O p-values (y-axis) are plotted against expected p-values (x-axis). λGC = 3.39. 
2.4.2 Independence of rs1546308 and rs149104283  
I investigated the independence of rs1546308 (missense variant in SLCO1B7 and intronic in 
SLCO1B3 from exome chip analysis) and rs149104283 (intronic variant in SLCO1B3 and 
SLCO1B7 from GWAS analysis) in samples with data available for both variants (55 cases 
and 4834 controls). The linkage disequilibrium between the two variants in our sample 
was r2 = 0.15, D’ = 0.84. In a conditional logistic regression, the strength of the association 
of rs1546308 with clozapine-associated neutropenia was attenuated from OR = 3.00 (95% 
CI: 1.735-5.189, P = 8.40 x 10-5) to OR = 2.16 (95% CI: 1.093-4.251, P = 0.027) after 
adjusting for rs149104283. Haplotype analysis did not strengthen the association signal. 
Thus, these two findings are not independent, and the associated region spans SLCO1B1, 
SLCO1B3 and SLCO1B7. Figure 2.12 displays associated region 12p12.2 from the discovery 
analysis and Figure 2.13 from the SNPs in meta-analysis. 
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Figure 2.12. LocusZoom plot of association of 12p12.2 in CLOZUK analysis. Genes within 
the region are shown in the lower panel, and the unbroken blue line indicates the 
recombination rate. Points represent the P-value for each SNP, with the top SNP 
rs149104283 shown in purple and the SNPs in the region coloured depending on their 
degree of correlation (r2) with rs149104283 (as estimated on the basis of CEU HapMap 
haplotypes). 
 
Figure 2.13. LocusZoom plot of meta-analysis SNPs in 12p12.2. Genes within the region are 
shown in the lower panel, and the unbroken blue line indicates the recombination rate. 
Points represent the P-value for each SNP, with the top SNP rs149104283 shown in purple 
and the SNPs in the region coloured depending on their degree of correlation (r2) with 
rs149104283 (as estimated on the basis of CEU HapMap haplotypes). 
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2.4.3 Predictive test analysis 
To assess the predictive value of the three key variants identified in this study, I calculated 
the sensitivity, specificity, positive predictive value (PPV) and negative predictive value 
(NPV) based on a prevalence of 3.7% for either agranulocytosis or neutropenia (Table 2.9). 
This prevalence is based on the cumulative risk of agranulocytosis (0.8%) and neutropenia 
(2.9%) in those taking clozapine (Atkin et al., 1996). The PPV and NPV values were adjusted 
by estimating the number of risk allele carriers based on the sensitivity and specificity 
values in a population with a prevalence of 3.7% (Parikh et al., 2008). rs149104283 was the 
intronic variant in SLCO1B3 and SLCO1B7 identified from the GWAS meta-analysis. 
rs1546308 was the missense variant in SLCO1B7, and intronic in SLCO1B3, identified in the 
exome array meta-analysis. rs113332494 (HLA-DQB1 6672G>C) was the genotyped 
candidate variant. The sensitivity for a test including these three risk variants was 29.17%, 
the specificity 90.61%, the PPV 9.94%, and the NPV 97.30%. The analyses indicate that 
29.17% of individuals with clozapine-associated neutropenia or agranulocytosis will carry 
at least one of the three identified risk alleles and that individuals that have any of these 
risk alleles have a 9.94% risk of neutropenia or agranulocytosis. 
 
rs149104283 rs1546308 rs149104283 & rs1536308 rs113332494 
rs149104283, 
rs1536308 & 
rs113332494 
N Cases 64 56 55 60 48 
N Controls 5391 4924 4832 305 245 
Sensitivity 10.94 28.57 30.91 5.00 29.17 
Specificity 97.61 88.57 89.26 99.67 90.61 
PPV 13.97 8.15 9.28 35.13 9.94 
NPV 96.86 97.22 97.32 96.73 97.30 
Table 2.9. Predictive test analysis. Analysis of utility of identified variants as a predictive 
test, based on a prevalence of 3.7%. Rows represent: number of cases in analysis (N Cases), 
number of controls in analysis (N Control), sensitivity, specificity, positive predictive value 
(PPV), negative predictive value (NPV).  
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2.4.4 Secondary analyses of neutropenia below ≤ 1000/mm3 
In secondary analyses, we assessed the association of single variants with clozapine-
associated neutropenia below ≤ 1000/mm3 in GWAS, HLA imputation, and exome array 
analyses, consistent with methods used for clozapine-associated neutropenia. 
GWAS 
A total of 6,231,759 genotyped and imputed variants were included in secondary analyses 
of a subset of the more severely affected cases with ANC ≤ 1000/mm3 (N=18) (QQ plot in 
Figure 2.14, λGC = 0.97). Table 2.10 lists the 10 most strongly associated SNPs from the 
discovery analysis. Two intronic loci reached GWS (Manhattan plot, Figure 2.15); 
rs76415963 in SLX4IP on chromosome 20 (OR =18.05, 95% CI: 6.79-48.00, P = 6.63 x 10-9) 
and rs138818969 in FAM228A on chromosome 2 (OR = 15.55, 95% CI: 5.99-40.32, P = 1.67 
x 10-8). Our sample size for clozapine-associated neutropenia ≤ 1000/mm3 analyses was 
80% powered to detect a GWS association (P < 5 x 10-8) with an effect size ≥ 10 and MAF ≥ 
0.20 (Figure 2.16). 
In total, there were 373 independent (r2 < 0.1) SNPs associated with clozapine-associated 
neutropenia below ≤ 1000/mm3 at P < 1 x 10-4 and we sought replication of these SNPs in 
the CIAC sample. Data was available for 361 SNPs and proxies identified for a further three 
SNPs. Appendices 3 details the proxy SNPs used and their LD with the original SNP. Table 
2.10 details the association in CIAC for the 10 most strongly associated SNPs in the CLOZUK 
analysis. Associations of rs76415963 in SLX4IP and rs138818969 in FAM228A were not 
replicated in CIAC (OR = 0.57, P = 0.31 and OR = 0.94, P = 0.97, respectively). Table 2.11 
lists the 10 most strongly associated SNPs from the meta-analysis. No SNP reached GWS in 
the meta-analysis. The most significantly associated SNP from the meta-analysis was 
rs143888465 in SCN8A on chromosome 12 (OR = 4.94, P = 3.72 x 10-6). 
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Figure 2.14. QQ plot for clozapine-associated neutropenia ≤ 1000/mm3 GWAS. The –log10 
observed logistic regression p-values (y-axis) are plotted against expected p-values (x-axis). 
λGC = 0.97. 
 
Figure 2.15. Manhattan plot of clozapine-associated neutropenia ≤ 1000/mm3 GWAS. –
log10 P-values (y-axis) for each SNP is presented on the basis of chromosomal position (x 
axis). The red line represents the GWS level (P < 5 x 10-8). 
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Figure 2.16. Power calculation for clozapine-associated neutropenia ≤ 1000/mm3 GWAS. 
Power calculations derived from Quonto software (http://biostats.usc.edu/Quanto.html) 
using an additive disease model, 1% disease prevalence for 18 cases and 5583 controls 
(1:312 ratio) to detect GWS variant (P = 5 x 10-8) at minor allele frequencies of 0.1 (red), 0.2 
(orange), 0.3 (pink), 0.4 (blue) and 0.5 (green) for effect sizes (OR) 1-10. 
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    CLOZUK  CIAC  Meta-analysis   
CHR SNP Position A1 P-value OR MAF A 
MAF 
U  P-value OR MAF A MAF U  P-value OR Gene Location 
20* rs76415963 10544516 T 6.63 x 10-9 14.57 19.0 1.97  0.311 0.57 1.24 2.32  5.68 x 10-5 4.66 SLX4IP Intronic 
2 rs138818969 24412084 A 1.67 x 10-8 15.55 19.1 2.05  0.9384 0.97 2.28 2.26  1.48 x 10-4 3.52 FAM228A Intronic 
20 rs2196239 80655 A 6.94 x 10-8 6.73 41.7 9.8  0.7354 0.93 8.7 9.32  9.96 x 10-3 1.62 DEFB125 3kb 
downstream  
6 rs3817796 166875819 T 9.47 x 10-8 6.91 41.7 10.1  0.7792 0.94 9.73 10.32  0.015 1.55 RPS6KA2 Intronic 
6 rs74416570 132931444 A 1.15 x 10-7 8.12 26.8 4.6  0.4751 0.77 2.89 4.31  2.04 x 10-3 2.29 TAAR3 / 
TAAR2 
1kb/7kb 
upstream 
5 rs78442711 84190774 T 1.16 x 10-7 9.25 24.0 3.84  0.8075 0.92 4.2 4.45  1.96 x 10-3 2.24  Intergenic 
19 rs12980608 17114605 T 1.33 x 10-7 6.90 62.55 22.5  0.4255 1.12 25.14 23.33  6.74 x 10-3 1.45 CPAMD8 Intronic 
10 rs148473220 27242377 C 1.65 x 10-7 10.45 19.44 2.39  0.9185 0.96 2.18 2.45  3.11 x 10-4 3.11  Intergenic 
1 rs149086962 117537116 C 2.39 x 10-7 15.85 13.95 1.42  0.1011 0.24 0.59 1.49  3.83 x 10-4 5.05 PTGFRN / 
CD101 
4kb 
downstream / 
7kb upstream 
2 rs75471613 78795665 G 2.52 x 10-7 10.07 19.41 2.44  0.8752 1.06 3.11 3.11  6.94 x 10-4 2.62  Intergenic 
Table 2.10. Top 10 SNPs for clozapine-associated neutropenia ≤ 1000/mm3 CLOZUK (discovery) GWAS. Results are ordered by CLOZUK analysis P-
value. Columns are: chromosome (CHR), variant ID (SNP), chromosomal position (Position), minor reference allele (A1), p-value, odds ratio (OR), minor 
allele frequency in cases (MAF A), and minor allele frequency for controls (MAF U) in CLOZUK and CIAC sample, p-value and combined odds ratio (OR) 
for meta-analysis, gene and location to gene.  
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    CLOZUK  CIAC  Meta-analysis   
CHR SNP Position A1 P-value OR MAF A 
MAF 
U  P-value OR 
MAF 
A 
MAF 
U  P-value OR Gene Location 
12 rs143888465 52010108 T 1.02 x 10-5 11.07 11.20 1.17  0.018 2.87 2.61 1.23  3.72 x 10-6 4.94 SCN8A Intronic 
8 rs548650 102585836 A 2.93 x 10-6 10.91 13.17 1.46  0.074 2.31 2.71 1.37  7.48 x 10-6 4.70 GRHL2 Intronic 
2 rs78626772 111707226 A 1.65 x 10-6 10.24 17.55 2.70  0.064 1.95 3.83 2.48  1.40 x 10-5 3.52 ACOXL Intronic 
3 rs181373231 97994503 A 5.86 x 10-6 15.08 10.89 1.08  0.237 2.34 0.05 0.98  1.62 x 10-5 12.85 OR5H2 7kb upstream  
1 rs141788696 83927911 T 2.44 x 10-6 18.15 10.53 1.11  0.156 0.43 1.31 0.99  1.68 x 10-5 0.16  Intergenic 
8 chr8_13107886
7_I 
131078867 I5 5.03 x 10-5 9.86 11.11 1.41  0.016 2.56 3.51 1.25  1.80 x 10-5 3.96 ASAP1 Insertion 
1 rs17028665 112355413 A 2.63 x 10-5 10.83 10.97 1.40  0.031 2.52 2.93 1.23  2.10 x 10-5 4.29 KCND3 Intronic 
5 rs114337922 2565908 G 8.42 x 10-5 12.53 9.34 1.24  0.032 3.17 1.93 0.99  3.05 x 10-5 0.18  Intergenic 
6 rs9365903 166070843 C 8.19 x 10-5 7.95 11.11 1.33  0.023 2.41 3.41 1.4  3.17 x 10-5 0.27 PDE10A Intronic 
1 rs185053659 60704250 A 4.33 x 10-6 14.31 12.31 1.42  0.101 2.13 2.26 1.33  3.45 x 10-5 4.44  Intergenic 
Table 2.11. Top 10 SNPs for clozapine-associated neutropenia ≤ 1000/mm3 GWAS meta-analysis. Results ordered by meta-analysis P-value. Columns 
are: chromosome (CHR), variant ID (SNP), chromosomal position (Position), minor reference allele (A1), p-value, odds ratio (OR), minor allele 
frequency in cases (MAF A), and minor allele frequency for controls (MAF U) in CLOZUK and CIAC sample, p-value and combined odds ratio (OR) for 
meta-analysis, gene and location to gene. 
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Imputed HLA analysis 
I performed an additional association analysis of clozapine-associated neutropenia ≤ 
1000/mm3 in 6,672 imputed classical HLA alleles and amino acid polymorphisms (QQ plot 
in Figure 2.17, λGC = 1.63). No polymorphism was associated at GWS (P < 5 x 10-8). Table 
2.12 lists the 10 most strongly associated SNPs from the discovery analysis. The most 
significant variant was rs3129963 (OR = 4.14, P = 3.94 x 10-5), located 5kb upstream of 
BTNL2 and present in 44.44% of cases and 16.94% of controls.  
Data was available within CIAC for 763 of the 839 HLA variants associated with clozapine-
associated neutropenia ≤ 1000/mm3 at P < 0.05. No imputed classical HLA allele or amino 
acid polymorphism was associated at GWS in the combined meta-analysis. Table 2.13 lists 
the 10 most strongly associated SNPs from the meta-analysis. rs3129963, 5kb from BTNL2, 
was weakly associated in CIAC (OR = 1.32, P = 0.048) (Table 2.12). The most significant 
variant from the meta-analysis was rs3129891 (OR = 1.91, P = 6.28 x 10-8), located 2kb 
downstream of HLA-DRA and present in 44.44% of cases and 18.83% of controls in the 
CLOZUK sample and 29.93% of cases and 19.97% of controls in the CIAC sample. Among 
the top associated variants in the meta-analysis were amino acid changes in HLA-B, a gene 
been previously implicated in clozapine-induced agranulocytosis (Goldstein et al., 2014). 
Due to complex LD in this region, independent SNPs were not identified. Thus it is likely 
that the variants listed do not represent independent signals. Figure 2.18 highlights the LD 
and association across BTNL2, HLA-DRA and other HLA genes in the CLOZUK sample. It was 
not possible to impute specific variants of interest in HLA-DQB1 (Athanasiou et al., 2011; 
Goldstein et al., 2014) with sufficient accuracy and thus this region is considered 
separately (section 2.4.2).  
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Figure 2.17. QQ plot for clozapine-associated neutropenia ≤ 1000/mm3 imputed HLA allele 
discovery analysis. The –log10 observed logistic regression p-values (y-axis) are plotted 
against expected p-values (x-axis). λGC = 1.63. 
 
Figure 2.18. LocusZoom plot of discovery HLA analysis for clozapine-associated 
neutropenia ≤ 1000/mm3. Genes within the region are shown in the lower panel, and the 
unbroken blue line indicates the recombination rate. Points represent the P-value for each 
SNP, with the top SNP rs3129963 shown in purple and the SNPs in the region coloured 
depending on their degree of correlation (r2) with rs3129963 (as estimated on the basis of 
CEU HapMap haplotypes). 
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    CLOZUK  CIAC  Meta-analysis   
CHR SNP Position A1 P-value OR MAF A MAF U  P-value OR MAF A MAF U  P-value OR Gene Location 
6 rs3129963 32380208 G 3.94 x 10-5 4.14 44.44 16.94  0.0476 1.32 20.99 17.14  6.98 x 10-4 1.56 BTNL2 5kb upstream 
6 rs3129881 32409484 T 4.44 x 10-5 4.13 61.11 28.24  0.7967 0.97 25.77 26.47  0.2262 1.16 HLA-DRA Intronic 
6 rs3129872 32407153 T 4.72 x 10-5 4.10 61.11 28.33  0.9087 1.01 27.78 27.62  0.1297 1.20 HLA-DRA 1kb upstream 
6 rs2395177 32405076 C 4.75 x 10-5 4.10 61.11 28.34  0.9794 1.00 27.52 27.56  0.1485 1.19 HLA-DRA 3kb upstream 
6 rs2395172 32399842 C 4.75 x 10-5 4.10 61.11 28.35  0.9732 1.00 28.15 28.30  0.1691 1.18 HLA-DRA 7kb upstream 
6 rs3129848 32397049 A 4.75 x 10-5 4.10 61.11 28.35  0.8605 1.02 27.78 27.45  0.1157 1.21  Intergenic 
6 rs3129853 32398648 A 4.75 x 10-5 4.10 61.11 28.35  0.9098 1.01 27.78 27.62  0.1301 1.20 HLA-DRA 9kb upstream 
6 rs3129858 32400520 A 4.75 x 10-5 4.10 61.11 28.35  0.9101 1.01 27.78 27.62  0.1302 1.20 HLA-DRA 7kb upstream 
6 rs3135339 32399261 C 4.75 x 10-5 4.10 61.11 28.35  0.9128 1.01 27.77 27.62  0.131 1.20 HLA-DRA 8kb upstream 
6 rs3135342 32396615 A 4.75 x 10-5 4.10 61.11 28.35  0.8603 1.02 27.78 27.45  0.1155 1.21  Intergenic 
Table 2.12. Top 10 imputed HLA alleles for clozapine-associated neutropenia ≤ 1000/mm3 CLOZUK (discovery) analysis. Results ordered by CLOZUK P-
value. Columns are: chromosome (CHR), variant ID (SNP), chromosomal position (Position), minor reference allele (A1), p-value, odds ratio (OR), minor 
allele frequency in cases (MAF A), and minor allele frequency for controls (MAF U) in CLOZUK and CIAC sample, p-value and combined odds ratio (OR) 
for meta-analysis, gene and location of variant to gene.   
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    CLOZUK  CIAC  Meta-analysis   
CHR SNP Position A1 P-value OR MAF A 
MAF 
U  P-value OR 
MAF 
A 
MAF 
U  P-value OR Gene Location 
6 rs3129891 32415080 A 2.64 x 10-4 3.44 44.44 18.83  1.05 x 10-5 1.76 29.93 19.97  6.28 x 10-8 1.91 HLA-DRA 2kb 
downstream 
6 rs3129890 32414273 C 0.0012 2.96 47.22 23.15  6.18 x 10-4 1.52 33.62 24.95  1.54 x 10-5 1.64 HLA-DRA 2kb 
downstream 
6 rs9268832 32427789 T 0.0071 2.51 61.11 38.44  4.89 x 10-4 1.49 47.38 38.08  3.13 x 10-5 1.57  Intergenic 
6 rs7754768 32420179 C 0.0038 2.75 63.89 39.09  7.82 x 10-4 1.47 48.13 39.03  4.21 x 10-5 1.56 HLA-DRA 7kb 
downstream 
6 SNP_C_31345234 31237255 G 0.0090 2.48 58.33 36.28  5.96 x 10-4 1.49 42.89 34.90  4.40 x 10-5 1.57 HLA-C Intronic 
6 SNP_B_31432910 31324931 A 0.0318 2.05 50.00 32.46  4.18 x 10-4 1.51 40.56 31.62  5.36 x 10-5 1.56 HLA-B Exonic 
6 AA_B_-23_31432910_L 31324931 P 0.0318 2.05 50.00 32.46  4.70 x 10-4 1.51 40.53 31.66  6.04 x 10-5 1.56 HLA-B Exonic 
6 AA_B_-21_31432904_M 31324925 P 0.0318 2.05 50.00 32.46  4.73 x 10-4 1.51 40.53 31.66  6.08 x 10-5 1.56 HLA-B Exonic 
6 SNP_B_31432808_G 31324829 P 0.0320 2.05 50.00 32.47  4.85 x 10-4 1.51 40.51 31.66  6.28 x 10-5 1.56 HLA-B Exonic 
6 SNP_B_31432809 31324830 G 0.0320 2.05 50.00 32.47  4.85 x 10-4 1.51 40.51 31.66  6.28 x 10-5 1.56 HLA-B Exonic 
Table 2.13. Top 10 imputed HLA alleles from clozapine-associated neutropenia ≤ 1000/mm3 meta-analysis. Results ordered by meta-analysis P-value. 
Columns are: chromosome (CHR), variant ID (SNP), chromosomal position (Position), minor reference allele (A1), p-value, odds ratio (OR), minor allele 
frequency in cases (MAF A), and minor allele frequency for controls (MAF U) in CLOZUK and CIAC sample, p-value and odds ratio (OR) for meta-
analysis, gene and location to gene. Nomenclature for (i) classical HLA alleles: HLA_[GENE]_[ALLELE], (ii) HLA Amino Acids: AA_[GENE]_[AMINO ACID 
POSITION]_[GENETIC POSITION]_[ALLELE], (iii) HLA intragenic SNPs: SNP_[GENE]_[POSITION]_[ALLELE], and (iv) Insertions / deletions: 
[VARIANT]_[GENE]_[POSITION]_[INSERTION/x=DELETION] i.e. one of above with x or insertion L=Leucine, M=Methionine, G=Glycine. 
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Exome array analysis 
I performed an additional analysis of 114,814 exome array variants in a subset of 16 cases 
with clozapine-associated neutropenia ≤ 1000/mm3. No single variant exceeded a 
significance threshold of P < 4.3 x 10-7, corresponding to a Bonferroni correction for 
115,000 variants tested (QQ plot displayed in Figure 2.19, λGC = 0.94). Table 2.14 lists the 
10 most strongly associated variants from the discovery analysis. The most significant 
variant was rs4445901 on chromosome 16 (P = 3.08 x 10-5), present in 78.12% of cases and 
44.82% of controls. 
A total of 1110 independent variants (r2 < 0.1) were associated with clozapine-associated 
neutropenia ≤ 1000/mm3 at P < 0.01 in the discovery analysis. Data was available for 990 
of these variants in CIAC. However, due to rarity of the variants in this analysis, only 291 
variants had a computable odds ratio (OR) in both samples; it was common for the minor 
allele to be absent from either cases or controls. Although we used a p-value based 
method for the meta-analysis, the OR is required to determine the direction of effect. Thus 
only these 291 variants could be included in our meta-analysis. Table 2.15 lists the 10 most 
strongly associated variants from the exome array meta-analysis. No variant exceeded a 
significance threshold of P < 4.3 x 10-7. The most significant variant was rs17139320 (P = 
7.56 x 10-6), a missense variant in ZNF679 and present in 12.5% of cases vs. 2.96% of 
controls in the CLOZUK sample and 7.41% of cases vs. 2.67% of controls in the CIAC 
sample. 
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Figure 2.19. QQ plot of clozapine-associated neutropenia below ≤ 1000/mm3 exome array 
analysis. The –log10 observed permuted logistic regression p-values (y-axis) are plotted 
against expected p-values (x-axis). λGC = 0.94. 
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CLOZUK  CIAC  Meta-analysis 
   
CHR Variant Position A1 P-value OR MAF A 
MAF 
U  P-value OR 
MAF 
A 
MAF 
U  P-value Gene Location Function 
16 rs4445901 51259725 T 3.08 x 10-5 4.63 78.12 44.82  0.248 1.20 47.53 43.34  9.78 x 10-5  Intergenic  
15 rs117116488 89390513 T 3.69 x 10-5 16.49 12.50 1.04  0.045 3.18 2.47 0.79  2.51 x 10-5 ACAN Exonic Missense 
11 rs34809643 488541 A 5.68 x 10-5 71.28 6.25 0.16  0.104 3.91 1.23 0.32  1.15 x 10-4 PTDSS2 Exonic Missense 
10 rs7918793 27497191 A 6.11 x 10-5 6.276 25.00 4.12  0.779 0.89 3.70 4.20  0.015 ACBD5 Exonic Missense 
15 rs147997234 54307871 A 6.53 x 10-5 886.1 3.13 0.03  1 0 0.00 0.09  - UNC13C Exonic Missense 
1 rs184646465 236762890 C 8.48 x 10-5 166.6 6.25 0.04  1 0 0.00 0.08  - HEATR1 Exonic Missense 
20 rs1780680 35769647 T 1.00 x 10-4 4.176 75.00 42.47  0.353 0.86 38.89 42.91  0.021 MROH8 Exonic Missense 
9 rs201613718 106864334 T 1.01 x 10-4 3308 3.13 0.01  - - 0.00 0.00  - SMC2 Exonic Missense 
16 rs61732874 3293257 A 1.04 x 10-4 66.82 6.25 0.17  0.429 1.85 0.62 0.33  0.0017 MEFV Exonic Missense 
19 rs4808551 17111297 A 1.15 x 10-4 4.18 43.75 16.99        CPAMD8 Exonic Missense 
Table 2.14. Top 10 exome array variants from clozapine-associated neutropenia ≤ 1000/mm3 CLOZUK (discovery) analysis. Results ordered by CLOZUK 
p-value. Columns are: chromosome (CHR), variant ID (Variant), chromosomal position (Position), minor reference allele (A1), p-value, odds ratio (OR), 
minor allele frequency in cases (MAF A), and minor allele frequency for controls (MAF U) for CLOZUK and CIAC sample, meta-analysis p-value, gene 
reference, location and function.   
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CLOZUK  CIAC  Meta-analysis 
   
CHR Variant Position A1 P-value OR MAF A 
MAF 
U  P-value OR 
MAF 
A 
MAF 
U  P-value Gene Location Function 
7 rs17139320 63726370 G 8.00 x 10-3 5.06 12.50 2.96  2.87 x 10-4 3.21 7.41 2.67  7.56 x 10-6 ZNF679 Exonic Missense 
20 rs150057397 3677326 A 3.24 x 10-3 123.6 3.13 0.05  1.69 x 10-3 82.34 1.23 0.02  1.71 x 10-5 SIGLEC1 Exonic Stop gained 
15 rs117116488 89390513 T 3.69 x 10-5 16.49 12.50 1.04  0.04477 3.18 2.47 0.79  2.51 x 10-5 ACAN Exonic Missense 
22 rs182012324 24237074 T 1.34 x 10-4 62.38 6.25 0.17  0.02731 9.14 1.23 0.14  3.15 x 10-5 MIF Exonic Missense 
16 rs4445901 51259725 T 3.08 x 10-5 4.63 78.13 44.82  0.2479 1.20 47.53 43.34  9.78 x 10-5  Intergenic  
11 rs138991613 117693150 T 2.00 x 10-3 81.16 3.13 0.07  0.01458 13.71 1.23 0.09  1.10 x 10-4 FXYD2,FXY
D6-FXYD2 
Exonic Missense 
17 rs4792739 16322676 C 1.49 x 10-3 5.87 15.63 3.23  0.01866 2.18 6.17 2.82  1.13 x 10-4 TRPV2 Intronic  
11 rs34809643 488541 A 5.68 x 10-5 71.28 6.25 0.16  0.1043 3.91 1.23 0.32  1.15 x 10-4 PTDSS2 Exonic Missense 
1 rs12073549 17720545 T 3.15 x 10-3 2.94 31.25 13.68  0.01631 1.61 20.37 13.86  1.64 x 10-4 PADI6 Exonic Synonymous 
9 rs140343430 5922080 G 1.96 x 10-3 53.04 3.13 0.11  0.0227 10.28 1.23 0.12  1.80 x 10-4 KIAA2026 Exonic Missense 
Table 2.15. Top 10 exome array variants from clozapine-associated neutropenia ≤ 1000/mm3 meta-analysis. Resuts ordered by meta-analysis p-value. 
Columns are: chromosome (CHR), variant ID (Variant), chromosomal position (Position), minor reference allele (A1), p-value, odds ratio (OR), minor 
allele frequency in cases (MAF A), and minor allele frequency for controls (MAF U) for CLOZUK and CIAC sample, meta-analysis p-value, gene 
reference, location and function 
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2.5. Discussion 
I have conducted a multifaceted genetic analysis of clozapine-associated neutropenia in 
the largest combined sample studied to date. Using GWAS, I identified a novel association 
implicating a family of organic anion transporters involved in drug metabolism which have 
been previously associated with adverse drug reactions. I also found evidence for effects 
of uncommon non-synonymous variants within UBAP2 and STARD9 and provide 
independent replication of a previously identified variant in HLA-DQB1. 
Novel association at SLCO1B3/SLCO1B7 
The primary GWAS finding from the meta-analysis was a genome-wide significant 
association with clozapine-associated neutropenia for rs149104283, an intronic SNP for 
transcripts of both SLCO1B3 and SLCO1B7. The associated region also contains a third 
member of this organic anion transporter family, SLCO1B1. SLCO1B7 encodes a putative 
protein (OAT1B7) that is poorly characterised, based on coding sequence prediction, and 
its functionality is currently unknown. SLCO1B3 and SLCO1B1 share sequence homology 
and encode liver-specific organic anion-transporter polypeptides (OATP1B3 and OATP1B1) 
that are multipass transmembrane proteins expressed exclusively in the basolateral 
membrane of hepatocytes (Konig et al., 2000). They facilitate uptake of exogenous 
substances, including drugs, from the portal vein into hepatocytes, where the substance is 
subsequently modified either via metabolism with cytochrome (CYP) 450 enzymes or 
excreted (International Transporter Consortium et al., 2010). 
Polymorphisms in SLCO1B1 and SLCO1B3 have been implicated in adverse reactions with 
other drugs. In 2008, a GWAS identified a missense variant rs4149056 in SLCO1B1 that 
increased the risk of simvastatin-induced myopathy by increasing the area under the curve 
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(AUC) for simvastatin, particularly in those taking high doses (Search Collaborative Group 
et al., 2008). This prominent pharmacogenetic finding has been widely replicated and has 
led to recommendations for its use as a routine pre-emptive clinical test (Ramsey et al., 
2014). Particularly relevant to the current study are reports of an association between 
rs11045585, an intronic variant in SLCO1B3, and severe leukopenia/ neutropenia induced 
by docetaxel, a chemotherapeutic agent, (Kiyotani et al., 2008), and that this may be 
secondary to alterations in the pharmacokinetics and bioavailability of the drug (Nambu et 
al., 2011; Yamakawa et al., 2011; Chew et al., 2012). These polymorphisms were not in 
high LD (r2 < 0.1 for both) with the index SNP in this study although rs11045585 was 
weakly associated with neutropenia in our CLOZUK sample (OR = 1.62, P = 0.03).  
Together, the findings suggest the hypothesis that genetic variants at SLCO1B3 (and/or 
SLCO1B1) increase risk of clozapine-associated neutropenia through a pharmacokinetic 
mechanism. It is unclear whether clozapine plasma levels are associated with development 
of neutropenia (Hasegawa et al., 1994; Centorrino et al., 1995; Mauri et al., 1998). One of 
the best-supported hypotheses to explain clozapine’s association with agranulocytosis 
relates to the bioactivation of clozapine, or a stable metabolite, to a chemically reactive 
nitrenium ion (Pirmohamed & Park, 1997). The propensity for nitrenium ions to cause 
apoptosis to neutrophils, or be toxic to neutrophil precursors, is dose dependent, lending 
support to the hypothesis that clozapine pharmacokinetics and bioavailability are related 
to its potential to cause neutropenia (Williams et al., 2000; Pereira & Dean, 2006).  
Further studies are required to determine if SLCO1B3 (and/or SLCO1B1) influence the 
uptake or metabolism of clozapine and sequencing of this chromosomal region is required 
to refine the association signal.  
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Rare variants 
In analysis of exome array data I found evidence of association with neutropenia for 
uncommon non-synonymous variants in STARD9 and UBAP2. STARD9 is a mitotic kinesin 
and STARD9-depleted cancer cells have abnormal cellular morphology and undergo 
apoptosis (Torres et al., 2011). In addition, STARD9-depletion was found to synergise with 
the chemotherapeutic agent taxol, the use of which is dose-limited due to neutropenia 
(Torres et al., 2011). The function of UBAP2 is undetermined though it has an ubiquitin-
associated domain and is widely expressed across tissues including bone marrow. The 
ubiquitination pathway has been shown to modulate the granulocyte colony-stimulating 
factor receptor (Ai et al., 2008; Kindwall-Keller et al., 2008), a critical regulator of 
neutrophil production. A recent study reported the association of a missense variant in the 
ubiquitin gene USP43 with clozapine-associated neutropenia (Tiwari et al., 2014).  
No single variant from the exome array was significantly associated with clozapine-
associated neutropenia or neutropenia ≤ 1000/mm3, although a number of functional but 
nominally associated variants were identified. However, the exome array does not capture 
all exonic variation. Exome- wide sequencing would prove the role of functional exonic 
variants definitively.  
A colleague, Elliott Rees, assessed the role of rare, exonic copy number variation (CNV) in 
clozapine-associated neutropenia. The identification and quality control of CNVs for the 
CLOZUK and CardiffCOGS samples has been previously described (Rees et al., 2014). CNVs 
were included if they had a frequency ≤ 0.01, contained ≥ 10 probes, and were ≥ 100kb in 
length. Samples that passed both CNV and GWAS quality control (63 cases and 5456 
controls) were used to test genes for enrichment of exon disrupting CNVs using a 2-sided 
Fisher’s exact test. Deletions and duplications were analysed separately and P-values were 
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adjusted for multiple testing by applying a Bonferroni correction of 20,000 genes. In this 
genome-wide analysis, no individual gene was significantly enriched for large, rare exonic 
CNVs. The CIAC study also failed to identify any CNV that was significantly associated with 
clozapine-associated neutropenia (Goldstein et al., 2014).  
HLA genes 
The final finding adds to the growing evidence implicating HLA-DQB1 in clozapine-
associated neutropenia, supporting the recently published CIAC study (Goldstein et al., 
2014). There have been further reports implicating SNPs within HLA-DQB1 (Yunis et al., 
1995; Dettling et al., 2001; Athanasiou et al., 2011) although these samples and those in 
CIAC are overlapping; thus we provide the first fully independent replication implicating 
this locus in clozapine-associated neutropenia/agranulocytosis. HLA-DQB1 belongs to the 
HLA class II beta chain paralogs and has been implicated in several autoimmune diseases 
including insulin-dependent diabetes and narcolepsy (Siebold et al., 2004). The HLA-DQB1 
variant alone has a positive predictive value of 35.1%. Whilst this is promising, the majority 
of those that develop neutropenia or agranulocytosis whilst taking clozapine are not 
carriers of this risk allele, or indeed the other alleles we have identified in this study. 
Secondary analyses of clozapine-associated neutropenia ≤ 1000/mm3 implicated variants 
in BTNL2, HLA-DRA and HLA-B, although none of these variants reached statistical 
significance. The CIAC study found evidence for association of missense variants in BTNL2, 
but this signal was not independent of that from HLA-DQB1. Variants in HLA-B have been 
previously implicated in clozapine-induced agranulocytosis (Yunis et al., 1992; Yunis et al., 
1995; Valevski et al., 1998; Goldstein et al., 2014). Our findings suggest that HLA genes 
may have a greater impact in those with a more severe phenotype. 
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Strengths and limitations  
Due to its rarity, genetic studies of clozapine-associated neutropenia are typically 
underpowered to detect associations that do not have a moderate to large effect. Thus, 
there may be causal variants of small effect that we were not able to detect in this study. 
However, a considerable strength of this study is the large control sample, all of which 
were treated with clozapine for at least a year without developing neutropenia. 
Nonetheless, the low statistical power in this study increases the likelihood that our 
findings may not represent true effects (Button et al., 2013). An important consideration is 
that our analyses included cases with neutropenia rather than agranulocytosis. It is now 
very rare to develop agranulocytosis because of the success of the monitoring system; in 
fact only four cases met this threshold in our sample. Lastly, the individuals examined in 
this study were limited to those of European ancestry and there may be differences in the 
clinical impact of associated variants between different populations. 
Clinical Implications 
Although the identified variants convey a substantially increased risk for clozapine-
associated neutropenia, they are currently on their own unlikely to have clinical utility for 
pharmacogenetic testing due to low sensitivity and positive predictive value (Verbelen et 
al., 2015), particularly as there is currently no alternative treatment for those with TRS. 
Nonetheless our findings provide novel insights into putative biological processes 
underlying clozapine-associated neutropenia. We have indicated a potential link between 
the pharmacokinetics of clozapine and risk of neutropenia/agranulocytosis with potentially 
important clinical implications. The development of such understanding should help widen 
the availability of clozapine with beneficial impact on those with TRS. 
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 Chapter 3
Methods (for studies presented in Chapter 4 and Chapter 5) 
This chapter describes in detail the sample used for Chapters 4 and 5 of this thesis. Data 
for both chapters were derived from a two-year retrospective cohort study of all patients 
starting their first clozapine trial over a five-year period (2007-2011, inclusive) in South 
London & Maudsley (SLaM) NHS Foundation Trust. Details of the setting, ethical approval, 
sample selection, study design and exposure variables are presented within this chapter. 
Study-specific details of additional inclusion criteria, measures, and data analysis 
procedures are presented in the relevant chapters.  
3.1. Setting 
The study used data from the Case Register Interactive Search (CRIS) system; a large, 
anonymised case register derived from South London & Maudsley (SLaM) NHS Foundation 
Trust electronic case records (Stewart et al., 2009). SLaM is the largest secondary mental 
health care provider in Europe serving approximately 1.2 million people from four London 
boroughs; Lambeth, Croydon, Lewisham and Southwark. SLaM provides specialist general 
adult, child and adolescent, forensic, older adult, learning disabilities and addiction mental 
health services as well as a number of national services. Electronic case records were 
implemented in SLaM in 2006 to allow sharing of information across services. The 
electronic case records contain structured fields for fixed data (e.g. demographic details, 
medication, ICD-10 diagnosis and structured assessments) and unstructured fields for free 
text (e.g. correspondence, referrals, clinical assessments, care plans and ward rounds).  
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The introduction of electronic case records provided a unique opportunity to create a large 
case register that could be used for secondary research purposes. The CRIS system is a 
large, anonymous case register derived for research purposes from SLaM’s electronic case 
records. There are in excess of 230,000 patients represented on the CRIS system (Stewart 
et al., 2009; Fernandes et al., 2013). CRIS was developed for use and is supported by the 
National Institute for Health Research (NIHR) Mental Health Biomedical Research Centre 
and Dementia Unit (BRC/U) and hosted by SLaM and King's College London. To protect the 
anonymity of the patients represented within CRIS, a unique BRC identifier is created from 
NHS numbers, which are not available for researchers, and any text within CRIS that 
matched the name, address or date of birth fields is replaced with ‘ZZZZZ’ (Fernandes et 
al., 2013).  
A major advantage of CRIS is that in the UK the National Health Service (NHS) provides 
nearly 100% of the health care and thus the whole population is captured by these 
services. The system automatically updates itself and keeps a history of previous entries, 
so for example you can see current and all previous diagnoses made. The CRIS system 
allows the researcher to search any combination of structured and unstructured fields 
from electronic case records in order to select cases and specify the output fields that are 
required, which is exportable for further analysis. In addition, data from CRIS can be linked 
to other datasets including the Office of National Statistics (ONS), which records 
information relating to death, and Hospital Episode Statistics (HES) derived from 
structured information collected from general hospital episodes. 
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3.2. Ethical approval 
Ethical approval for the use of CRIS as a research dataset was given by Oxfordshire 
Research Ethics Committee C (08/H0606/71) and permission for the studies in this PhD 
were granted by the CRIS oversight committee.  
3.3. Sample selection 
The cohort consisted of patients who had a primary ICD-10 diagnosis of a psychotic 
disorder (F20-F29, inclusive) and began a first trial of clozapine between 1 January 2007 
and 31 December 2011. We selected this study period because electronic case records 
were fully implemented during 2006 and clozapine initiations on or before 31 December 
2011 permitted a two-year duration to the time of data collection (January 2014). Patients 
were aged 18-65 years at the start of clozapine treatment and initiated clozapine under 
secondary mental health care services, either as an inpatient or outpatient. Patients who 
solely received tertiary care from SLaM national services (such as the National Psychosis 
Unit) and were not residing in SLaM were excluded because complete follow-up data were 
not always available and they were not representative of clozapine patients in general. 
Patients receiving care from national services are likely to have complex and co-morbid 
mental illness and were thus excluded in order to make results widely applicable.  
The process of cohort identification is detailed in Figure 3.1. The sample was initially 
extracted using a General Architecture for Text Engineering (GATE) application, developed 
and validated against manual annotations (Cunningham et al., 2013; Hayes et al., 2015). 
GATE applications can take into account linguistic context when extracting data from free 
text, therefore distinguishing between a current prescription of clozapine and the mention 
of clozapine in other contexts (Hayes et al., 2015). The application used multiple data 
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sources to identify medication use including pharmacy dispensing events, structured 
medication field, clinical correspondence and free text entries, resulting in a high degree of 
sensitivity (Hayes et al., 2015). The application detected a total of 3242 patients, from 
approximately 230,000 represented in CRIS, whom had evidence of current or previous 
clozapine use. I then selected patients who had (i) first clozapine prescription between 1 
November 2006 (extended due to the fact clinical discussions about clozapine can precede 
its initiation) and 31 December 2011, (ii) had entries that spanned more than a single day 
(iii) ICD-10 F20-F29 diagnosis, and (iv) aged 18 years or over on 31 December 2011 and 65 
years or less on 1 January 2007. The data for the 799 patients who met these criteria were 
manually screened and study eligibility verified from their electronic clinical records. A 
total of 316 patients were included in the study (see Figure 3.1).  
3.4. Design 
The study comprised of a two-year retrospective cohort of all patients starting their first 
clozapine trial over a five-year period (2007-2011, inclusive) in SLaM. The study period 
began at clozapine initiation and ended with discontinuation, death or 24 months after 
treatment onset (whichever of these occurred first). In the event that an individual was 
lost to follow-up, their data was treated as censored. The date of clozapine initiation was 
derived from case notes, defined as the date the patient took their first dose of clozapine. 
The date of discontinuation was defined as the date the patient was last known to take 
clozapine (as stated in case notes), where this was followed by at least three consecutive 
months without clozapine treatment. Therefore, patients who stopped clozapine but were 
successfully re-titrated within three months were not classed as discontinued. The timing 
and the reasons for discontinuation were assessed in a case note review if the patient 
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discontinued clozapine treatment within 24 months of initiation (further details provided 
in section 5.3).  
 
Figure 3.1. Sample identification. 
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3.5. Study clinical assessments 
To assess response to clozapine treatment, I administered clinical research assessments 
retrospectively to CRIS case notes at the start of clozapine treatment (baseline) and 1, 2, 3, 
6, 9, 12, 18 and 24 months after clozapine initiation. These time points were selected to 
account for the greater likelihood of change within the first few months of treatment. If 
the patient discontinued clozapine prior to the end of the study period, clinical 
assessments were administered until the date clozapine treatment was ceased.  
We selected the Clinical Global Impressions (CGI) scale (Guy, 1976) as it is a widely 
accepted research tool that captures clinical improvement, originally designed for use in 
clinical trials, but has also been utilised in retrospective case note studies (Agid et al., 
2011). We also selected this instrument for pragmatic reasons given that the majority of 
clinical notes were seen to contain the necessary information to make CGI ratings whereas 
there was often insufficient detail in order to rate more comprehensive rating scales 
retrospectively such as the Brief Psychiatric Rating Scale (BPRS) (Overall & Gorham, 1962) 
or the Positive and Negative Syndrome Scale (PANSS) (Kay et al., 1987).  This decision was 
informed by the experiences of a previous medical student who attempted to administer 
BPRS scales retrospectively from case notes and found that there was insufficient 
information to do so. The CGI (Guy, 1976) is a global measure that is comprised of two 
scores (i) CGI-Severity (CGI-S), and (ii) CGI-Improvement (CGI-I). CGI-S is a seven-point 
scale measuring the severity of the illness in question (detailed in Table 3.1) and CGI-I is a 
seven-point scale measuring the change in psychopathology from baseline, frequently 
treatment initiation (detailed in Table 3.2). Ratings rely on the rater’s prior experience of 
the psychopathology in question and take into account all available information, such as 
symptoms, behaviour, psychosocial circumstances and the impact of the symptoms on the 
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patient’s ability to function (Busner & Targum, 2007). The CGI-S and CGI-I scales were 
administered in this study in line with published guidance (Busner & Targum, 2007) and 
additional coding guidelines written by JW and SL. Information used for the CGI ratings 
came from the descriptive case notes within CRIS. Frequently used sources were ward 
round or multi-disciplinary team meeting summaries, medication reviews, nursing notes, 
admission details, discharge summaries and tribunal reports.  
Baseline was defined as the week prior to clozapine initiation. Assessments at subsequent 
time points took a global impression of the time period from the last assessment. Several 
assessments, from different times and sources, were used to form a global impression of 
response to clozapine during that time period. Clinical information was used for a 
designated time point if the date of the assessment was closer than halfway between each 
assessment point (for example, if an assessment was one month and three weeks after the 
onset of clozapine, it would have been used for the month two assessment). Ratings were 
not made if the patient was non-adherent at that follow-up date, as it would not have 
reflected response to clozapine. Of 2106 possible time-point assessments, 2034 (97%) 
were made, ranging from 94% to 99% for each time point (Table 3.3). 
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CGI-Severity score Description  
1 Normal, not at all ill Not at all ill, symptoms of disorder not present past seven days 
2 Borderline mentally ill Subtle or suspected pathology 
3 Mildly ill Clearly established symptoms with minimal, if any, distress or 
difficulty in social and occupational function 
4 Moderately ill Overt symptoms causing noticeable, but modest, functional 
impairment or distress; symptom level may warrant 
medication 
5 Markedly ill Intrusive symptoms that distinctly impair social/occupational 
function or cause intrusive levels of distress 
6 Severely ill Disruptive pathology, behaviour and function are frequently 
influenced by symptoms, may require assistance from others 
7 Extremely ill Pathology drastically interferes in many life functions; may be 
hospitalised 
Table 3.1. CGI-Severity guidelines, adapted from (Busner & Targum, 2007). 
 
CGI-Improvement score Description 
1 Very much improved Nearly all better; good level of functioning; minimal symptoms; 
represents a very substantial change 
2 Much improved Notably better with significant reduction of symptoms; 
increase in the level of functioning but some symptoms remain 
3 Minimally improved Slightly better with little or no clinically meaningful reduction 
of symptoms. Represents very little change in basic clinical 
status, level of care, or functional capacity 
4 No change Symptoms remain essentially unchanged 
5 Minimally worse Slightly worse but may not be clinically meaningful; may 
represent very little change in basic clinical status or functional 
capacity 
6 Much worse Clinically significant increase in symptoms and diminished 
functioning 
7 Very much worse Severe exacerbation of symptoms and loss of functioning 
Table 3.2. CGI-Improvement guidelines, adapted from (Busner & Targum, 2007).  
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Time point of 
assessment 
Taking clozapine 
at time point (n) 
Assessments 
completed (n) 
Assessments 
completed (%) 
Baseline 316 313 99.05 
1 month 277 271 97.83 
2 months 261 247 94.63 
3 months 252 242 96.03 
6 months 233 223 95.71 
9 months 210 198 94.23 
12 months 197 188 95.43 
18 months 185 181 97.84 
24 months 175 168 96.00 
Total 2106 2034 96.58 
Table 3.3. CGI assessments completed at each follow-up assessment. 
Rater reliability 
The CGI assessments were carried out by a single rater (SL), whom had extensive prior 
experience with clinical assessments used for research purposes (SCAN, CAPA), and in 
conducting retrospective case note reviews. JW (primary supervisor and consultant 
psychiatrist) provided initial training on administering the CGI and advice throughout the 
rating process. Formal consensus ratings were made between SL and JW for marginal 
assessments. To assess reliability, a colleague Johnny Downs (psychiatrist) rated 12 
randomly selected patients (every 15th who had taken clozapine for at least 30 days). In 
total, 79 CGI-S and 66 CGI-I assessments were second rated. Intraclass correlations (ICC) 
were calculated to assess reliability, using a two-way mixed-effects model for absolute 
agreement. Higher values for ICC indicate greater inter-rater reliability: an ICC of 1 
indicating perfect agreement and 0 random agreement. For CGI-S the ICC was 0.65 (95% 
CI: 0.51-0.76) and for CGI-I the ICC was 0.61 (95% CI: 0.43-0.74). These scores were both in 
the ‘good’ range (0.60-0.74) as outlined in established guidelines (Cicchetti, 1994). We did 
not assess test-retest reliability (repeatability) due to time constraints.  
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3.6. Exposure variables 
Demographic and clinical details of age, gender, marital status, ethnicity, diagnosis, 
inpatient status and detention under the Mental Health Act were obtained from 
structured fields within CRIS. I was unable to collect data prior to clozapine initiation (such 
as age of onset, duration of untreated psychosis or theoretical delay to treatment) 
because data in CRIS was only available from 2006 onwards, when electronic records were 
fully introduced in SLaM. Age was defined as age at the date of clozapine initiation. Marital 
status was classified into currently married/cohabiting (married, cohabiting or civil 
partnership) and single (single, divorced, civil partnership dissolved, separated, widowed, 
surviving civil partnership or unknown). Self-reported ethnicity was coded as Black 
African/Caribbean (African, Caribbean and any other Black background) or other (White 
British, Irish, Indian, Bangladeshi, Pakistani, Chinese, and mixed or other ethnic group 
background). The decision to aggregate into these categorises was based on Black 
African/Caribbean ethnicity being the largest group within our sample, the relatively small 
cell counts of other ethnic groups, and approaches taken in the literature (Moeller et al., 
1995; Davis et al., 2014). Diagnosis was classified into schizophrenia (ICD-10 code: F20) 
and non-schizophrenia F21-9 diagnosis (F21- F29, inclusive). If an individual had more than 
one psychotic disorder diagnosis, the diagnosis closest in date to the start of clozapine was 
selected. Inpatient status was determined by whether clozapine was initiated as an 
inpatient or outpatient. Legal status was determined by whether the patient was detained 
under the Mental Health Act or not at the time of clozapine initiation. Level of deprivation 
was calculated from the Index of Multiple Deprivation (IMD) for England (2007). The IMD 
is made up of seven individual measures of deprivation (income, employment, health 
deprivation and disability, education skills and training, barriers to housing and services, 
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crime, and living environment) and is an established score for investigating social 
deprivation. The IMD score is calculated for geographical areas, which are ranked from 
one (most deprived) to 32482 (least deprived). Deprivation ranks were divided to give 
three roughly equal groups: high (1-5500), intermediate (5501-10000) and low (10001-
32482). The patient’s home address closest to the start of the study period (1st January 
2007) was used, with a separate category assigned to those who were homeless. 
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 Chapter 4
Discontinuation of Clozapine 
4.1. Summary 
Clozapine is uniquely effective in the management of treatment-resistant schizophrenia 
(TRS). However, a substantial proportion of patients discontinue treatment and this carries 
a poor prognosis. I investigated the risk factors, reasons and timing of clozapine 
discontinuation in a two-year retrospective cohort study of 316 patients with TRS receiving 
their first course of clozapine. Reasons for discontinuation of clozapine and duration of 
treatment were obtained from case notes and Cox regression was employed to test the 
association of baseline clinical factors with clozapine discontinuation. A total of 142 (45%) 
patients discontinued clozapine within two years. By studying the reasons for 
discontinuations due to a patient decision, we found that adverse drug reactions (ADRs) 
accounted for over half of clozapine discontinuations. Sedation was the most common 
ADR cited as a reason for discontinuation and the risk of discontinuation due to ADRs was 
highest in the first few months of clozapine treatment. High levels of deprivation in the 
neighbourhood where the patient lived were associated with increased risk of clozapine 
discontinuation (HR=2.12, 95% CI 1.30-3.47). This study indicates that clinical management 
to reduce the burden of ADRs in the first few months of treatment may have a significant 
impact on clozapine discontinuation and help more patients experience the benefits of 
clozapine treatment.  
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4.2. Introduction 
The superior efficacy of clozapine has been consistently demonstrated for those with TRS 
(Kane et al., 1988; McEvoy et al., 2006; Leucht et al., 2009), which is defined by the 
National Institute for Health and Care Excellence (NICE) as a failure to respond to two 
antipsychotic trials at a therapeutic dose for at least six weeks (National Institute for 
Health and Care Excellence, 2009). A third of patients with schizophrenia are estimated to 
be treatment-resistant (Meltzer, 1997) and thus potentially eligible for clozapine 
treatment.  
Clinical trials indicate that clozapine substantially reduces psychotic symptoms in 30-60% 
of TRS patients (Kane et al., 1988; Lieberman et al., 1994b). In addition, treatment with 
clozapine in comparison to other antipsychotic medications has been associated with 
decreased rates of mortality (Hayes et al., 2015), suicide (Meltzer et al., 2003a; Tiihonen et 
al., 2009), aggression (Chengappa et al., 2002), and financial costs due to reduced 
hospitalisations (Honigfeld & Patin, 1990; Hayhurst et al., 2002). Despite this evidence, an 
estimated 40% of patients eligible for clozapine in the UK have not received a trial (Royal 
College of Psychiatrists, 2012) and in those that have, there is a four-year delay from 
eligibility to first treatment (Howes et al., 2012b). The widespread underutilisation of 
clozapine may be due in part to its significant side effect profile (Atkin et al., 1996; 
Henderson et al., 2000). Of particular importance is the risk of agranulocytosis, which 
necessitates regular blood monitoring (Atkin et al., 1996). 
Discontinuation of clozapine can cause a rapid deterioration in psychotic symptoms 
(Seppala et al., 2005) and subsequent increased rates of compulsory treatment, 
hospitalisation, and poorer functioning (Atkinson et al., 2007; Wheeler et al., 2009b). 
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Unfortunately, approximately 40% of patients will discontinue clozapine treatment within 
24 months of initiation (Ciapparelli et al., 2000; Whiskey, 2003; Davis et al., 2014).  
Considering the favourable outcomes of clozapine treatment, and poor prognosis for those 
that discontinue, efforts have been made to identify patients that may be at increased risk 
and understand the causes of discontinuation. Older age at clozapine initiation, Black 
African/Caribbean ethnicity and substance abuse have been found to increase risk for 
clozapine discontinuation (Moeller et al., 1995; Krivoy et al., 2011; Davis et al., 2014). 
Adverse effects, patient decision and non-adherence have been identified as common 
reasons for clozapine discontinuation in previous studies (Atkinson et al., 2007; Taylor et 
al., 2009; Pai & Vella, 2012; Davis et al., 2014; Mustafa et al., 2015). Although patient 
decision and non-adherence have been identified as major reasons for discontinuation of 
clozapine, there has been no exploration of reasons behind this choice.  
As far as we are aware, only one study has been in a systematically attained sample of 
patients receiving their first trial of clozapine (Davis et al., 2014), which allows timing to be 
studied in detail and comparisons made with patients that continue. In addition, reasons 
for discontinuation of subsequent trials may differ from the first. Only one study has been 
conducted in the UK (Taylor et al., 2009), and given the differences in clozapine utilisation 
across health care systems, there may be limited generalisability of other studies to UK 
patients.  
4.2.1 Aims of the study 
The aims of the study were to (i) assess the reasons for discontinuation of clozapine, (ii) 
investigate the timing of reasons for discontinuation, (iii) determine which ADRs lead to 
discontinuation, and (iv) characterise the patients who are at increased risk of 
discontinuing clozapine. For each of these aims, we explored the differences between 
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discontinuations resulting from a clinician/clinical team decision and those as a result of 
patient non-adherence, referred to as patient decision. To achieve these aims a two-year 
retrospective cohort study of all patients starting their first clozapine trial over a five-year 
period (2007-2011, inclusive) in South London & Maudsley (SLaM) NHS Foundation Trust 
was conducted.  
4.3. Method 
Full details of the setting, ethical approval and sample selection are presented in sections 
3.1, 3.2 and 3.3, respectively. 
4.3.1 Sample 
The sample used for this analysis consisted of a cohort of patients who had an ICD-10 
primary diagnosis of a psychotic disorder (F20-F29, inclusive) and began a first trial of 
clozapine between 1 January 2007 and 31 December 2011 in SLaM. Patients were aged 18-
65 years at the start of clozapine treatment and initiated clozapine under standard 
secondary mental health care services, either as an inpatient or outpatient.  
4.3.2 Outcome measure 
I assessed the timing and the reasons for discontinuation in a case note review if the 
patient discontinued clozapine treatment within 24 months of initiation. The date of 
clozapine initiation was defined as the date the patient took their first dose of clozapine. 
The date of discontinuation was defined as the date the patient was last known to take 
clozapine, where this was followed by at least three consecutive months without clozapine 
treatment. Therefore, patients who stopped clozapine but were successfully re-titrated 
within three months were not classed as discontinued.  
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Reasons for discontinuation were obtained from case notes when explicitly stated by the 
patient’s clinical team. These were categorised into mutually exclusive reasons, as outlined 
below, and were consistent with the previous literature (Atkinson et al., 2007; Taylor et al., 
2009; Pai & Vella, 2012; Davis et al., 2014; Mustafa et al., 2015). If there were multiple 
reasons that spanned more than one category (of which there were only five instances), 
the most likely primary reason was inferred after discussion with a consultant psychiatrist 
(primary supervisor, JW).  
Reasons for discontinuation were coded into categories consistent with the previous 
literature; (i) adverse drug reaction (ADR) defined as any unwanted or harmful reaction 
attributed to clozapine including intolerable side effects, (ii) non-adherence not otherwise 
specified defined as patient declining to take medication, not attending for blood 
monitoring, or missing doses without informing their clinical team and with no reason for 
doing so stated (iii) inadequate response defined as insufficient improvement in 
symptoms, (iv) blood monitoring defined as a stated dislike of either blood tests or 
inconvenience of frequent clinic visits, (v) belief medication not required defined as a 
patient belief that clozapine would not help them or that they did not need any 
medication, (vi) delusional belief held by the patient specifically regarding clozapine, (vii) 
anticipated non-adherence defined as pre-emptive discontinuation initiated by the clinical 
team as it was believed the patient would become non-adherent upon discharge from 
inpatient services, (vii) death, regardless of whether the cause was attributed to clozapine, 
and (ix) any other reason. If a patient discontinued due to non-adherence but cited a 
reason for doing so, they would be classified under the reason cited. To investigate 
differences in patients that were non-adherent, discontinuations were further classified as 
a clinician-led decision or patient decision. Clinician-led decision was defined as a 
discontinuation that was led by the clinical team, although in most cases this was a 
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consensual decision between the patient and clinical team. Patient decision was defined as 
discontinuation due to non-adherence by declining to take medication, not attending for 
blood monitoring, or missing doses without informing their clinical team. 
The specific ADR was recorded if it was stated to be the reason for discontinuation. These 
were not classified into mutually exclusive causes because in the majority of cases a 
number of ADRs were cited per patient and since we wanted to reflect the broad adverse 
effect profile responsible for treatment discontinuation. 
4.3.3 Exposure variables 
Details of age, gender, marital status, ethnicity, diagnosis, inpatient status and detention 
under the Mental Health Act were obtained from structured fields within CRIS. Level of 
deprivation was calculated from the Index of Multiple Deprivation (IMD) for England 
(2007) for the patient’s home address. Key definitions regarding these variables are 
described in section 3.6. 
4.3.4 Analysis  
A Kaplan-Meier survival curve was used to display the time to all-cause clozapine 
discontinuation and reasons for discontinuation. Having checked proportional hazard 
assumptions, a Cox regression was employed to model the association between all-cause 
clozapine discontinuation and gender, age, marital status, ethnicity, level of deprivation, 
diagnosis, inpatient status and detention under the Mental Health Act. Associations with 
all-cause discontinuation were assessed in a crude univariable analysis, and also in models 
that had been fully adjusted for all variables examined. Level of deprivation was entered 
into the model as a categorical dummy variable. A likelihood ratio test was used to test the 
appropriateness of entering age as a continuous variable. Interaction effects with age, 
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gender and ethnicity were investigated for variables significantly associated with all-cause 
discontinuation (P < 0.05). Sensitivity analyses were conducted whereby (i) death was 
classified as censored data rather than as a reason for all-cause discontinuation, and (ii) 
only patients with a diagnosis of schizophrenia (F20) were included. Competing-risks 
regression (Fine & Gray, 1999; Kim, 2007) was employed to model the impact of predictors 
on cause-specific discontinuation, whilst taking into account the other causes, firstly in a 
crude analysis and secondly, fully adjusted for all covariates examined. The specific causes 
of discontinuation investigated were; ADRs, non-ADRs (all reasons other than ADRs), 
clinician-led decision and patient decision. All statistical analyses were performed using 
STATA version 12 (StataCorp, 2011).  
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4.4. Results 
4.4.1 Patient characteristics 
A total of 316 patients were included in the study. Sample characteristics are presented in 
Table 4.1. The mean age at clozapine initiation was 36 years. The majority of the sample 
had a diagnosis of schizophrenia (n=285). Non-schizophrenia diagnoses included 
schizoaffective disorder (n=21), acute and transient psychotic disorder (n=3), unspecified 
nonorganic psychosis (n=3), persistent delusional disorder (n=2), schizotypal disorder 
(n=1), and other nonorganic psychotic disorder (n=1). In the other ethnicity category, 127 
were White British, 17 Asian and 21 of other ethnicity. Of the 162 (51.3%) who were 
detained under the Mental Health Act at the time of clozapine initiation, the majority were 
under section 3 (detention for treatment, n=124) or under sections 37-49 (forensic, n=30). 
Characteristic N % 
Male gender 205 64.9 
Mean age (years) 36.23 SD=10.9 
Married or cohabiting 27  8.5 
Black African/Caribbean ethnicity 151 47.8 
Level of deprivation   
    Low  84 26.6 
    Intermediate 112 35.4 
    High 100  31.7 
    Homeless 14  4.4 
Schizophrenia diagnosis 285 90.2 
Inpatient 262 82.9 
Detained under Mental Health Act 162 51.3 
Table 4.1. Sample characteristics. SD = standard deviation. Percentages relate to total 
sample (n=316).  
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4.4.2 Reasons for discontinuation 
A total of 142 (45%) patients discontinued their first trial of clozapine within 24 months of 
initiation. Table 4.2 details the reasons for clozapine discontinuation. In total, 65 
discontinuations (45.8% of total discontinuations) were from a clinician-led decision and 74 
(52.1%) were from a patient decision. Three patients died within the study period. Cause 
of death as determined by the case notes was available for two patients: one pulmonary 
embolism and the other ‘natural causes’. The majority of discontinuations from a clinician-
led decision were due to ADRs (n=54), and other reasons included periods spent in other 
countries (n=3), lack of response for tardive dyskinesia (n=1) and inability to obtain blood 
samples due to lack of venous access (n=1). It was possible to obtain reasons for 49 of the 
74 discontinuations resulting from a patient decision and thus the remaining 25 patients 
were classified as non-adherence NOS. ADRs were the most common reason for 
discontinuation from a patient decision (n=26), followed by a dislike of blood monitoring 
(n=10), inadequate response (n=5), a belief that the medication was not required (n=4), 
and a delusional belief regarding clozapine (n=4). Combined, ADRs attributed to clozapine 
were responsible for over half of the total discontinuations (n=80). Discontinuations due to 
blood monitoring (n=11) and an inadequate response (n=8) were more frequent for patient 
than clinician-led discontinuations. 
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Reason for discontinuation 
 
Clinician-led decision 
N (%) 
Patient decision 
N (%) 
Combined 
N (%) 
Adverse drug reaction 54 (38.0) 26 (18.3) 80 (56.3) 
Non-adherence NOS - 25 (17.6) 25 (17.6) 
Blood monitoring 1 (0.7) 10 (7.0) 11 (7.8) 
Inadequate response 3 (2.1) 5 (3.5) 8 (5.6) 
Belief medication not required 0 (0.0) 4 (2.8) 4 (2.8) 
Delusional belief 0 (0.0) 4 (2.8) 4 (2.8) 
Anticipated non-adherence 2 (1.4) 0 (0.0) 2 (1.4) 
Other 5 (3.5) 0 (0.0) 5 (3.5) 
Death - - 3 (2.1) 
Total 65 (45.8) 74 (52.1) 142 (100.0) 
Table 4.2. Reasons for clozapine discontinuation. Columns represent discontinuations 
resulting from a clinician-led decision, patient decision, and combined total reasons. 
Percentages relate to total discontinued (n=142). 
4.4.3 Time to clozapine discontinuation 
Figure 4.1 displays a Kaplan-Meier survival curve for the time to all-cause clozapine 
discontinuation and for overall reasons of ADRs, non-adherence NOS, blood monitoring 
and inadequate response. Due to the small number of observations, the timings of 
discontinuations due to reasons of a belief medication is not required, delusional belief, 
anticipated non-adherence, death and other were not displayed. Appendix 4 details the 
timings for all combined reasons.  
A substantial proportion of those who initiated clozapine discontinued within the first few 
months: 12.3% within one month, 20% within three months and 38% within a year. The 
mean time to all-cause discontinuation was 5.9 months and the median 4.0 months 
(analysis restricted to those that discontinued within 24 months). The risk of 
discontinuations due to ADRs was highest in the first few months of clozapine treatment 
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(see Figure 4.1). By contrast, the risk of discontinuation due to non-adherence NOS, blood 
monitoring and inadequate response were evenly distributed across the study period.  
In a comparison of all-cause clozapine discontinuation timings of clinician-led decisions and 
patient decisions (Figure 4.2), the risk in the first three months of treatment was higher for 
clinician-led than patient discontinuations. The frequencies of reasons of discontinuations 
in three monthly intervals due to clinician-led and patient decision are listed in appendix 5 
and 6, respectively. 
 
Figure 4.1. Kaplan-Meier survival curve demonstrating proportion remaining on clozapine 
over initial 24 months of clozapine treatment. Blue line represents all-cause 
discontinuation. Other lines represent discontinuations due to adverse drug reactions 
(green), non-adherence not otherwise specified (grey), blood monitoring (red) and 
inadequate response (orange). 
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Figure 4.2. Kaplan-Meier survival curve demonstrating cumulative timing of 
discontinuations due to a clinician-led decision or patient decision. 
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4.4.4 Adverse drug reactions 
The 80 patients who discontinued clozapine due to ADRs cited a total of 130 individual 
ADRs. Figure 4.3 displays the proportion of discontinuations due to ADRs that were from a 
clinician-led or patient decision (frequencies listed in Appendix 7). Overall, sedation (n=28), 
neutropenia (n=15) and tachycardia (n=13) were the most common ADRs cited as a reason 
for discontinuation of clozapine. The most common ADRs cited for clinician-led 
discontinuations were neutropenia (n=15), sedation (n=13), tachycardia (n=12) and 
dizziness (n=8). The most common ADRs cited as a reason for discontinuation from a 
patient decision were sedation (n=15), followed by nausea (n=6), hypersalivation (n=4) and 
weight gain (n=4).  
 
Figure 4.3. Adverse drug reactions (ADRs) cited as a reason for discontinuation of clozapine 
for 80 patients (130 ADRs). ADRs are not exclusive and differentiated by whether the 
discontinuation was a clinician-led decision (blue) or patient decision (grey).  
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4.4.5 Risk factors for discontinuation 
Table 4.3 details the association of baseline clinical factors with all-cause clozapine 
discontinuation. In the fully adjusted model, intermediate (hazard ratio (HR) = 1.74, 95% CI 
1.06-2.83) and high neighbourhood deprivation (HR = 2.12, 95% CI 1.30-3.47) were 
associated with increased risk for all-cause clozapine discontinuation. Black 
African/Caribbean ethnicity was associated with all-cause discontinuation in the crude 
analysis (HR = 1.55, 95% CI 1.11-2.16) but the association attenuated in the fully adjusted 
model (HR = 1.26, 95% CI 0.89-1.80). Gender, age, marital status, diagnosis, inpatient 
status and detention under the Mental Health Act were not associated with all-cause 
clozapine discontinuation in either the crude or fully adjusted models. No interaction 
effects were identified and there were no differences in sensitivity analyses where death 
was not classed as a cause of discontinuation (Table 4.4). In a second sensitivity analysis 
restricted to those with a schizophrenia diagnosis, initiating clozapine as an inpatient was 
associated with a reduced risk of discontinuation in the fully adjusted model (HR=0.53, 
95% CI 0.31-0.90, Table 4.5). 
Competing-risks regressions were used to investigate risk for cause-specific 
discontinuations. The association of predictors with discontinuations due to ADRs and non-
ADRs are detailed in Table 4.6. There was a significant association between level of 
deprivation and non-ADR discontinuations, but this was no longer significant in the fully 
adjusted model. The association of predictors with discontinuation due to a clinician-led 
decision or patient decision were also investigated (Table 4.7). High deprivation was 
significantly associated with patient decision discontinuations, in both the crude and fully 
adjusted models (HR = 2.17, 95% CI 1.11-4.24).  
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   Crude  Fully Adjusted
1 
Characteristic 
Discontinued  
(n=142) 
N (%) 
Continued  
(n=174) 
N (%) 
Hazard ratio  
(95% CI) P-value  
Hazard ratio  
(95% CI) P-value 
Male gender 89 (62.68) 116 (66.67) 0.86 (0.61-1.21) 0.381  0.77 (0.53-1.10) 0.155 
Age at clozapine onset (years, SD) 36.11 (11.29) 36.33 (10.66) 1.00 (0.98-1.01) 0.717  0.99 (0.98-1.01) 0.423 
Currently married or cohabiting 14 (9.86) 13 (7.47) 1.26 (0.73-2.19) 0.407  1.40 (0.76-2.57) 0.284 
Black African/Caribbean ethnicity 81 (57.04) 70 (40.23) 1.55 (1.11-2.16) 0.010  1.26 (0.89-1.80) 0.194 
Level of deprivation        
    Low  26 (18.31) 58 (33.33) Ref   Ref  
    Intermediate 53 (37.32) 59 (33.91) 1.72 (1.08-2.75) 0.024  1.74 (1.06-2.83) 0.027 
    High 55 (38.73) 45 (25.86) 2.21 (1.38-3.52) 9.10 x 10-4  2.12 (1.30-3.47) 0.003 
    Homeless 6 (4.23) 8 (4.60) 1.44 (0.59-3.50) 0.419  1.51 (0.61-3.71) 0.373 
Non-schizophrenia F20 diagnosis 14 (9.86) 17 (9.77) 1.01 (0.58-1.76) 0.966  0.82 (0.46-1.46) 0.497 
Inpatient 115 (80.99) 147 (84.48) 0.84 (0.55-1.27) 0.401  0.66 (0.39-1.11) 0.119 
Detained under Mental Health Act 81 (57.04) 81 (46.55) 1.32 (0.95-1.84) 0.104  1.34 (0.88-2.03) 0.168 
Table 4.3. Risk for clozapine discontinuation. Columns represent characteristics for those that discontinued or continued clozapine, hazard ratio and 
P-value from crude and fully adjusted Cox regression. 1Fully adjusted includes all variables. Data for all 316 patients was available for each variable 
other than level of deprivation, which was available for 310 patients. 
Note: Follow-up period begins at start of clozapine treatment (from January 1, 2007 to December 31, 2011, inclusive) and ends with discontinuation, 
death or end of study period (24 months after treatment onset). 
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Crude  Fully Adjusted1 
Characteristic 
Hazard ratio  
(95% CI) P-value  
Hazard ratio  
(95% CI) P-value 
Male gender 0.88 (0.63-1.25) 0.487  0.79 (0.55-1.14) 0.210 
Age at clozapine onset (years, SD) 0.99 (0.98-1.01) 0.620  0.99 (0.98-1.01) 0.422 
Currently married or cohabiting 1.19 (0.67-2.11) 0.547  1.32 (0.70-2.47) 0.394 
Black African/Caribbean ethnicity 1.53 (1.10-2.15) 0.013  1.27 (0.88-1.81) 0.197 
Level of deprivation      
    Low  Ref   Ref  
    Intermediate 1.72 (1.08-2.75) 0.023  1.71 (1.05-2.79) 0.032 
    High 2.09 (1.30-3.34) 0.0023  1.98 (1.20-3.25) 0.007 
    Homeless 1.44 (0.59-3.51) 0.418  1.49 (0.61-3.68) 0.384 
Non-schizophrenia F20 diagnosis 1.04 (0.60-1.80) 0.899  0.85 (0.48-1.52) 0.588 
Inpatient 0.81 (0.54-1.24) 0.338  0.64 (0.38-1.08) 0.092 
Detained under Mental Health Act 1.31 (0.93-1.83) 0.117  1.36 (0.89-2.08) 0.152 
Table 4.4. Sensitivity analysis of Cox regression including death as censored data rather 
than a reason for discontinuation. Columns represent hazard ratio and P-value from crude 
and fully adjusted Cox regression. 1Fully adjusted includes all variables. Data for all 316 
patients was available for each variable other than level of deprivation, which was 
available for 310 patients.  
 
Crude  Fully Adjusted1 
Characteristic 
Hazard ratio  
(95% CI) P-value  
Hazard ratio  
(95% CI) P-value 
Male gender 0.84 (0.58-1.20) 0.341  0.73 (0.50-1.08) 0.112 
Age at clozapine onset (years, SD) 0.99 (0.98-1.01) 0.467  0.99 (0.97-1.01) 0.295 
Currently married or cohabiting 1.22 (0.66-2.26) 0.536  1.46 (0.73-2.91) 0.279 
Black African/Caribbean ethnicity 1.67 (1.17-2.38) 0.0046  1.34 (0.92-1.95) 0.128 
Level of deprivation      
    Low  Ref   Ref  
    Intermediate 1.91 (1.16-3.14) 0.011  1.99 (1.18-3.33) 0.009 
    High 2.44 (1.49-4.01) 0.00043  2.32 (1.38-3.90) 0.001 
    Homeless 1.70 (0.69-4.19) 0.245  1.78 (0.71-4.46) 0.216 
Inpatient 0.70 (0.45-1.07) 0.103  0.53 (0.31-0.90) 0.020 
Detained under Mental Health Act 1.27 (0.90-1.80) 0.180  1.37 (0.88-2.14) 0.167 
Table 4.5. Sensitivity analysis for clozapine discontinuation only including patients with a 
schizophrenia diagnosis (ICD-10 F20) (n=285). Columns represent Cox regression hazard 
ratio and P-value from crude and fully adjusted Cox regression. 1Fully adjusted includes all 
variables. Data for all 285 patients was available for each variable other than level of 
deprivation, which was available for 279 patients.  
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 Crude  Fully Adjusted
1 
Characteristic 
SHR  
(95% CI) P-value  
SHR 
(95% CI) P-value 
i. Discontinuation due to ADRs      
Male gender 0.73 (0.47-1.14) 0.169  0.66 (0.41-1.07) 0.093 
Age at clozapine onset (years, SD) 1.00 (0.98-1.02) 0.829  0.99 (0.97-1.02) 0.461 
Currently married or cohabiting 1.74 (0.88-3.45) 0.112  1.79 (0.79-4.04) 0.164 
Black African/Caribbean ethnicity 1.37 (0.88-2.13) 0.161  1.13 (0.68-1.88) 0.628 
Level of deprivation      
    Low  Ref   Ref  
    Intermediate 1.70 (0.92-3.15) 0.089  1.79 (0.90-3.55) 0.097 
    High 1.66 (0.89-3.12) 0.112  1.68 (0.84-3.34) 0.141 
    Homeless 1.18 (0.35-3.91) 0.790  1.36 (0.39-4.72) 0.631 
Non-schizophrenia F20 diagnosis 1.36 (0.71-2.63) 0.353  1.06 (0.50-2.23) 0.875 
Inpatient 0.79 (0.46-1.37) 0.411  0.63 (0.31-1.27) 0.195 
Detained under Mental Health Act 1.19 (0.76-1.84) 0.445  1.27 (0.73-2.23) 0.402 
ii. Discontinuations not due to ADRs 
Male gender 1.15 (0.67-1.95) 0.618  1.07 (0.60-1.91) 0.815 
Age at clozapine onset (years, SD) 1.00 (0.98-1.02) 0.933  1.00 (0.98-1.03) 0.905 
Currently married or cohabiting 0.69 (0.23-1.83) 0.457  0.88 (0.32-2.44) 0.805 
Black African/Caribbean ethnicity 1.65 (0.99-2.75) 0.054  1.42 (0.84-2.41) 0.191 
Level of deprivation      
    Low  Ref   Ref  
    Intermediate 1.48 (0.72-3.04) 0.286  1.37 (0.67-2.80) 0.392 
    High 2.33 (1.16-4.69) 0.017  2.06 (0.98-4.31) 0.056 
    Homeless 1.71 (0.49-6.03) 0.401  1.54 (0.44-5.41) 0.504 
Non-schizophrenia F20 diagnosis 0.61 (0.22-1.70) 0.345  0.64 (0.21-1.93) 0.424 
Inpatient 0.96 (0.50-1.83) 0.900  0.78 (0.35-1.76) 0.553 
Detained under Mental Health Act 1.43 (0.86-2.38) 0.169  1.39 (0.72-2.69) 0.327 
Table 4.6. Competing risks regression to model impact of predictors on (i) discontinuation 
due to ADRs, whilst taking into account the other causes of discontinuation and (ii) 
discontinuation due to reasons other than ADRs, whilst taking into account 
discontinuations due to ADRs. SHR = subhazard ratio. 1Fully adjusted includes all variables. 
Data for all 316 patients was available for each variable other than level of deprivation, 
which was available for 310 patients.  
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 Crude  Fully Adjusted
1 
Characteristic 
SHR  
(95% CI) P-value  
SHR 
(95% CI) P-value 
i. Clinician-led decision  
Male gender 0.87 (0.53-1.43) 0.589  0.87 (0.51-1.49) 0.603 
Age at clozapine onset (years, SD) 1.00 (0.98-1.03) 0.765  1.00 (0.97-1.02) 0.879 
Currently married or cohabiting 2.18 (1.10-4.33) 0.026  2.17 (0.95-4.95) 0.067 
Black African/Caribbean ethnicity 1.45 (0.89-2.36) 0.131  1.26 (0.74-2.13) 0.399 
Level of deprivation      
    Low  Ref   Ref  
    Intermediate 1.67 (0.84-3.35) 0.146  1.62 (0.76-3.48) 0.213 
    High 1.73 (0.86-3.50) 0.124  1.53 (0.71-3.31) 0.277 
    Homeless 1.43 (0.43-4.74) 0.561  1.68 (0.49-5.73) 0.405 
Non-schizophrenia F20 diagnosis 1.75 (0.89-3.42) 0.102  1.43 (0.66-3.11) 0.360 
Inpatient 0.68 (0.38-1.21) 0.188  0.48 (0.22-1.07) 0.072 
Detained under Mental Health Act 1.26 (0.78-2.05) 0.341  1.56 (0.81-3.01) 0.183 
ii. Patient decision 
Male gender 0.91 (0.57-1.44) 0.677  0.75 (0.46-1.25) 0.270 
Age at clozapine onset (years, SD) 0.99 (0.97-1.02) 0.555  0.99 (0.97-1.02) 0.604 
Currently married or cohabiting 0.54 (0.21-1.41) 0.210  0.66 (0.24-1.81) 0.422 
Black African/Caribbean ethnicity 1.51 (0.96-2.39) 0.076  1.24 (0.75-2.07) 0.403 
Level of deprivation      
    Low  Ref   Ref  
    Intermediate 1.55 (0.82-2.91) 0.176  1.59 (0.83-3.06) 0.165 
    High 2.15 (1.15-4.00) 0.016  2.17 (1.11-4.24) 0.024 
    Homeless 1.40 (0.39-4.96) 0.605  1.30 (0.34-4.89) 0.701 
Non-schizophrenia F20 diagnosis 0.47 (0.18-1.25) 0.129  0.44 (0.15-1.25) 0.122 
Inpatient 1.11 (0.60-2.05) 0.733  0.99 (0.48-2.02) 0.975 
Detained under Mental Health Act 1.31 (0.83-2.07) 0.247  1.14 (0.64-2.01) 0.661 
Table 4.7. Competing risks regression to model impact of predictors on (i) discontinuations 
due to a clinician-led decision, taking into account discontinuations due to a patient 
decision and (ii) discontinuations due to a patient decision, taking into account 
discontinuations from a clinician-led decision. SHR = subhazard ratio. 1Fully adjusted 
includes all variables. Data for all 316 patients was available for each variable other than 
level of deprivation, which was available for 310 patients.  
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4.5. Discussion 
In a retrospective cohort study, 45% of patients discontinued their first trial of clozapine 
within 24 months of initiation. Adverse drug reactions (ADRs) were responsible for over 
half of clozapine discontinuations and the risk of discontinuations due to ADRs was highest 
in the first few months of clozapine treatment. Neighbourhood deprivation was associated 
with an increased risk of all-cause clozapine discontinuation. 
4.5.1 Reasons for discontinuation 
This is the first study to examine in detail the reasons for discontinuations due to a patient 
decision and distinguish them from clinician-led or joint decisions to discontinue. 
Consistent with previous research, discontinuations due to a patient decision were more 
common than discontinuations involving the clinical team (Taylor et al., 2009; Davis et al., 
2014). By studying, where possible, the reasons for discontinuation due to a patient 
decision, we found that ADRs accounted for over half of clozapine discontinuations. The 
results suggest that the role of ADRs has been underestimated as previous studies have 
used a restricted number of categories for discontinuation (i.e. patient choice and non-
adherence), with no studies categorising the underlying reasons for non-adherence (Taylor 
et al., 2009; Krivoy et al., 2011; Pai & Vella, 2012; Davis et al., 2014; Mustafa et al., 2015). 
Furthermore, the results are consistent with studies that have shown a quarter to two 
thirds of non-adherence to other antipsychotics was attributable to ADRs (Fenton et al., 
1997; Hudson et al., 2004).  
The adverse effect most frequently cited was sedation, which accounted for 20% of all 
discontinuations. Interestingly, over half of discontinuations due to sedation were from 
discontinuations due to a patient decision. This is particularly worrying since sedation is 
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usually transient and can almost always be minimised by reducing the dose and/or 
titration rate of clozapine, adjusting the timing of the dose or partial substitution with less 
sedating drugs such as aripiprazole (Nair & MacCabe, 2014). Around 10% of patients who 
start clozapine are discontinuing for this reason; it is likely many could probably remain on 
clozapine if this adverse effect was more actively managed and monitored by the clinical 
team.  
The second most common ADR was neutropenia, which occurred in 4.7% of the total 
sample. Previous research has shown that in many cases, neutropenia is not related to 
clozapine or is transient, and with the correct expertise, 80% can be reinstated on 
clozapine (Meyer et al., 2015). In this study, 10 of the 15 discontinuations due to 
neutropenia were in Black African/Caribbean patients and only a minority (3/10) had a 
haematological assessment for benign ethnic neutropenia. This raises the possibility that 
this condition remains under recognised (Whiskey et al., 2011). 
A question that remains to be explored is whether the side effect profile of patients who 
discontinue clozapine differs from patients who continue with the treatment. It has been 
suggested that many discontinuations due to ADRs could be avoided (Nielsen et al., 2013), 
although the appropriateness of any given reason was not assessed in this study. 
Nonetheless, these findings suggest that prompt identification and appropriate 
management of ADRs has the potential to improve continuation of clozapine treatment.  
Consistent with earlier reports (Taylor et al., 2009; Pai & Vella, 2012; Davis et al., 2014; 
Mustafa et al., 2015), discontinuation due primarily to an inadequate response to 
clozapine was rare, occurring in only 2.5% of patients. Given that non-response to 
clozapine has been estimated between 40-70% (Kane et al., 1988; Lieberman et al., 
1994b), this result is unlikely to reflect the true rates of non-response to clozapine but 
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rather that non-response is seldom recorded as the primary reason to discontinue 
treatment. A patient (or clinician) may be more likely to tolerate an ADR and be willing to 
persevere with clozapine if they are experiencing a good clinical response to clozapine, but 
might instead discontinue clozapine, citing adverse effects, in the absence of a clinical 
response. The decision to discontinue clozapine is likely to be a multifactorial one involving 
a judgement as to the balance of the likely benefits versus harms of continuing versus 
stopping clozapine, taking into account the views of the patient and of his or her carers. 
Nevertheless, the small percentage of patients who discontinue primarily due to 
inadequate response is striking. It could be driven partly by concern over risk of further 
relapse upon cessation (Seppala et al., 2005) and partly by a lack of any other evidence-
based treatment options.  
An interesting and novel insight was the observation that discontinuation of clozapine due 
to dislike of blood monitoring was reported in 3.5% of patients. This raises the question of 
whether rates would be higher in all those eligible for clozapine, an important issue given 
that low rates of clozapine prescription have been attributed to the burden of blood 
monitoring (Nielsen et al., 2010). 
In this cohort of patients initiating clozapine, three patients died (2% of discontinuations) 
during the follow-up period. It would be prudent not to over interpret this finding, but it 
does contrast with cross-sectional studies of clozapine discontinuation, which reported 
death as accounting for 13% of clozapine discontinuations (Taylor et al., 2009; Davis et al., 
2014; Mustafa et al., 2015). This inconsistency is likely due to differences in study design. 
Previous studies assessed all discontinuations over a study period, regardless of duration 
of clozapine treatment, whereas this study assessed the discontinuations within 24 
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months of initiation. Consequently, the mean duration of exposure to clozapine and the 
average age of patients are lower in this sample. 
4.5.2 Risk factors for discontinuation 
This is the first study to observe an association between level of social deprivation and risk 
of clozapine discontinuation. Furthermore, it was found this result was driven by 
discontinuations resulting from a patient decision. Previous studies have reported mixed 
results regarding the relationship between socio-economic status and non-adherence to 
medication (Kane et al., 2013), although it is not measured in many studies. It is likely 
social deprivation is a proxy marker for other factors that underlie discontinuation and 
non-adherence and further research is needed to determine whether particular 
characteristics of these patient groups increase risk for clozapine discontinuation or 
perhaps whether clinical teams supporting areas in high deprivation are under increased 
pressure or have more limited resources. 
Consistent with previous studies, there were increased rates of all-cause clozapine 
discontinuation in Black African/Caribbean patients (Moeller et al., 1995; Davis et al., 
2014); 54% of Black African/Caribbean patients discontinued compared with 40% of non-
Black African/Caribbean patients. However, this association attenuated and was not 
statistically significant after adjusting for other factors. There was no evidence to support 
previous findings that higher age at clozapine initiation increased risk for discontinuation 
(MacGillivray et al., 2003; Krivoy et al., 2011; Davis et al., 2014). 
4.5.3 Study limitations 
A limitation of this study is its retrospective nature, specifically that the quality of data 
available was limited to information entered into the electronic case note system by the 
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patient’s clinical team. However, benefits of this study design are that the results are 
reflective of routine clinical care and there was universal capture of patients commencing 
clozapine in a defined geographical area covering a population of 1.2 million people, with 
consequently little or no selection bias. The fact that informed consent was not required 
also eliminated the selection bias in favour of higher functioning patients that bedevils 
research on psychosis. Recall bias was minimised by the use of contemporaneous records 
and the minimal missing data allowed us to determine the reasons for discontinuation for 
all of the patients. Furthermore, CRIS incorporates routinely collected data from multiple 
sources, such as pharmacy dispensing information, to increase reliability.  
The exclusion of patients who solely received tertiary care in SLaM national services (such 
as the National Psychosis Unit) may mean that our findings do not extend to a group of 
patients with particularly complex or co-morbid mental illness. However, patients who 
were residing in SLaM but received tertiary care were included in the study and so these 
findings should be widely applicable.  
An additional limitation is that only the discontinuations within the first 24 months of 
treatment onset were assessed. However, previous studies show that a substantial 
proportion of those who discontinue do so within the first year of treatment (Pai et al., 
2012; Davis et al., 2014). The proportion of patients that discontinued clozapine in this 
study is in the mid-range (20%-57%) of other studies whose durations ranged from 6 
months to 15 years (Moeller et al., 1995; Laker et al., 1998; Ciapparelli et al., 2000; 
Hayhurst et al., 2002; MacGillivray et al., 2003; Krivoy et al., 2011; Pai & Vella, 2012; Davis 
et al., 2014). Additional confidence in the study design and its generalisability comes from 
the fact the frequencies of reasons for discontinuation, other than rates of death, are 
similar to studies with longer follow-ups suggesting discontinuations after two years are 
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not qualitatively different. Furthermore, the study design allowed an analysis of timing of 
first clozapine discontinuation and comparison with those that continued with treatment. 
The sample is comparable to the population in London with a diagnosis of schizophrenia 
(Morgan et al., 2006) but has higher proportions of Black African/Caribbean ethnicity and 
lower proportions of Asian ethnicity in comparison to England as a whole (Stewart et al., 
2009). However, the National Audit of Schizophrenia (2012) suggest that the service use in 
London is comparable to the rest of the UK (Royal College of Psychiatrists, 2012). The only 
other UK study investigating clozapine discontinuation was conducted in the same area as 
this study, but the samples are entirely independent (Taylor et al., 2009).  
4.5.4 Clinical implications 
Considering that clozapine is the most effective treatment for TRS (Kane et al., 1988; 
Lieberman et al., 1994b), it is important that avoidable discontinuation is minimised. By 
examining the reasons for discontinuations due to a patient decision we found that ADRs 
accounted for the majority of clozapine discontinuations. It is important that clinicians 
identify and treat ADRs attributed to clozapine, particularly in the first few months after 
treatment onset, before they lead to discontinuation. Patients who live in an area of high 
deprivation are at an increased risk of discontinuing clozapine and may need additional 
support to maintain engagement with treatment.   
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 Chapter 5
Clozapine Response 
5.1. Summary 
Clinical trials indicate that 30-60% of patients with treatment-resistant schizophrenia (TRS) 
will respond to clozapine treatment. Predictors of response would be valuable in assisting 
clinicians in deciding if clozapine treatment is likely to be beneficial. The predictive factors 
and timing of long-term response to clozapine were investigated in a two-year 
retrospective cohort study of patients with TRS receiving their first course of clozapine. 
The Clinical Global Impressions (CGI) scale was administered from case notes at the start 
of clozapine treatment and after 1, 2, 3, 6, 9, 12, 18 and 24 months. Due to the substantial 
variability of clozapine response definitions used in previous studies, we considered 
several definitions of response. In total, 114 (41.2%) patients experienced an absolute 
response (CGI-I ≤ 2 and CGI-S ≤ 3), 48.4% of patients had a relative response (reduction ≥ 2 
CGI-S scores), and 19.1% had an exceptional response (CGI-I score of 1) over the study 
period. In a fully adjusted Cox regression, female gender was significantly associated with 
a good response to clozapine (hazard ratio (HR) = 0.63, 95% CI 0.41-0.96), regardless of the 
response definition. In contrast there was an inconsistent association between baseline 
severity and response; higher baseline CGI severity was associated with poor absolute (HR 
= 0.43, 95% CI 0.31-0.60) and exceptional (HR = 0.60, 95% CI 0.38-0.95) response, but good 
relative response (HR = 3.24, 95% CI 2.34-4.50). Clinical improvement after one month of 
treatment was a strong predictor of response within 24 months. We found that 75% of 
absolute responders were at least much improved (CGI-I score of 2) at two months, which 
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increased to 92% at six months. Of the patients who were either minimally improved or 
not changed after two months of treatment, 23% and 38% went on to meet absolute and 
relative response criteria within 24 months, respectively. By six months this proportion 
reduced to 14%. The results suggest that responders are more likely to be female, tend to 
have a good initial response to clozapine. However, six months of treatment may be 
required to determine non-response.  
5.2. Introduction 
The superior efficacy of clozapine has been consistently demonstrated for those with 
treatment-resistant schizophrenia (TRS) (Kane et al., 1988; McEvoy et al., 2006; Leucht et 
al., 2009), defined by the National Institute for Health and Care Excellence (NICE) as a 
failure to respond to two antipsychotic trials at a therapeutic dose for at least six weeks 
(National Institute for Health and Care Excellence, 2009). A third of patients with 
schizophrenia are estimated to be treatment-resistant (Meltzer, 1997) and thus potentially 
eligible for clozapine treatment.  
In addition to substantially reduced psychotic symptoms, treatment with clozapine in 
comparison to other antipsychotic medications has been associated with decreased rates 
of mortality (Hayes et al., 2015), suicide (Meltzer et al., 2003a; Tiihonen et al., 2009), 
aggression (Chengappa et al., 2002), and financial costs due to reduced hospitalisations 
(Honigfeld & Patin, 1990; Hayhurst et al., 2002). However, clinical trials indicate that only 
30-60% of patients with TRS will respond to clozapine (Kane et al., 1988; Lieberman et al., 
1994b) and previous studies indicate that this response can be detected within the first 6-
8 weeks of clozapine treatment (Rosenheck et al., 1999b; Suzuki et al., 2011a). 
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An estimated 40% of patients eligible for clozapine in the UK have not received a trial 
(Royal College of Psychiatrists, 2012) and in those that have, there is a four-year delay 
from eligibility to first treatment (Howes et al., 2012b). The widespread underutilisation of 
clozapine may be due in part to its significant side effect profile (Atkin et al., 1996; 
Henderson et al., 2000). Of particular importance is the risk of agranulocytosis, which 
necessitates regular blood monitoring (Atkin et al., 1996). This burden of monitoring limits 
the acceptability of clozapine to patients, and poses an additional obstacle to clinician 
recommendation and use in clinical practice. 
Predictors of clozapine response would be valuable in assisting clinicians in deciding if 
clozapine treatment is likely to be beneficial and may increase the number of patients who 
are likely to benefit being offered clozapine. A number of studies have attempted to 
address this question and there have been several reviews (Chung & Remington, 2005; 
Suzuki et al., 2011c). Severe baseline symptoms (Hasegawa et al., 1993; Lieberman et al., 
1994b; Rosenheck et al., 1998; Ciapparelli et al., 2000; Umbricht et al., 2002; Semiz et al., 
2007; Kelly et al., 2010) and an early response, even after one week of treatment (Stern et 
al., 1994; Semiz et al., 2007), have been associated with significantly better response to 
clozapine. Other clinical markers including premorbid functioning (Umbricht et al., 2002; 
Kelly et al., 2010), age at clozapine initiation (Hofer et al., 2003; Mauri et al., 2003; Semiz 
et al., 2007; Kelly et al., 2010), age at onset of schizophrenia (Ciapparelli et al., 2004; Semiz 
et al., 2007; Kelly et al., 2010; Nielsen et al., 2012), diagnosis (Fenton & Lee, 1993; 
Ciapparelli et al., 2004; Semiz et al., 2007), and previous extrapyramidal symptoms (Pickar 
et al., 1994; Umbricht et al., 2002) have yielded less consistent results. Reports regarding 
the role of gender have also been contradictory (Lieberman et al., 1994a; Szymanski et al., 
1996; Hofer et al., 2003; Mauri et al., 2003; Ciapparelli et al., 2004; Semiz et al., 2007; Usall 
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et al., 2007) whilst results have been consistent in the lack of association between 
ethnicity and response (Lieberman et al., 1994a; Rosenheck et al., 1998; Kelly et al., 2010).  
These somewhat conflicting reports may be due to the considerable variability in response 
definitions as well as trial durations, resulting in limited comparability between studies. 
Several studies have used the absolute response criteria defined by Kane and Colleagues; a 
20% decrease in Brief Psychiatric Rating Scale (BPRS) total score, and either a post-
treatment Clinical Global Impressions (CGI) severity score ≤ 3 or BPRS ≤ 35 (Kane et al., 
1988). Other studies have focused purely on percentage change and adopted a relative 
response criteria, for example a ≥20% decrease in Positive and Negative Syndrome Scale 
(PANSS) or BPRS total scores (Usall et al., 2007; Suzuki et al., 2012). A recent review 
recommended a response definition of a CGI-Improvement score of 2 or better (Suzuki et 
al., 2012), which approximately corresponds to a 40-53% reduction in BPRS total score 
(Leucht et al., 2005a; Leucht & Engel, 2006).  
The study duration of previous studies investigating clozapine response has tended to be 
short (Meltzer et al., 1989a) and consequently may not have considered a group of 
patients that take longer to meet the response criteria. This may be particularly important 
for patients starting clozapine, as they are likely to be highly symptomatic. In addition, 
many studies are conducted in relatively small sample sizes and clinical trial data may not 
be generalisable to patients receiving clozapine in standard health care settings.  
5.2.1 Aims of the study 
In a two-year retrospective cohort study of all patients starting their first clozapine trial 
over a five-year period (2007-2011, inclusive) in SLaM, the study aims were to: (i) select a 
primary response criterion by comparing the sensitivity and specificity of different 
response definitions against the groups outlined by group-based trajectory modeling, (ii) 
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identify demographic and baseline clinical predictors of clozapine response, (iii) assess 
whether early improvement is indicative of long-term response, and (iv) explore the timing 
of response to clozapine and the duration of treatment required to detect a response. 
5.3. Method 
Full details of the setting, ethical approval and sample selection are presented in sections 
3.1, 3.2 and 3.3, respectively. The procedures used for clinical assessments are specified in 
section 3.5. 
5.3.1 Sample 
The sample used for this analysis consisted of a cohort of patients who had an ICD-10 
primary diagnosis of a psychotic disorder (F20-F29, inclusive) and began a first trial of 
clozapine between 1 January 2007 and 31 December 2011 in SLaM. Patients were aged 18-
65 years at the start of clozapine treatment and initiated clozapine under standard 
secondary mental health care services, either as an inpatient or outpatient. Patients who 
discontinued clozapine within the first month of treatment were excluded from this 
analysis, as they did not have an adequate clozapine trial and thus the level of response 
could not be reliably measured. 
5.3.2 Clinical assessments 
To assess response to clozapine, the Clinical Global Impressions (CGI) scale was 
administered at the start of clozapine treatment (baseline) and at 1, 2, 3, 6, 9, 12, 18 and 
24 months after clozapine initiation. The CGI is a global measure that comprises two scores 
(i) severity (CGI-S, detailed in Table 3.1), and (ii) improvement (CGI-I, detailed in Table 3.2). 
Information used for the CGI ratings came from the descriptive case notes within CRIS. 
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Baseline was defined as the week prior to clozapine initiation. Assessments at subsequent 
time points took a global impression of the time period from the last assessment. Further 
details of procedures used are given in section 3.5. 
5.3.3 Clozapine response 
Due to variability of clozapine response definitions used in previous studies (Suzuki et al., 
2011b; Suzuki et al., 2012), three definitions of response were considered: absolute, 
relative and exceptional. If the patient met the relevant criteria at any assessment over the 
study period they were classed as a responder. If the patient did not meet these criteria at 
any assessment they were classed as a poor responder. 
Absolute response: CGI-S score of 3 (mildly ill) or less and a CGI-I score of 2 (much 
improved) or less. This definition is focused on patients who achieved a good level of 
functioning and is reflective of frequently used criteria originally defined by Kane and 
colleagues (Kane et al., 1988), which included a post-treatment severity threshold in 
addition to improvement.  
Relative response: Reduction of 2 or more CGI-S scores. For example, if the patient’s CGI-S 
score was 6 at baseline and reached a 4 within the study period they would be classified as 
a relative responder. This second definition is purely focused on the change from baseline. 
Exceptional response: CGI-I score of 1 (very much improved). This definition is focused on 
the patients that experienced the greatest benefit from clozapine treatment. 
The study period began at clozapine initiation and ended with discontinuation, death, or 
after 24 months of treatment. The date of clozapine initiation was defined as the date the 
patient took their first dose of clozapine. The date of discontinuation was defined as the 
date the patient was last known to take clozapine, where this was followed by at least 
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three consecutive months without clozapine treatment. Time to clozapine response was 
defined as the duration from baseline to the assessment that the patient first met the 
relevant response criteria. 
5.3.4 Exposure variables 
Details of age, gender, marital status, ethnicity, diagnosis, inpatient status and detention 
under the Mental Health Act were obtained from structured fields within CRIS. Level of 
deprivation was calculated from the Index of Multiple Deprivation (IMD) for England 
(2007) for the patient’s home address. Key definitions regarding these variables are 
described in section 3.6. 
5.3.5 Analysis 
To select a primary response definition, group membership was compared for each patient 
between that identified by group-based trajectory modeling (GBTM) and absolute and 
relative response definitions. GBTM is an application of finite mixture modeling and is 
designed to identify clusters of individuals with similar developmental trajectories (Nagin 
& Odgers, 2010). GBTM identifies homogenous groups based on growth parameters 
describing each patient’s initial rating level and rate of change of CGI-S scores with each 
patient being assigned a probability of belonging to each group (Nagin, 2005; Jones & 
Nagin, 2013). In comparison to growth mixture modeling, it identifies groups to 
approximate a continuous distribution of trajectories of unknown shape, rather than 
assuming there are distinct subpopulations (Nagin & Odgers, 2010). I specified for GBTM 
to identify two groups: responders and poor responders. The definition of response with 
the optimal sensitivity and specificity was selected for the main analyses.  
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A Kaplan-Meier survival curve was used to display the time to clozapine response. Having 
checked proportional hazard assumptions, a Cox regression was employed to model the 
association between clozapine response and gender, age, marital status, ethnicity, level of 
deprivation, diagnosis, inpatient status, detention under the Mental Health Act and 
baseline CGI-S score. Associations with clozapine response were assessed in a crude 
analysis, and also fully adjusted for all covariates examined. Level of deprivation was 
entered into the model as a categorical dummy variable. A likelihood ratio test was used 
to test the appropriateness of entering age and baseline CGI-S as a continuous variable. 
Interaction effects with age, gender and ethnicity for variables associated with clozapine 
response at P < 0.05 were investigated. A sensitivity analysis was conducted excluding 
patients without ICD-10 schizophrenia diagnosis. Secondary analyses using the alternative 
definition of clozapine response (i.e. the definition not selected from the GBTM) were 
conducted to assess consistency of results. In addition, a Cox regression was used to 
investigate the association of the above factors with exceptional response. The association 
of baseline clinical and demographic factors with gender were assessed in a crude and fully 
adjusted logistic regression. 
To assess the impact of early improvement on response to clozapine, Cox regression was 
employed to test the association between CGI-I score after one month of treatment and 
each clozapine response definition. Additional sensitivity analyses were conducted (i) 
adjusting for other significant predictors identified, (ii) fully adjusted for all covariates, and 
(iii) excluding patients that met response criteria within one month.  
To investigate how long to wait for a response to clozapine the likelihood of a delayed 
response was assessed by calculating the proportion of patients with a CGI-I score of 3 or 4 
(minimally improved or no change) at particular time points that subsequently met 
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response criteria. These groups were combined due to low numbers in each individual 
group and because a CGI-I score of 3 (minimally improved) represents a slight 
improvement with little or no clinically meaningful reduction of symptoms (Busner & 
Targum, 2007).  
All statistical analyses were performed using STATA version 12 (StataCorp, 2011). 
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5.4. Results 
5.4.1 Patient Characteristics 
A total of 316 patients were initiated on clozapine during the study period, 39 of which 
discontinued treatment within 30 days. Thus, 277 patients were included in this analysis. 
Table 5.1 provides sample characteristics. The mean age at clozapine initiation was 36 
years. The majority of the sample had a diagnosis of schizophrenia (n=250) and the most 
common non-schizophrenia F21-9 diagnosis was schizoaffective disorder (n=18). Of the 
143 (51.6%) that were detained under the Mental Health Act at the time of clozapine 
initiation, the majority were detained under a section 3 (detention for treatment, n=109) 
or under sections 37-49 (forensic, n=27). The mean baseline CGI-S score for the total 
sample at the time of clozapine initiation was 5.15 (SD 0.67, markedly ill). 
Characteristic N % 
Male gender 184 66.4 
Mean age (years) 36.34 SD: 10.9 
Married or cohabiting 21 7.6 
Ethnicity   
    White British / White other 111 40.1 
    Black African / Caribbean 133 48.0 
    Asian 15 5.4 
    Other 18 6.5 
Level of deprivation   
    Low  75 27.1 
    Intermediate 99 35.7 
    High 84 30.3 
    Homeless 13 4.70 
Schizophrenia diagnosis 250 90.2 
Inpatient 231 83.4 
Detained under Mental Health Act 143 51.6 
Mean baseline CGI-Severity 5.15 SD: 0.67 
Table 5.1. Sample characteristics. SD = standard deviation. Percentages relate to total 
sample (n=277). Data for all 277 patients was available for each variable other than level 
of deprivation, which was available for 271 patients. 
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5.4.2 Defining clozapine response 
A substantial proportion of the sample had much improved (CGI-I score of 2, n=162) or 
very much improved (CGI-I score of 1, n=53) over the study period in comparison to their 
condition at clozapine initiation. The remaining sample was either minimally improved 
(CGI-I score of 3, n=50) or experienced no change (CGI-I score of 4, n=12). Figure 5.1 
displays the mean CGI-S scores over the study period based on the patient’s lowest (most 
improved) CGI-I score. The mean reduction over the study period of CGI-S score was 2.34 
(from 5.04 to 2.70) for very much improved patients, 1.55 (from 5.19 to 3.64) for much 
improved patients, 0.76 (from 5.18 to 4.42) for minimally improved and 0.08 (from 4.92 to 
4.83) for those who experienced no change. The raw data for Figure 5.1 is presented in 
Appendix 8.  
 
Figure 5.1. Mean CGI-Severity scores at time assessment points for patients who had an 
improvement score of 1 (very much improved, blue), 2 (much improved, grey), and either 3 
or 4 (minimally improved or no change, green). Error bars represent 95% confidence 
intervals. 
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A total of 114 (41.2%) patients showed an absolute response (CGI-I ≤ 2 and CGI-S ≤ 3) to 
clozapine over the study period. Alternatively, 134 (48.4%) patients experienced a relative 
response (reduction ≥ 2 CGI-S score) and 58 (19.1%) demonstrated an exceptional 
response (CGI-I score of 1) to clozapine.  
Group-based trajectory modeling (GBTM) classified 40.7% of the sample into one response 
trajectory and 59.3% of the sample into the second response trajectory (see Figure 5.2). 
The former group had more substantial reductions in severity and thus we refer to this 
group as responders. Using these groups as the gold standard, the sensitivity and 
specificity of the absolute response definition was 0.88 and 0.91, respectively. The relative 
response definition had a sensitivity of 0.68 and specificity of 0.65. Therefore, absolute 
response was selected as the primary response definition. Although the 163 (58.8%) other 
patients may have improved somewhat, for the purposes of these analyses they were 
classified as poor absolute responders.  
 
Figure 5.2. Clozapine response groups as classified by group-based trajectory modeling 
(GBTM) from CGI-Severity scores. Percentages relate to proportion of total sample in each 
group.  
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5.4.3 Predictors of response 
Table 5.2 details the association of baseline clinical factors with absolute response to 
clozapine. In a fully adjusted Cox regression model, female gender (hazard ratio (HR) = 
0.63, 95% confidence intervals (CI) 0.41-0.96) and lower CGI-S (less unwell) at baseline (HR 
= 0.43, 95% CI 0.31-0.60) were associated with good absolute response. Age, marital 
status, ethnicity, level of deprivation, diagnosis, inpatient status and detention under MHA 
were not associated with absolute response. No interaction effects were identified and 
there were no differences in a sensitivity analysis restricted to those with a schizophrenia 
diagnosis (Table 5.6).  
I also conducted a secondary analysis considering the alternative definition of relative 
response (Table 5.3). In a fully adjusted Cox regression model, female gender (HR = 0.49, 
95% CI 0.33-0.72) and a higher CGI-S at baseline was strongly associated with good relative 
response (HR = 3.24, 95% CI 2.34-4.50). In a further analysis regarding exceptional 
response, female gender (HR = 0.41, 95% CI 0.23-0.73) and lower CGI-S at baseline (HR = 
0.60, 95% CI 0.38-0.95) were associated with an exceptional response to clozapine (Table 
5.4). 
Due to the observed relationship between gender and clozapine response, the association 
of other baseline clinical and demographic factors with gender was investigated (Table 
5.5). In a fully adjusted logistic regression, male patients were significantly younger than 
females (HR = 0.95, 95% CI 0.93-0.98); the mean age at clozapine initiation was 34.6 years 
for males and 39.8 years for females. Males were also less likely to be of Black 
African/Caribbean ethnicity (HR = 0.52, 95% CI 0.11-0.64) and were more likely to live in an 
area of intermediate (HR = 2.27, 95% CI 1.13-4.56) or high (HR = 2.38, 95% CI 1.14-4.95) 
deprivation. In addition, males were also less likely to have non-schizophrenia F20 
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diagnosis (HR = 0.27, 95% CI 0.11-0.64). However, controlling for these factors did not 
impact on the strength of the association between gender and clozapine response.  
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   Crude  Fully Adjusted 
Characteristic 
Absolute 
responders 
(N=114) 
Poor  
responders 
(N=163) 
Hazard Ratio 
(95% CI) P  
Hazard Ratio 
(95% CI) P 
Demographic factors        
Male gender 68 (59.65) 116 (71.17) 0.67 (0.46-0.98) 0.038  0.63 (0.41-0.96) 0.034 
Age (mean years) 36.91 (SD: 10.32) 35.94 (SD: 11.35) 1.00 (0.99-1.02) 0.587  1.00 (0.98-1.02) 0.873 
Married or cohabiting 12 (10.53) 9 (5.52) 1.59 (0.88-2.90) 0.127  1.12 (0.58-2.19) 0.736 
Black African / Caribbean ethnicity 51 (44.74) 82 (50.31) 0.93 (0.64-1.35) 0.699  0.98 (0.65-1.47) 0.915 
Level of deprivation        
    Low  40 (35.09) 35 (21.47) Ref   Ref  
    Intermediate 37 (32.46) 62 (38.04) 0.79 (0.50-1.23) 0.296  0.93 (0.57-1.52) 0.775 
    High 31 (27.19) 53 (32.52) 0.82 (0.51-1.31) 0.412  1.01 (0.61-1.68) 0.976 
    Homeless 3 (2.63) 10 (6.13) 0.42 (0.13-1.35) 0.146  0.66 (0.20-2.19) 0.497 
Clinical factors        
Non-schizophrenia F20 diagnosis 8 (7.02) 19 (11.66) 0.74 (0.36-1.51) 0.407  0.60 (0.28-1.26) 0.176 
Inpatient 93 (81.58) 138 (84.66) 0.76 (0.48-1.23) 0.266  1.42 (0.79-2.55) 0.235 
Detained under Mental Health Act 52 (45.61) 91 (55.83) 0.76 (0.53-1.10) 0.144  0.92 (0.59-1.43) 0.712 
Baseline CGI-Severity (mean) 4.94 (SD: 0.71) 5.29 (SD: 0.61) 0.47 (0.35-0.63) 3.14 x 10-7  0.43 (0.31-0.60) 5.05 x 10-7 
Table 5.2. Predictors of absolute clozapine response, defined as CGI-I ≤ 2 and CGI-S ≤ 3. Columns represent characteristics for responders and poor 
responders, hazard ratio and P-value from crude and fully adjusted Cox regression. The fully adjusted model included all variables. Data for all 277 
patients was available for each variable other than level of deprivation, which was available for 271 patients. Note: Follow-up period began at start of 
clozapine treatment and ended with response, discontinuation, death or end of study period (24 months after treatment onset). 
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   Crude  Fully Adjusted 
Characteristic 
Relative 
responders 
(N=134) 
Poor  
responders 
(N=143) 
Hazard Ratio 
(95% CI) P  
Hazard Ratio 
(95% CI) P 
Demographic factors        
Male gender 78 (58.21) 106 (74.13) 0.56 (0.40-0.79) 9.60 x 10-4  0.49 (0.33-0.72) 2.50 x 10-4 
Age (mean years) 37.03 (SD: 10.81) 35.68 (SD: 11.03) 1.01 (0.99-1.02) 0.303  0.99 (0.98-1.01) 0.396 
Married or cohabiting 12 (8.96) 9 (6.29) 1.21 (0.67-2.19) 0.525  1.29 (0.68-2.43) 0.432 
Black African / Caribbean ethnicity 61 (45.5) 72 (50.35) 0.99 (0.70-1.38) 0.932  0.91 (0.62-1.34) 0.645 
Level of deprivation        
    Low  45 (33.58) 30 (20.98) Ref   Ref  
    Intermediate 43 (32.09) 56 (39.16) 0.76 (0.50-1.15) 0.198  0.81 (0.52-1.25) 0.342 
    High 37 (27.61) 47 (32.87) 0.83 (0.54-1.28) 0.405  0.85 (0.53-1.36) 0.505 
    Homeless 5 (3.73) 8 (5.59) 0.69 (0.27-1.73) 0.423  0.51 (0.20-1.32) 0.165 
Clinical factors        
Non-schizophrenia F20 diagnosis 8 (5.97) 19 (13.29) 0.51 (0.25-1.05) 0.067  0.41 (0.20-0.87) 0.021 
Inpatient 124 (92.54) 107 (74.83) 3.01 (1.58-5.74) 8.10 x 10-4  1.87 (0.90-3.87) 0.092 
Detained under Mental Health Act 77 (57.46) 66 (46.15) 1.50 (1.07-2.12) 0.020  1.00 (0.67-1.49) 0.981 
Baseline CGI-Severity (mean) 5.44 (SD: 0.62) 4.87 (SD: 0.60) 3.06 (2.28-4.09) 5.88 x 10-14  3.24 (2.34-4.50) 1.96 x 10-12 
Table 5.3. Predictors of relative clozapine response, defined as a reduction of 2 or more CGI-S scales. Columns represent characteristics for responders 
and poor responders, hazard ratio and P-value from crude and fully adjusted Cox regression. Fully adjusted model included all variables. Data for all 
277 patients was available for each variable other than level of deprivation, which was available for 271 patients. Note: Follow-up period began at 
start of clozapine treatment and ended with discontinuation, death or end of study period (24 months after treatment onset). 
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   Crude model  Fully Adjusted model 
Characteristic 
Exceptional 
responders 
(N=53) 
Poor 
responders 
(N=224) 
Hazard Ratio 
(95% CI) P  
Hazard Ratio 
(95% CI) P 
Demographic factors        
Male gender 26 (49.06) 158 (70.54) 0.43 (0.25-0.74) 0.002  0.41 (0.23-0.73) 0.003 
Age (mean years) 37.02 (SD: 10.43) 36.17 (SD: 11.06) 1.01 (0.98-1.03) 0.625  1.00 (0.97-1.03) 0.936 
Married or cohabiting 7 (13.21) 14 (6.25) 2.02 (0.91-4.48) 0.082  1.71 (0.71-4.12) 0.235 
Black African / Caribbean ethnicity 25 (47.17) 108 (48.21) 1.07 (0.63-1.84) 0.794  1.30 (0.71-2.40) 0.394 
Level of deprivation        
    Low  19 (35.85) 56 (25.00) Ref   Ref  
    Intermediate 19 (35.85) 80 (35.71) 0.87 (0.46-1.65) 0.680  1.25 (0.62-2.50) 0.535 
    High 12 (22.64) 72 (32.14) 0.71 (0.34-1.46) 0.354  0.99 (0.45-2.16) 0.974 
    Homeless 2 (3.77) 11 (4.91) 0.66 (0.15-2.82) 0.572  0.98 (0.22-4.47) 0.984 
Clinical factors        
Non-schizophrenia F20 diagnosis 3 (5.66) 24 (10.71) 0.56 (0.17-1.78) 0.322  0.42 (0.13-1.40) 0.159 
Inpatient 47 (88.68) 184 (82.14) 1.57 (0.67-3.68) 0.297  2.57 (0.98-6.77) 0.056 
Detained under Mental Health Act 24 (45.28) 119 (53.13) 0.82 (0.48-1.40) 0.463  0.69 (0.37-1.27) 0.231 
Baseline CGI-Severity (mean) 5.04 (SD: 0.73) 5.17 (SD: 0.66) 0.73 (0.49-1.10) 0.135  0.60 (0.38-0.95) 0.031 
Table 5.4. Predictors of exceptional clozapine response, defined as CGI-I score of 1 (very much improved). Columns represent characteristics for 
responders and poor responders, hazard ratio and P-value from crude and fully adjusted Cox regression. Fully adjusted model included all variables. 
Data for all 277 patients was available for each variable other than level of deprivation, which was available for 271 patients. Note: Follow-up period 
began at start of clozapine treatment and ended with discontinuation, death or end of study period (24 months after treatment onset). 
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   Crude model  Fully Adjusted model 
Characteristic Male (N=184) 
Female 
(N=93) 
OR 
(95% CI) P  
OR 
(95% CI) P 
Demographic factors        
Age (mean years) 34.58 (SD: 9.90) 39.80 (SD: 12.05) 0.96 (0.93-0.98) 0.002  0.95 (0.93-0.98) 3.10 x 10-4 
Married or cohabiting 9 (4.89) 12 (12.90) 0.35 (0.14-0.86) 0.022  0.62 (0.22-1.74) 0.364 
Black African / Caribbean ethnicity 87 (47.28) 46 (49.46) 0.92 (0.56-2.92) 0.732  0.52 (0.29-0.94) 0.031 
Level of deprivation        
    Low  42 (23.46) 33 (35.87) Ref     
    Intermediate 69 (38.55) 30 (32.61) 1.81 (0.97-3.38) 0.064  2.27 (1.13-4.56) 0.021 
    High 58 (32.40) 26 (28.26) 1.69 (0.92-3.36) 0.090  2.38 (1.14-4.95) 0.020 
    Homeless 10 (5.59) 3 (3.26) 2.62 (0.67-10.29) 0.168  3.11 (0.72-13.46) 0.129 
Clinical factors        
Non-schizophrenia F20 diagnosis  12 (6.52) 15 (16.13) 0.36 (0.16-0.81) 0.014  0.27 (0.11-0.64) 0.003 
Inpatient 150 (81.52) 81 (87.10) 0.65 (0.32-1.33) 0.241  0.59 (0.24-1.46) 0.249 
Detained under Mental Health Act 94 (51.09) 49 (52.69) 0.94 (0.57-1.55) 0.801  1.23 (0.65-2.31) 0.528 
Baseline CGI-Severity (mean) 5.13 (SD: 0.67) 5.19 (SD: 0.68) 0.86 (0.59-1.25) 0.423  0.92 (0.59-1.44) 0.722 
Table 5.5. Association of baseline demographic and clinical factors with gender. Percentages relate to total sample (n=277). Columns represent 
characteristics for male and female patients, odds ratio (OR) and P-value from crude and fully adjusted logistic regression. Fully adjusted model 
included all variables. Data for all 277 patients was available for each variable other than level of deprivation, which was available for 271 patients. 
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 Crude  Fully Adjusted
1 
Characteristic 
Hazard ratio  
(95% CI) P-value  
Hazard ratio  
(95% CI) P-value 
Male gender 0.60 (0.41-0.89) 0.010  0.64 (0.41-0.98) 0.042 
Age at clozapine onset (years, SD) 1.01 (0.99-1.02) 0.543  1.00 (0.98-1.02) 1.000 
Currently married or cohabiting 1.53 (0.80-2.94) 0.199  1.32 (0.66-2.66) 0.434 
Black African/Caribbean ethnicity 0.95 (0.65-1.39) 0.781  1.05 (0.69-1.60) 0.812 
Level of deprivation      
    Low  Ref   Ref  
    Intermediate 0.80 (0.50-1.26) 0.336  0.93 (0.57-1.52) 0.784 
    High 0.79 (0.48-1.28) 0.334  0.89 (0.53-1.50) 0.660 
    Homeless 0.46 (0.14-1.48) 0.190  0.53 (1.16-1.73) 0.290 
Inpatient 0.86 (0.51-1.44) 0.569  1.04 (0.57-1.87) 0.574 
Detained under Mental Health 
Act 0.79 (0.54-1.16) 0.233  0.82 (0.52-1.27) 0.524 
Table 5.6. Sensitivity analysis for absolute clozapine response only including patients with a 
schizophrenia diagnosis (ICD-10 F20) (n=250). Columns represent Cox regression hazard 
ratio and P-value from crude and fully adjusted Cox regression. 1Fully adjusted includes all 
variables. Data for all 250 patients was available for each variable other than level of 
deprivation, which was available for 244 patients.  
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5.4.4 Early improvement predicts good response 
After one month of treatment, those who met absolute response criteria within 24 months 
had a mean CGI-I score of 2.70 (SD 0.79) compared to 3.11 (SD 0.80) for poor responders. 
Cox regression models (Table 5.7) indicated a strong association between a lower (more 
improved) CGI-I score at one month and good absolute response by 24 months (HR = 0.56, 
95% CI 0.44-0.71), which remained significant and not substantially reduced in strength 
after adjusting for gender and baseline severity, or after adjusting for all covariates used in 
the prediction analyses. In addition, CGI-I score at one month was also strongly associated 
with relative response (HR = 0.53, 95% CI 0.43-0.66), and exceptional response (HR = 0.42, 
95% CI 0.27-0.63). Removing the 22 individuals that met absolute response criteria within 
the first month reduced the strength of the association (HR = 0.72, 95% CI 0.55-0.93). 
 Hazard Ratio (95% CI) P 
Absolute response   
Crude 0.56 (0.44-0.72) 3.82 x 10-6 
Adjusting for gender and baseline severity 0.50 (0.38-0.64) 9.97 x 10-8 
Fully Adjusted 0.48 (0.36-0.63) 2.27 x 10-7 
Removing 22 that met response criteria within 1 month 0.72 (0.55-0.93) 0.013 
Relative response   
Crude 0.53 (0.42-0.66) 2.51 x 10-8 
Adjusting for gender and baseline severity 0.53 (0.42-0.67) 1.93 x 10-7 
Fully Adjusted 0.49 (0.40-0.64) 9.53 x 10-8 
Exceptional response   
Crude 0.42 (0.28-0.62) 4.07 x 10-5 
Adjusting for gender and baseline severity 0.43 (0.29-0.64) 2.92 x 10-5 
Fully Adjusted 0.43 (0.28-0.65) 5.66 x 10-5 
Table 5.7: Association between early improvement and clinical response. 
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5.4.5 Timing of clozapine response 
Figure 5.3 displays the Kaplan-Meier survival curve for time to absolute response. Of all 
patients starting their first trial of clozapine, 7% achieved absolute response after 1 month 
of treatment, 18% by 3 months, 24% by 6 months, 34% by 12 months and 41% by 24 
months. Although patients continued to meet absolute response across the study period, 
change was more pronounced in the initial three months. Time to relative response shows 
a similar pattern (Figure 5.5). Rather than indicating delayed response, this pattern of 
results may reflect continued gradual improvement; 45% of the absolute responders were 
much improved (CGI-I score of 2) at 1 month, 75% by 2 months and 92% by 6 months.  
Figure 5.4 displays the mean CGI-S and CGI-I scores over the study period for absolute 
responders and poor responders (relative response displayed in Figure 5.6). The CGI-S 
score for the total sample decreased by an average of 1.51 scores in 24 months, from 5.15 
to 3.64. The mean CGI-S change for absolute responders was 2.09 (4.94 to 2.85) and for 
poor responders 1.08 (5.29 to 4.21).  
Likelihood of delayed response 
A third of patients (33.5%) who had either a CGI-I score of 3 (minimally improved) or 4 (no 
change in psychopathology) after one month of treatment went on to meet absolute 
response criteria within 24 months. This proportion reduced to 22.9% at 2 months, 20.7% 
at 3 months, 14.1% at 6 months, 13.5% at 9 months, 7.3% at 12 months, and 0% at 18 
months. The results were comparable for relative response (38.1%, 37.6%, 27.6%, 14.1%, 
13.5%, 12.2% and 10.3% at 1, 2, 3, 6, 9, 12 and 18 months respectively). The raw data for 
these figures are provided in Appendix 9. 
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Figure 5.3. Kaplan-Meier survival curve demonstrating proportion achieving absolute 
response to clozapine over initial 24 months of clozapine treatment. 
 
Figure 5.4. Mean clinical assessment scores for responders (blue) and poor responders 
(grey) over initial 24 months of clozapine treatment. Graph (A) displays mean CGI-Severity 
score and (B) displays mean CGI-Improvement scores. Error bars represent 95% confidence 
intervals.  
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Figure 5.5. Kaplan-Meier survival curve demonstrating proportion achieving relative 
response to clozapine over initial 24 months of clozapine treatment. 
 
Figure 5.6. Mean clinical assessment scores for relative responders (blue) and poor 
responders (grey) over initial 24 months of clozapine treatment. Graph A displays mean 
CGI-Severity score and graph B displays mean CGI-Improvement scores. Error bars 
represent 95% confidence intervals.   
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5.5. Discussion 
In a long-term retrospective cohort study of 277 patients with TRS, 41.2% of patients 
experienced an absolute response to their first trial of clozapine within 24 months. 
Considering alternative definitions, 48.4% of patients had a relative response and 19.1% 
had an exceptional response over the study period. We found that female gender was 
significantly associated with a good response to clozapine, regardless of the response 
definition. In contrast, the association of baseline severity with response was inconsistent; 
higher baseline severity was associated with poor absolute and exceptional response, but 
good relative response. Clinical improvement after one month of treatment was a strong 
predictor of response within 24 months. However, up to six months of treatment may be 
required to determine non-response to clozapine. 
5.5.1 Gender and clozapine response  
Female gender was significantly associated with a good response to clozapine and the 
strength of this association remained unchanged for different response definitions and 
after adjusting for potential confounders. Previous studies have reported conflicting 
findings regarding the role of gender (Lieberman et al., 1994a; Szymanski et al., 1996; 
Hofer et al., 2003; Mauri et al., 2003; Ciapparelli et al., 2004; Semiz et al., 2007; Usall et al., 
2007). Small sample sizes, short study durations and differing response definitions are 
likely to have contributed to the lack of consistent findings. However, the findings in this 
study are supported by the SOHO study, one of the largest studies reported to date, which 
found that females had significantly better response to typical antipsychotics and 
clozapine (Usall et al., 2007). The SOHO study was similar to our study in regards to sample 
size (n=274), long follow-up period (six months), and definition of response. 
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There were important sociodemographic and clinical differences between males and 
females in our sample. Male patients were an average of five years younger than female 
patients at the start of clozapine treatment. Because it was not possible to adjust for the 
age of onset of schizophrenia since this data was not readily available in CRIS, this does not 
necessarily indicate a delay to clozapine treatment for females. However, a recent study 
demonstrated that female patients had a significantly longer delay to clozapine treatment 
(Ucok et al., 2015) and a UK study reported a mean delay to clozapine treatment of 39.5 
months for males compared to 64.8 months for females, although this difference was not 
statistically significant (Howes et al., 2012b). The male patients in this study were also 
more likely to live in areas of higher deprivation, less likely to be of African/Caribbean 
ethnicity, and more likely to have a schizophrenia diagnosis. However, controlling for these 
factors did not impact on the strength of the association between gender and clozapine 
response.  
Further investigations should aim to understand the underlying causes of the association 
between female gender and good clozapine response. For example, there may be an 
overrepresentation of other risk factors for poor response in males such as substance 
abuse, non-adherence, prominent negative symptoms and poor social functioning (Thorup 
et al., 2014). Previous studies have reported higher clozapine and norclozapine levels, 
after controlling for dose, in females compared to males and particularly male smokers 
(Haring et al., 1989; Kim, 2015), suggesting that females have a lower clearance of 
clozapine. Further studies controlling for clozapine levels, given they are strongly 
predictive of response (Mauri et al., 2007), may help to interpret the gender differences 
found in this study.  
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5.5.2 Baseline severity and clozapine response 
The relationship between baseline severity and clozapine response was dependant on the 
definition of response used. Higher baseline CGI-S was strongly associated with good 
relative response, a definition solely indicating change. If an additional post-treatment 
severity threshold was included, indicating absolute response, a higher severity score 
predicted poor response. Previous studies have consistently reported an association 
between severe baseline symptoms and significantly better response to clozapine 
(Hasegawa et al., 1993; Lieberman et al., 1994b; Rosenheck et al., 1998; Ciapparelli et al., 
2000; Umbricht et al., 2002; Semiz et al., 2007; Kelly et al., 2010) although many of these 
studies defined clozapine response purely in terms of symptom reduction (Meltzer et al., 
1989a; Rosenheck et al., 1998; Umbricht et al., 2002; Ciapparelli et al., 2004; Kelly et al., 
2010), closely fitting our relative response definition. Studies that have included a post-
treatment severity threshold in their clozapine response definition have reported only 
trend level associations with baseline severity (Rodriguez et al., 1998; Semiz et al., 2007). 
Defining response solely based on symptom reduction will favour highly symptomatic 
patients because they have more scope for improvement and thus the measurable effect 
of clozapine on response will be greater (Rosenheck et al., 1998). Conversely, a definition 
that includes a severity threshold may favour patients with a lower severity because they 
are more likely to meet the criteria within the limited study period. Nonetheless, this study 
indicates that patients that are highly symptomatic at the start of clozapine treatment are 
more likely to experience greater improvement compared to baseline but are less likely to 
achieve an absolute response within 24 months. This study does not indicate that 
clozapine is more or less efficacious in highly symptomatic patients.  
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5.5.3 Association of other factors with clozapine response 
There have been inconsistent reports regarding the role of age (Hofer et al., 2003; Mauri 
et al., 2003; Semiz et al., 2007; Kelly et al., 2010) and we found no evidence to suggest that 
the age at onset of clozapine treatment had any impact on clozapine response. Consistent 
with previous literature, we also found no association between ethnicity and clozapine 
response (Lieberman et al., 1994a; Rosenheck et al., 1998; Kelly et al., 2010). This strongly 
argues for clozapine being made available across the adult age range (18-65 in this study) 
and ethnic groups. 
5.5.4 Timing of clozapine response 
Improvement at one month was a strong predictor of good clinical response by 24 months 
and the strength of this association remained unchanged for different response definitions 
and after adjusting for potential confounders. This is consistent with previous studies 
which report early response to clozapine is indicative of later response; response after one 
week of treatment predicted response at 5 weeks (Stern et al., 1994), and response after 4 
weeks predicted response at 16 weeks (Semiz et al., 2007). Our study expands on these 
previous findings in a naturalistic setting with a long-term follow-up.  
There has been substantial interest in the duration of clozapine treatment required to 
detect a response to clozapine, with most studies concluding that response can be 
detected within the first 6-8 weeks of treatment (Rosenheck et al., 1999b; Suzuki et al., 
2011a). However, we found that of the patients that were either minimally improved or 
not changed after two months of treatment, 23% would subsequently experience an 
absolute response and 38% a relative response within 24 months. After minimal or no 
improvement after six months of treatment, 14% went on to meet either absolute or 
relative response criteria in 24 months, indicating a small proportion of patients 
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experience a delayed response to clozapine. Conversely, we found that 75% of absolute 
responders were at least much improved (CGI-I score of 2) at two months, which increased 
to 92% at six months. These results indicate that although the majority of responders 
experience significant improvement within the first two months, this is not long enough to 
determine non-response. Further investigations using more advanced modeling 
techniques may provide valuable insights into this clinically important question. 
Nonetheless, our findings support current clinical practice to treat patients with clozapine 
for up to six months before determining the level of clinical response. 
5.5.5 Definition of response 
The somewhat conflicting results from previous studies investigating predictors of 
clozapine response may be due in part to the considerable variability in response 
definitions. Thus various response definitions were considered in this analysis and as far as 
we are aware, this is the first study to evaluate the sensitivity of response definitions 
against homogenous response groups identified by GBTM. We chose not to use the groups 
identified by GBTM as the primary outcome in this study to allow comparisons with the 
previous literature. An absolute response definition had higher sensitivity (0.88) and 
specificity (0.91) than relative response when compared to groups identified by GBTM. The 
definition of absolute response is focused on patients who achieved a good level of 
functioning and reflective of previously used criteria (Kane et al., 1988). A relative 
response criterion was considered because recent studies have tended to focus purely on 
the degree of change (Usall et al., 2007; Suzuki et al., 2012). The proportion of the sample 
that was classified as absolute and relative responders was comparable to previous studies 
(Kane et al., 1988; Lieberman et al., 1994b). Although a recommended definition of a CGI-I 
score of 2 or better was considered (Suzuki et al., 2012), which would correspond to a 40-
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53% reduction in BPRS score (Leucht et al., 2005a; Leucht & Engel, 2006), a large 
proportion of our sample (78%) met this criteria within 24 months, possibly due to the 
longer follow-up period. 
5.5.6 Study limitations 
A limitation of this study is its retrospective nature, specifically that the quality of data 
available was limited to information entered into the electronic case note system by the 
patient’s clinical team. However, strengths of this study design are that the results are 
reflective of routine clinical care, there was no recruitment bias, and recall bias was 
eliminated by the use of contemporaneous records. In addition, there was no attrition 
during the study period and minimal missing data. A further advantage of the study is that 
in the UK the National Health Service (NHS) provides nearly 100% of the health care and so 
the whole population is captured. The sample is comparable to the population in London 
with a diagnosis of schizophrenia (Morgan et al., 2006) but has higher proportions of Black 
African/Caribbean ethnicity and lower proportions of Asian ethnicity in comparison to 
England as a whole (Stewart et al., 2009). However, the National Audit of Schizophrenia 
(2012) suggests that the service use in London is comparable to the rest of the UK (Royal 
College of Psychiatrists, 2012). 
It was not possible to control for concurrent medications, plasma levels or time until 
plateau of dose titration, which may have impacted on the timing of clozapine response 
(Fabrazzo et al., 2002; Schulte, 2003). A further limitation is that I was unable to collect 
data prior to clozapine initiation (such as age of onset, duration of untreated psychosis or 
theoretical delay to treatment) because data in CRIS was only available from 2006 
onwards.  
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Although the CGI scale has been demonstrated to have equal validity to lengthier scales 
such as the BPRS (Leucht & Engel, 2006) and PANSS (Rabinowitz et al., 2010), the specific 
effects of clozapine on positive, negative or cognitive symptoms could not be analysed. 
The validity of the CGI has received some criticism (Beneke & Rasmus, 1992), and has been 
reported to be influenced by unrelated information such as adverse events (Busner et al., 
2009). In addition, it is unclear whether change in CGI-S or CGI-I scales should be used to 
define treatment response (Jiang & Ahmed, 2009).  
5.5.7 Clinical implications and conclusions 
It is important to consider the clinical response definition when interpreting study results 
of clozapine response. This study indicates that clozapine responders are more likely to be 
female and further investigations should aim to understand the underlying causes of the 
association. We found that clozapine responders tend to have a good initial response to 
clozapine. However, up to six months of treatment may be required to determine non-
response.   
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 Chapter 6
Discussion 
6.1. Summary of results 
In this thesis I investigated three outcomes of clozapine treatment: neutropenia, 
discontinuation and clinical response. To examine the genetic susceptibility to clozapine-
associated neutropenia, I conducted a multifaceted genetic analysis in the largest 
combined sample studied to date (Chapter 2). Using GWAS, I identified a novel genome-
wide significant (GWS) association with rs149104283, a SNP intronic to transcripts of 
SLCO1B3 and SLCO1B7, members of a family of hepatic transporter genes involved in drug 
uptake. In an analysis of exome array data I found evidence of association with clozapine-
associated neutropenia for uncommon non-synonymous variants in STARD9 and UBAP2. 
Furthermore, I replicated a previously reported association between neutropenia and a 
variant in HLA-DQB1. Thus Chapter 2 indicates variants that may increase susceptibility to 
clozapine-associated neutropenia and implicates biological pathways through which 
clozapine may act to cause this serious adverse effect. 
A retrospective cohort of 316 patients with treatment-resistant schizophrenia (TRS) who 
received their first course of clozapine treatment over a five-year period was used to 
investigate clozapine discontinuation and clinical response. I found that 45% of patients 
discontinued clozapine within two years of starting treatment (Chapter 4). By studying the 
reasons for discontinuations due to a patient decision I found that adverse drug reactions 
(ADRs) accounted for over half of clozapine discontinuations. Sedation was the most 
common ADR cited as a reason for discontinuation, accounting for 20% of all 
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discontinuations, and the risk of discontinuation due to ADRs was highest in the first few 
months of clozapine treatment. Lastly, I found patients who live in an area of high 
deprivation are at an increased risk of discontinuing clozapine and may need additional 
support to maintain engagement with treatment. These findings highlight the importance 
for clinicians to identify and where possible treat ADRs attributed to clozapine before they 
lead to discontinuation. 
In Chapter 5 I assessed the clinical predictors of clozapine response using several 
definitions: absolute response (CGI-I ≤ 2 and CGI-S ≤ 3), relative response (reduction ≥ 2 
CGI-S scores), and exceptional response (CGI-I score of 1). I found that male gender was 
significantly associated with a poor response to clozapine and the strength of this 
association remained unchanged for different response definitions and after adjusting for 
potential confounders. There was an inconsistent association between baseline CGI 
severity and response; higher baseline severity was associated with a good relative 
response, but a poor absolute and exceptional response. In investigations of the timing of 
response, I found that clinical improvement after one month of treatment was a strong 
predictor of response within 24 months. Of the patients who were either minimally 
improved or not changed after two months of treatment, 23% and 38% went on to meet 
absolute and relative response criteria within 24 months, respectively. By six months this 
proportion reduced to 14%. This chapter indicates that clozapine responders are more 
likely to be female and tend to have a good initial response. However, more than two 
months of treatment may be required to determine non-response. 
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6.2. Key contributions to knowledge and clinical implications 
6.2.1 Novel genetic associations with clozapine-associated neutropenia 
The primary finding from the GWAS meta-analysis was a genome-wide significant 
association with clozapine-associated neutropenia for rs149104283, an intronic SNP for 
transcripts of both SLCO1B3 and SLCO1B7, members of a family of hepatic transporter 
genes involved in drug uptake. The associated region in this study also contained a third 
member of this organic anion transporter family, SLCO1B1. Although the functionality of 
SLCO1B7 is unknown, SLCO1B3 and SLCO1B1 encode liver-specific organic anion-
transporter polypeptides (OATP1B3 and OATP1B1). These transmembrane proteins 
facilitate uptake of exogenous substances, including drugs, from the portal vein into 
hepatocytes, where the substance is subsequently modified either via metabolism with 
cytochrome (CYP) 450 enzymes or excreted (International Transporter Consortium et al., 
2010). These novel findings suggest the hypothesis that genetic variants at SLCO1B3 
(and/or SLCO1B1) may increase risk of clozapine-associated neutropenia through a 
pharmacokinetic mechanism. 
Support for this hypothesis comes from evidence implicating polymorphisms within 
SLCO1B1 and SLCO1B3 in adverse reactions of other drugs. A widely replicated missense 
variant in SLCO1B1 has been demonstrated to increase the risk of simvastatin-induced 
myopathy by impacting the pharmacokinetics of simvastatin, leading to an increase in 
plasma concentrations, and is now recommended for use as a routine pre-emptive clinical 
test (Search Collaborative Group et al., 2008; Ramsey et al., 2014). Furthermore, an 
intronic variant in SLCO1B3 has been associated with docetaxel-induced severe 
leukopenia/ neutropenia (Kiyotani et al., 2008), although there is inconclusive evidence 
regarding whether this is secondary to alterations in the pharmacokinetics and/or 
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bioavailability of the drug (Nambu et al., 2011; Yamakawa et al., 2011; Chew et al., 2012). 
If genetic variants at SLCO1B3 and SLCO1B1 increase the risk of clozapine-associated 
neutropenia through a pharmacokinetic mechanism, we may expect to observe a 
correlation with plasma concentrations of clozapine. There is currently limited evidence to 
suggest an association with clozapine plasma levels and agranulocytosis or neutropenia 
(Hasegawa et al., 1994; Centorrino et al., 1995; Combs et al., 1997; Mauri et al., 1998; 
Oyewumi et al., 2002); however, previous studies have either failed to include patients 
with abnormally low neutrophil levels (Centorrino et al., 1995; Combs et al., 1997; Mauri 
et al., 1998; Oyewumi et al., 2002) or control for treatment duration or dosage (Hasegawa 
et al., 1994; Centorrino et al., 1995). Furthermore, considering the marked inter-individual 
variation in clozapine plasma levels (Olesen et al., 1995), previous studies have been 
conducted in relatively small samples (Hasegawa et al., 1994). 
The precise aetiology of clozapine-induced agranulocytosis and neutropenia is currently 
unknown. The best-supported hypotheses to date include a direct toxicity of clozapine 
metabolites, an immune-related mechanism, or a combination of the two. There is 
evidence indicating that agranulocytosis and neutropenia are caused by the activation of 
clozapine, or a stable metabolite of clozapine, to a chemically reactive nitrenium ion (Liu & 
Uetrecht, 1995; Maggs et al., 1995; Pirmohamed & Park, 1997). The propensity for 
nitrenium ions to cause apoptosis to neutrophils, or be toxic to neutrophil precursors, is 
dose dependent, lending support to the hypothesis that clozapine pharmacokinetics and 
bioavailability are related to its potential to cause neutropenia (Williams et al., 2000; 
Pereira & Dean, 2006).  
I found evidence of association with neutropenia for uncommon non-synonymous variants 
in STARD9 and UBAP2. STARD9 is a mitotic kinesin and STARD9-depleted cancer cells have 
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abnormal cellular morphology and undergo apoptosis (Torres et al., 2011). In addition, 
STARD9-depletion was found to synergise with the chemotherapeutic agent taxol, the use 
of which is dose-limited due to neutropenia (Torres et al., 2011). The function of UBAP2 is 
undetermined though it has an ubiquitin-associated domain and is widely expressed 
across tissues. A recent study reported the association of a missense variant in the 
ubiquitin gene USP43 with clozapine-associated neutropenia (Tiwari et al., 2014). Our 
findings regarding STARD9 and UBAP2 have not been replicated and thus can only be 
interpreted cautiously.  
6.2.2 HLA-DQB1 6672G>C and clozapine-associated neutropenia 
I found independent support for the association of HLA-DQB1 6672G>C (rs113332494), an 
association that strengthened when considering only cases with ANC below ≤ 1000/mm3. 
This finding adds to the growing evidence implicating HLA-DQB1 in clozapine-associated 
neutropenia and agranulocytosis. HLA genes have been long hypothesised to be involved 
given their role in immune response and thus the majority of previous genetic association 
studies have primarily focused on candidate genes from the HLA region. Early candidate 
studies reported significant associations of variants in HLA-DQB1 and clozapine-induced 
agranulocytosis (Yunis et al., 1995; Dettling et al., 2001) and in 2011, Athanasiou and 
colleagues reported a significant association with HLA-DQB1 6672G>C (OR = 16.9) 
(Athanasiou et al., 2011). Furthermore, the CIAC study reported a significant association of 
an amino acid polymorphism (126Q) in HLA-DQB1 (Goldstein et al., 2014). Although we 
could not impute the amino acid polymorphism implicated in CIAC, it is in high linkage 
disequilibrium with HLA-DQB1 6672G>C (Goldstein et al., 2014). However, it is important 
to note that the samples used in the previous studies overlap. Due to the rarity of this side 
effect, there is a limited amount of independent samples available (Zhang & Malhotra, 
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2013). Thus, in this thesis I present the first fully independent replication implicating this 
locus in clozapine-associated neutropenia. Furthermore, the effect size in our study (OR = 
15.6) was comparable to previous reports (Athanasiou et al., 2011). The association of 
HLA-DQB1 adds support for an immune-related mechanism in clozapine-associated 
neutropenia, although the functional roles of the implicated polymorphisms are currently 
unclear.  
6.2.3 Pharmacogenetic tests of clozapine-associated neutropenia  
The goal of pharmacogenetic studies, as in Chapter 2, is to identify genetic variants that 
could be used to personalise medicine and tailor treatment choices for individual or 
groups of patients. A sensitive and reliable predictor of clozapine-associated neutropenia 
could conceivably be used as a test to identify patients at high risk (Zhang & Malhotra, 
2013). For those at low risk, there could be a reduced need for regular monitoring, which 
limits the acceptability of clozapine to patients, and poses an obstacle to its use in clinical 
practice (Patel, 2012). Although the HLA-DQB1 variant alone has a positive predictive value 
(PPV) of 35.1%, the majority of those that develop neutropenia whilst taking clozapine are 
not carriers of this risk allele, or indeed the other alleles we have identified in this study. 
The sensitivity for a test including all three risk variants (GWS intronic variant in SLCO1B3 
and SLCO1B7, missense variant in SLCO1B7, and HLA-DQB1 6672G>C) was 29.17%, the 
specificity 90.61%, the PPV 9.94%, and the NPV 97.30%. This indicates that 29.2% of 
individuals with clozapine-associated neutropenia will carry at least one of the three 
identified risk alleles and that individuals that carry any of these risk alleles have a 9.9% 
risk of clozapine-associated neutropenia. HLA-DQB1 6672G>C was marketed as a genetic 
predictive test on the basis of the study by Athanasiou and colleagues (Athanasiou et al., 
2011), but the low sensitivity limited its clinical utility and it has now been withdrawn from 
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the market due to low uptake (Chowdhury et al., 2011). Although the identified variants in 
this thesis convey a substantially increased risk for clozapine-associated neutropenia, they 
are currently on their own unlikely to have clinical utility for pharmacogenetic testing due 
to low sensitivity and positive predictive value (Verbelen et al., 2015), particularly as there 
is currently no alternative treatment for those with TRS. Nonetheless our findings provide 
novel insights into putative biological processes underlying clozapine-associated 
neutropenia, particularly the potential link with the pharmacokinetics of clozapine. The 
development of such understanding should help widen the availability of clozapine with 
beneficial impact on those with TRS. 
6.2.4 ADRs are the most common reason for discontinuation 
In Chapter 4, I present the first study to examine the reasons for clozapine discontinuation 
due to a patient decision. By studying these reasons, I found that ADRs accounted for over 
half of clozapine discontinuations. Previous studies have consistently reported patient 
decision (or non-adherence) to be the most common cause of clozapine discontinuation, 
without further specifying reasons, and that 25-35% of discontinuations were due to ADRs 
(Atkinson et al., 2007; Taylor et al., 2009; Krivoy et al., 2011; Davis et al., 2014; Mustafa et 
al., 2015). My results suggest that the role of ADRs has been underestimated as previous 
studies have used a restricted number of categories for discontinuation (i.e. patient choice 
and non-adherence), with no studies categorising the underlying reasons for non-
adherence.  
I found that the adverse effect most frequently cited was sedation, which accounted for 
20% of all discontinuations. Interestingly, over half of discontinuations due to sedation 
were from discontinuations due to a patient decision. This is a clinically important 
observation since sedation is usually transient and can almost always be minimised by 
191 
 
reducing the dose and/or titration rate of clozapine, adjusting the timing of the dose or 
partial substitution with less sedating drugs such as aripiprazole (Nair & MacCabe, 2014). If 
this adverse effect was more actively managed and monitored it is likely many could 
remain on clozapine. My results highlight the importance for clinicians to identify and treat 
ADRs attributed to clozapine, particularly in the first few months after treatment onset, 
before they lead to discontinuation. 
6.2.5 Neighbourhood deprivation increases the risk of discontinuation 
In Chapter 4, I present the first study to observe an association between level of social 
deprivation and risk of all-cause clozapine discontinuation. Furthermore, I found that this 
association was driven by patient rather than clinician-led discontinuations. Of note 
neighbourhood deprivation had no impact on clinical response (Chapter 5). No previous 
study has assessed the relationship between social deprivation and risk of clozapine 
discontinuation, but there have been studies investigating the relationship between socio-
economic status and non-adherence to antipsychotic medication in general (Kane et al., 
2013), although the results have been inconsistent. Previous studies have consistently 
reported increased rates of all-cause clozapine discontinuation in patients of Black 
African/Caribbean ethnicity (Moeller et al., 1995; Davis et al., 2014). However, I found that 
after controlling for neighbourhood deprivation, the association with ethnicity attenuated, 
indicating that this association could be related to factors relevant to deprivation rather 
than ethnicity. It is likely social deprivation is a proxy marker for other factors that underlie 
discontinuation and non-adherence and further research is needed to determine whether 
particular characteristics of these patient groups increase risk for clozapine 
discontinuation or perhaps whether clinical teams supporting areas in high deprivation are 
under increased pressure or have more limited resources. Nonetheless, this study 
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indicates that patients who live in an area of high deprivation are at an increased risk of 
discontinuing clozapine and may need additional support to maintain engagement with 
treatment. 
6.2.6 Defining clinical response to clozapine is complex 
Despite a significant amount of studies, there has been a lack of consistent findings 
regarding clinical and demographic predictors of clinical response to clozapine. The 
somewhat conflicting results may be due, in part, to the considerable variability in 
response definitions, resulting in limited comparability across studies. Thus, I considered 
various response definitions in the analysis of clozapine response (Chapter 5): absolute 
response (CGI-I ≤ 2 and CGI-S ≤ 3), relative response (reduction ≥ 2 CGI-S scores), and 
exceptional response (CGI-I score of 1). This was the first study to evaluate the sensitivity 
of response definitions against homogenous response groups identified by group-based 
trajectory modeling (GBTM). I found that absolute response had higher sensitivity and 
specificity than relative response in comparison to groups identified by GBTM, and was 
thus used as the primary outcome. The impact of different response definitions is 
highlighted in our findings regarding baseline severity. I found that higher baseline CGI-S 
was strongly associated with good relative response but poor absolute response. Previous 
studies reporting an association between severe baseline symptoms and significantly 
better response to clozapine have defined clozapine response purely in terms of symptom 
reduction, similar to our relative response definition (Hasegawa et al., 1993; Lieberman et 
al., 1994b; Rosenheck et al., 1998; Ciapparelli et al., 2000; Umbricht et al., 2002; Semiz et 
al., 2007; Kelly et al., 2010). Defining response solely based on symptom reduction will 
favour highly symptomatic patients because they have more scope for improvement and 
thus the measurable effect of clozapine on response will be greater (Rosenheck et al., 
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1998). Conversely, a definition that includes a severity threshold may favour patients with 
a lower severity because they are more likely to meet the criteria within the limited study 
period. There was considerable variability in the level of response that individuals in our 
study experienced and the majority had at least minimal improvement. Determining a 
binary definition is an imperfect measure of response and my findings highlight the 
importance of considering the response definition used when interpreting study results 
and benefits of presenting a range of definitions to evaluate whether study effects remain 
consistent (Leucht et al., 2007b). 
6.2.7 Male gender is associated with poor clozapine response 
I found that male gender was significantly associated with a poor clozapine response 
(Chapter 5). The strength of this association remained unchanged for different response 
definitions and after adjusting for potential confounders. Previous studies have reported 
conflicting findings regarding the role of gender in clozapine response (Lieberman et al., 
1994a; Szymanski et al., 1996; Hofer et al., 2003; Mauri et al., 2003; Ciapparelli et al., 2004; 
Semiz et al., 2007). Small sample sizes, short study durations and differing response 
definitions are likely to contribute to the lack of consistent findings. My findings are 
supported by the SOHO study, which found that females had significantly better response 
to typical antipsychotics and clozapine (Usall et al., 2007). The SOHO study was similar to 
our study in regards to a large sample size, a longer follow-up period, and the definition of 
clozapine response.  
Further investigations should aim to understand the underlying causes of this association. 
For example, there may be an overrepresentation in males of other possible risk factors 
that we were not able to measure such as substance abuse, non-adherence, prominent 
negative symptoms and poor social functioning (Thorup et al., 2014). We found that the 
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males in our study were significantly younger than females at the onset of clozapine 
treatment, less likely to be of Black African/Caribbean ethnicity, and were more likely to 
live in an area of high deprivation and have a diagnosis of schizophrenia. However, 
controlling for these factors did not impact on the strength of the association between 
gender and clozapine response. Of note is that gender had no impact on rates of 
discontinuation (Chapter 4). Previous studies have reported higher clozapine and 
norclozapine levels, after controlling for dose, in females compared to males and 
particularly male smokers (Haring et al., 1989; Kim, 2015), suggesting that females have a 
lower clearance of clozapine. Further studies controlling for clozapine levels, given they 
are predictive of response (Mauri et al., 2007), may help to interpret the gender 
differences found in this study. We intend to address this clinically important question in a 
recently acquired sample. 
6.2.8 Timing of clozapine response 
I found that early improvement after one month of treatment was a strong predictor of 
good clinical response by 24 months (Chapter 5). The strength of this association remained 
unchanged for different response definitions and after adjusting for potential 
confounders. This is consistent with previous studies which report that early response to 
clozapine is indicative of later response: response after one week of treatment predicted 
response at five weeks (Stern et al., 1994), and in another study response after four weeks 
predicted response at 16 weeks (Semiz et al., 2007). Our study expands on these previous 
findings in a naturalistic setting with a longer-term follow-up.  
There has been substantial interest in the duration of clozapine treatment required to 
detect a response to clozapine. If such a time point could be identified, patients who have 
not shown sufficient improvement could be regarded as non-responders and their 
195 
 
clozapine treatment augmented or discontinued. However, if this specified time is too 
short, patients who would have eventually experienced benefit may be discontinued, and 
if too long, nonresponsive patients may continue to unnecessarily receive treatment that 
will not benefit them. Previous studies have concluded that clozapine response can be 
detected within the first six to eight weeks of treatment (Rosenheck et al., 1999b; Suzuki 
et al., 2011a). However, other studies have suggested that clozapine trials should last far 
at least six months (Meltzer, 1992). Although we found that early response was predictive 
of later response, our analyses suggested that eight weeks would not be long enough to 
determine non-response. I found that of the patients that were either minimally improved 
or not changed (CGI-I score of 3 or 4) after two months of treatment, 23% would 
experience an absolute response and 38% a relative response within 24 months. After 
minimal or no improvement by six months of treatment, 14% went on to meet either 
absolute or relative response criteria within 24 months, indicating a small proportion of 
patients experienced a delayed response to clozapine. We found that only 75% of absolute 
responders were at least much improved (CGI-I score of 2) at two months, which increased 
to 92% at six months. It is important to note that minimally improved was defined in our 
study as ‘slightly better with little or no clinically meaningful reduction of symptoms; 
represents very little change in basic clinical status, level of care, or functional capacity’ 
(Busner & Targum, 2007). These results indicate that although the majority of those who 
respond to clozapine show signs of improvement within two months, at least six months of 
treatment may be required to determine non-response. Further investigations using more 
advanced modeling techniques may provide valuable insights into this clinically important 
question. 
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6.2.9 Outcome of clozapine treatment 
There are currently no reliable predictors of clozapine treatment outcome, and thus 
clinicians are unable to determine a priori whether clozapine is likely to be beneficial. 
Previous studies have focused on specific outcomes such as clinical response and ADRs 
(particularly agranulocytosis, weight-gain and diabetes). A clinical challenge will be 
combining and weighing up the genetic and clinical predictors for each different outcome. 
However, discontinuation of clozapine encapsulates all kinds of drug failure and reflects 
real-world practice. It represents a synthesis of clinician and patient judgements that an 
assigned treatment was either insufficiently efficacious or tolerable (McEvoy et al., 2006). 
In analyses conducted recently and thus not presented in this thesis, I compared the 
validity of using discontinuation as a proxy of clinical response using the data presented in 
Chapters 4 and 5. Using Receiver Operating Characteristic (ROC) curve analyses, I found 
that the area under the curve (AUC) for clozapine discontinuation was 0.71 indicating a fair 
test for clinical response (defined here as a CGI-I score of 1 or 2). We determined that the 
best combination between sensitivity and specificity was at 24 months of treatment; with 
a sensitivity of 71%, specificity 66%, PPV 88% and NPV 40%. This illustrates that those who 
continued clozapine treatment beyond 24 months were very likely to have responded to 
clozapine (PPV = 88%). However, those that discontinued within 24 months are a 
combination of non-responders and responders that likely found clozapine intolerable 
(NPV = 40%). These findings support the concept that the use of a discontinuation 
phenotype encapsulates drug failure.  
I have recently conducted a preliminary GWAS using clozapine discontinuation as a 
measure of clozapine failure. I considered 131 individuals who discontinued clozapine 
within 24 months as cases (those in whom adverse effects or lack of efficacy outweighed 
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benefits) and 6667 individuals who remained on clozapine for at least 24 months as 
controls (for whom benefits outweighed adverse effects) from a recently acquired 
clozapine sample from Leyden Delta. The most significant variant associated (which was 
GWS) with clozapine discontinuation was rs113821156 on chromosome 13, intronic to 5-
Hydroxytryptamine Receptor 2A (HRT2A, also known as 5-HT2A) and this was present in 4% 
of cases and 0.4% of controls. Clozapine has a high affinity for the serotonin 5-HT2A 
receptor (Meltzer, 1999) and variants in 5-HT2A have been previously implicated in 
candidate studies of clozapine response (Arranz et al., 1998a; Arranz et al., 1998b). 
Furthermore, serotonin impacts on appetite and variants within 5-HT2C have been 
associated with the clozapine-induced weight gain (Muller & Kennedy, 2006; Lett et al., 
2012). However, this analysis is still in the preliminary stages and replication will be 
required given the small sample size.  
Monitoring of plasma concentrations of clozapine to confirm that therapeutic levels of 
clozapine have been achieved is widely applied in the clinical management of clozapine 
treatment. There are many factors that influence plasma clozapine levels including age, 
gender, smoking and metabolic factors (Haring et al., 1989; Lane et al., 1999; Kim, 2015). 
This thesis indicates the importance for careful management of plasma concentrations and 
dose of clozapine. I found that sedation was the most common ADR used as a reason for 
discontinuation, a side effect that can be minimised by reducing the dose and/or titration 
rate of clozapine (Chapter 4). Female gender was associated with greater clinical response 
to clozapine (Chapter 5) and previous studies indicate that females have a lower clearance 
of clozapine (Haring et al., 1989; Kim, 2015). Lastly, I implicated a pharmacokinetic 
mechanism for clozapine-associated neutropenia (Chapter 2). Together, these findings 
indicate that careful dose titration and on going monitoring of clozapine plasma levels 
should support more people to stay on clozapine. 
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6.3. Strengths and limitations 
6.3.1 Clozapine-associated neutropenia 
Due to its rarity, genetic studies of clozapine-associated neutropenia are underpowered to 
detect associations that do not have a moderate to large effect size. Thus, there may be 
causal variants of small effect that we were not able to detect in this study. However, a 
considerable strength of this study is the large control sample, all of which were treated 
with clozapine for at least a year without developing neutropenia. Although the CIAC study 
also had a large number of controls, the majority were not treated with clozapine 
(Goldstein et al., 2014). This disparity may have contributed to the lack of replication of 
some of our variants in the CIAC sample.  
An important consideration is that our analyses included cases with both neutropenia and 
agranulocytosis. Large epidemiological studies have reported different demographic risk 
factors for agranulocytosis and neutropenia, suggesting that they may have distinct 
aetiologies (Flanagan & Dunk, 2008). However, it is now very rare to develop 
agranulocytosis because of the success of the monitoring system; in fact only four cases 
met this threshold in our sample. Given that within the field there are valid concerns that a 
more stringent threshold may produce more reliable results, I additionally conducted 
secondary analyses on a subset of the more severely affected cases with ANC ≤ 1000/mm3. 
However, these samples were also included in the primary analyses thus limiting 
comparisons. A further limitation of this study is that there was very little information 
regarding the phenotype: Novartis only informed us of those that had developed 
neutropenia whilst taking clozapine and where available, the recorded lowest neutrophil 
counts of these individuals were supplied. However, individuals were excluded if another 
reason for the blood dyscrasia was suggested on the monitoring system and thus we can 
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be confident that the occurrence of neutropenia or agranulocytosis was related to 
clozapine.  
Although GWAS allows a hypothesis free and affordable approach to identifying genetic 
susceptibility variants for a given disease or phenotype, a limitation is that many of the 
SNPs detected from GWAS are noncoding variants with an unknown impact (Ward & Kellis, 
2012). Thus, subsequent investigations are required to determine the causal SNP(s) and 
any biological impact. Improved annotation of these signals together with recent advances 
in whole-genome sequencing should provide definitive answers in this regard.  
A strength of this study is the analysis of both common and rare variants. Rare variants 
may have a larger effect in comparison to common variants, and thus may be more 
informative in the prediction of clozapine-associated neutropenia. However, a limitation of 
the exome array is that it does not capture all exonic variation. Exome- wide sequencing in 
a larger sample is required to prove the role of functional exonic variants definitively. 
Nonetheless, the approaches and subsequent findings in Chapter 2 contribute to the 
current understanding of clozapine-associated neutropenia and agranulocytosis. 
6.3.2 Retrospective cohort used for Chapters 4 and 5 
Chapters 4 and 5 were conducted in a retrospective cohort of 316 patients starting their 
first clozapine trial over a five-year period (2007-2011, inclusive) in South London & 
Maudsley (SLaM) NHS Foundation Trust. A limitation of this study design is its 
retrospective nature, specifically that the quality of data available was limited to 
information entered into the electronic case note system by the patient’s clinical team. 
However, benefits of this study design are that the results are reflective of routine clinical 
care.  
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Only one other study has investigated clozapine discontinuation in a systematically 
attained sample of patients receiving their first trial of clozapine (Davis et al., 2014), which 
allows timing to be studied in detail and comparisons made with patients that continue. 
The previous studies of clozapine discontinuation that were not conducted in patients 
receiving their first trial of clozapine may have been biased by previous clozapine trials 
(Taylor et al., 2009; Pai & Vella, 2012). An alternative, prospective study of clozapine 
discontinuation could allow in-depth interviews with clinicians and patients to fully 
investigate reasons for discontinuation. However, this is a timely and costly approach. 
Furthermore, patients starting clozapine treatment are often severely impaired and 
consequently may be difficult to engage in research. Patients who are non-adherent may 
also be likely to disengage from research, leading to biased attrition.  
The data I used was extracted from the Case Register Interactive Search (CRIS) system; a 
large, anonymised case register derived from SLaM electronic case records (Stewart et al., 
2009). This allowed a universal capture of patients commencing clozapine in a defined 
geographical area covering a population of 1.2 million people, with consequently little or 
no selection bias. The fact that informed consent was not required also eliminated the 
selection bias in favour of higher functioning patients. Recall bias was minimised by the 
use of contemporaneous records and the minimal missing data allowed us to determine 
the reasons for discontinuation for all of the patients and administer a very high 
proportion of CGI assessments (96.6%). Furthermore, CRIS incorporates routinely collected 
data from multiple sources, such as pharmacy dispensing information, which increases 
reliability. A limitation of using CRIS is that data is only available from 2006 onwards, as 
this was when electronic records were fully introduced in SLaM. Although there is some 
data prior to this date, it is not consistently available. As a consequence, I was unable to 
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collect data prior to clozapine initiation such as age of onset, duration of untreated 
psychosis or theoretical delay to clozapine treatment.  
The CRIS sample is comparable to the population in London with a diagnosis of 
schizophrenia (Morgan et al., 2006) but has higher proportions of Black African/Caribbean 
ethnicity and lower proportions of Asian ethnicity in comparison to England as a whole 
(Stewart et al., 2009). However, the National Audit of Schizophrenia (2012) suggest that 
the service use in London is comparable to the rest of the UK (Royal College of 
Psychiatrists, 2012). 
6.3.3 Discontinuation of clozapine 
The primary reasons for discontinuation in Chapter 4 were classified into mutually 
exclusive categories. This approach simplifies the data, making interpretation easier, and 
has been the method used in all previous studies (Taylor et al., 2009; Krivoy et al., 2011; 
Pai & Vella, 2012; Davis et al., 2014), thus allowing us to make direct comparisons. 
However, a limitation of this approach is that for many cases the reasons for 
discontinuation were multifactorial. For example, a patient (or clinician) may be more 
likely to tolerate an ADR if they are experiencing a good clinical response to clozapine, but 
might instead discontinue clozapine, citing adverse effects, in the absence of a clinical 
response. Chapter 4 addressed this limitation to some degree by integrating the reasons 
for non-adherence of clozapine. However, the reasons for non-adherence in our study 
were limited to what had been disclosed by the patient to the clinical team. The optimum 
approach to this question would be to interview patients and clinicians at the time of 
discontinuation or shortly after. 
It is likely that our study has not captured the role that clinical response plays in 
discontinuation of clozapine. Chapter 4 indicates that discontinuation due primarily to an 
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inadequate response to clozapine is rare, occurring in only 2.5% of patients. This finding is 
consistent with earlier reports (Taylor et al., 2009; Pai & Vella, 2012; Davis et al., 2014; 
Mustafa et al., 2015). Chapter 5 indicates that, consistent with previous studies, 
approximately between 40-70% of patients will respond to clozapine (Kane et al., 1988; 
Lieberman et al., 1994b). The reason for why clozapine response is seldom recorded as the 
primary cause of clozapine discontinuation may be driven partly by concern over risk of 
further relapse upon cessation (Seppala et al., 2005) and partly by a lack of any other 
evidence-based treatment options.  
6.3.4 Clozapine response 
A key strength of the clozapine response analysis is the consideration of various response 
definitions and a long-term study period. The somewhat conflicting results from previous 
studies may be due, in part, to the considerable variability in response definitions and trial 
durations. Previous study durations have tended to be short and consequently may not 
have considered a group of patients that take longer to meet the response criteria 
(Meltzer et al., 1989a). An additional strength is the large sample size and the naturalistic 
setting. Many previous studies have derived data from clinical trials and thus may not be 
generalisable to patients receiving clozapine in standard health care settings. 
We selected the CGI scale (Guy, 1976) to measure clozapine response as it is a widely 
accepted research tool that captures clinical improvement, originally designed for use in 
clinical trials, but has also been utilised in retrospective case note studies (Agid et al., 
2011). We also selected this instrument for pragmatic reasons given that the majority of 
clinical notes contained the necessary information to make CGI ratings whereas there was 
often insufficient detail in order to rate more comprehensive rating scales retrospectively 
such as the BPRS (Overall & Gorham, 1962) or the PANSS (Kay et al., 1987). This decision 
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was informed by the experiences of a previous medical student who attempted to 
retrospectively rate BPRS scales from case notes and found that there was insufficient 
information to do so. The CGI scale has been demonstrated to have equal validity to the 
BPRS (Leucht & Engel, 2006) and PANSS (Rabinowitz et al., 2010). However, there are 
several limitations of the CGI. The validity of the CGI has received some criticism (Beneke 
& Rasmus, 1992), and ratings have been reported to be influenced by unrelated 
information such as adverse events (Busner et al., 2009). Furthermore, because it is a 
global scale, the specific effects of clozapine on positive, negative or cognitive symptoms 
could not be analysed. We were also unable to assess whether improvements made in 
general psychopathology translated to improvements in quality of life or functional 
measures. For example, a previous study found that although female gender was 
associated with a good response based on the CGI, there was no difference between males 
and females based on a quality of life scale (Usall et al., 2007). 
6.4. Suggestions for future work 
There are a number of possible, closely related analyses to those presented in this thesis 
that have the potential to further our understanding of treatment response and adverse 
effects of clozapine. Firstly, further studies are required to determine if SLCO1B3, SLCO1B7 
or SLCO1B1 mediate clozapine uptake and to investigate what affect the identified 
polymorphisms in this thesis may have. Sequencing of this chromosomal region would 
refine the association signal and potentially identify the causal variant. Although we found 
that no single variant from the exome array was significantly associated with clozapine-
associated neutropenia, coverage of the exome array is incomplete and exome-wide 
sequencing in a larger sample is needed to prove the role of functional exonic variants 
definitively. In addition, further studies are required to replicate the association of 
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uncommon non-synonymous variants in STARD9 and UBAP2. We have plans to conduct 
these analyses in a recently acquired sample, described below. 
In a larger sample, further studies could dissect the neutropenia and agranulocytosis 
phenotype. For example, to investigate whether neutropenia or agranulocytosis that 
occurs early on in clozapine treatment has a distinct aetiology from occurrences after 
many years of treatment and whether agranulocytosis and neutropenia have distinct 
causes. Furthermore, studies to date have been unable to differentiate between a 
transient neutropenia, a fall and then return to normal neutrophil counts, and neutropenia 
that progresses to agranulocytosis (Flanagan & Dunk, 2008). Lastly, future studies could 
specifically examine the group of individuals that develop a subsequent neutropenia or 
agranulocytosis upon rechallenge with clozapine. 
We have recently acquired an additional sample of approximately 7000 individuals that 
were prescribed clozapine in the UK by the pharmaceutical company Leyden Delta, 200 of 
whom have had an occurrence of neutropenia or agranulocytosis. This sample was 
acquired as part of CRESTAR, a project funded by a grant from the European Union via the 
Seventh Framework Programme for Research and Technological Development. A 
significant advantage of this sample is the substantial phenotypic information in 
comparison to CLOZUK and the suggestions outlined above can be readily answered in this 
new sample. Another area of research that warrants attention is the genetic aetiology of 
agranulocytosis and neutropenia in individuals of non-European ancestry. An unpublished 
GWAS analysis conducted by Professor Dan Rujescu, from the University of Halle in 
Germany and as part of CRESTAR, includes individuals from many populations. 
Furthermore, we have plans to address this question in the sample from Leyden Delta. 
Sample size has proven to be a limiting factor in genetic studies of clozapine-associated 
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agranulocytosis and neutropenia. Thus, we are involved in initial discussions to contribute 
to a large meta-analysis involving CLOZUK, CIAC, CRESTAR and the new sample from 
Leyden Delta. These combined samples would amount to at least 600 cases with 
neutropenia and the identification of sensitive genetic markers should make significant 
advances in current understanding of the aetiology and could comprise a clinically useful 
pharmacogenetic test.  
The findings in this thesis indicate that the role of a pharmacokinetic mechanism in the 
occurrence of agranulocytosis and neutropenia warrants further investigation. The first 
step could be to re-assess the relationship between plasma clozapine levels and 
neutropenia. Furthermore, a GWAS of plasma clozapine levels may help to understand the 
aetiology underlying the inter-individual variability in plasma levels and potentially have 
widespread implications given their role in several ADRs and clozapine response. 
The approach used for the clozapine-associated neutropenia analysis provides a proof of 
principal for an approach that could be used for a genetic investigation of other clozapine 
outcomes such as clinical response. To date, no GWAS of clozapine response or 
discontinuation has been published.  
A question that remains to be explored is whether the side effect profile of patients who 
discontinue clozapine differs from patients who continue with the treatment. It would be 
worthwhile for future studies to investigate the reasons for patient-led discontinuations 
and non-adherence, ideally by interviewing patients directly at the time of discontinuation 
or shortly after. A further area of future research indicated in this thesis is the contribution 
of neighbourhood and social deprivation to clozapine discontinuation. It is likely social 
deprivation is a proxy marker for other factors that underlie discontinuation and non-
adherence and further research is needed to determine whether particular characteristics 
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of these patient groups increase risk for clozapine discontinuation or perhaps whether 
clinical teams supporting areas in high deprivation are under increased pressure or have 
more limited resources. 
Further investigations should aim to understand the underlying causes of the association 
between gender and response to clozapine. To assess the duration of clozapine treatment 
required to detect a response, additional studies are required using more advanced 
modeling techniques. Finally, defining the outcome phenotypes of treatment response, 
discontinuation, and clozapine-associated neutropenia presented a considerable 
challenge. This has lead to an appreciation of the importance and challenge in defining 
treatment outcomes, even for superficially simple phenotypes. 
6.5. Conclusions 
The work presented in this thesis contributes to the understanding and prediction of 
clozapine treatment outcomes. This research indicates that genetic variants at SLCO1B3 
(and/or SLCO1B1) increase the risk of clozapine-associated neutropenia, implicating a 
pharmacokinetic mechanism and providing novel insights into the aetiology of clozapine-
associated neutropenia. Furthermore, this thesis adds to the growing evidence implicating 
HLA-DQB1 in clozapine-associated neutropenia and agranulocytosis. Although the 
identified variants convey a substantially increased risk for clozapine-associated 
neutropenia, they are currently on their own unlikely to have clinical utility for 
pharmacogenetic testing. By examining the reasons for discontinuations due to a patient 
decision, it was found that ADRs accounted for the majority of clozapine discontinuations. 
These findings indicate the importance for clinicians to identify and treat ADRs attributed 
to clozapine, particularly in the first few months after treatment onset, before they lead to 
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discontinuation. Patients who live in an area of high deprivation are at an increased risk of 
discontinuing clozapine and may need additional support to maintain engagement with 
treatment. This thesis highlights the importance of considering clinical response definitions 
in interpreting study results. Lastly, clozapine responders are more likely to be female and 
tend to have a good initial response. However, up to six months of treatment may be 
required to determine non-response. This thesis contributes to the understanding of the 
causes of different clozapine treatment outcomes and aids identification of reliable 
predictors of clozapine outcome, which should ultimately aid clinicians in determining 
whether clozapine is likely to be beneficial.  
  
208 
 
Appendix 
Appendix 1: GWAS quality control and imputation procedures 
Quality control procedures and imputation was conducted at the Broad Institute as part of 
the PGC2 pipeline (Schizophrenia Working Group of the Psychiatric Genomics Consortium, 
2014). The quality control parameters for retaining SNPs and subjects were: SNP 
missingness < 0.05 (before sample removal), subject missingness < 0.02, autosomal 
heterozygosity deviation (Fhet < 0.2), SNP missingness < 0.02 (after sample removal), and 
SNP Hardy-Weinberg equilibrium P > 5x10-6. Imputation was performed using IMPUTE2 
(Howie et al., 2009) (chunk size of 3 Mb and default parameters) with a reference dataset 
consisting of 2,186 phased haplotypes from the full 1000 Genomes Project dataset (August 
2012, 30,069,288 variants, release “v3.macGT1”).  
After imputation, SNPs with high imputation quality (INFO > 0.8) and low missingness ( < 
0.01) were identified for further quality control. After linkage disequilibrium pruning (r2 > 
0.02) and frequency filtering (MAF > 0.05), there were 19,551 autosomal SNPs across all 49 
datasets of European ancestry in PGC2. This SNP set was used for robust relatedness 
testing and population structure analysis. Relatedness testing was done with PLINK 
(Purcell et al., 2007) and pairs of subjects with 𝜋𝜋 > 0.2 were identified and one member of 
each pair removed at random after preferentially retaining cases over controls and trio 
members over case-control members. 
Appendix 2: Exome array quality control procedures 
First pass QC was performed using PLINK (Purcell et al., 2007) on genotypes called using 
GenCall. Initial QC for probe base exclusions included Hardy-Weinberg equilibrium (HWE) 
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P < 1x10-8, call rate < 98%, and non-autosomal location. Initial QC for subject exclusions 
were based on call rate < 98%, as well as relatedness based on identity by descent (IBD) 
analysis (PI-HAT > 0.1), heterozygosity, and Principal Component Analysis PCA. PCA was 
run using EIGENSTRAT (Price et al., 2006) based on 3022 SNPs with MAF > 1%. The sample 
and healthy controls were merged with 1100 samples from 11 populations using the 
HapMap 3 dataset (Ripke et al., 2013), and outliers that did not cluster near to the 
HapMap European individuals were removed to minimize ancestral heterogeneity. In total 
we excluded 1204 individuals and 16841 markers prior to the zCall post-processing 
procedure. 
zCall is a post-processing step designed to improve the calling of SNVs (Goldstein et al., 
2012). We applied zCall to batches using batch-specific intensity data. Markers were 
subsequently excluded if they were monomorphic, had call rates < 99%, had HWE P<10-6 in 
any batch, or had a difference in call rate between batches > 1%. We also excluded probes 
where the allele frequencies differed between the two groups of healthy controls (blood 
donors versus 1958 Birth cohort) at P < 0.001, or between the cases assayed on the two 
types of chip at P<0.0005. These p-value thresholds were derived from QQ-plots of the 
within healthy control and within case analyses. Lastly, we excluded variants that did not 
show a sufficient difference in mean intensity between different genotype clusters 
(GenTrain score < 0.4, cluster separation metric < 0.08).  
We applied a further round of QC to the individuals based on the Z-call genotypes, 
excluding samples on the basis of call rate (>99% required for inclusion), heterozygosity 
(separately for variants above and below 1% MAF) and concordance between database 
and genetically determined sex. 
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Appendix 3: Proxy SNPs used in clozapine-associated neutropenia 
and neutropenia ≤1000/mm3 meta-analyses 
SNP CHR BP Proxy SNP Distance (bp) r2 D’ 
Clozapine-associated neutropenia 
rs116216021 6 3417882 rs116552069 11430 0.96 1 
Clozapine-associated neutropenia ≤ 1000/mm3 
rs111698467 8 25624468 rs113539283 84249 0.807 0.992 
rs111242461 10 37404727 chr10_37367098_I 37629 0.840 0.932 
rs76415963 20 10544516 rs74762384 7575 0.814 1 
Proxy SNPs used for clozapine-associated neutropenia and clozapine-associated 
neutropenia ≤ 1000/mm3 meta-analyses. Columns are: SNP = name of original variant 
identified in CLOZUK analysis; CHR = chromosome; BP = base pair position (hg19); Proxy 
SNP = proxy SNP identified within CIAC; Distance (bp) = distance between original and 
proxy SNP; r2 = LD between original and proxy SNP; D’ = LD between original and proxy 
SNP. 
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Appendix 4: Number of patients who discontinued clozapine by three monthly intervals for each overall reason 
for discontinuation 
Month N taking clozapine ADR 
Non-
adherence 
NOS 
Inadequate 
response 
Blood 
monitoring 
Belief 
medication 
not required 
Delusional 
belief 
Anticipated 
non-
adherence 
Death Other 
x ≤ 3 316 44 8 1 4 2 2 0 1 2 
3 > x ≤ 6 252 11 4 2 0 1 0 0 0 2 
6 > x ≤ 9 232 8 2 2 4 1 0 2 2 1 
9 > x ≤ 12 210 7 4 0 1 0 2 0 0 0 
12 > x ≤ 15 197 4 1 0 1 0 0 0 0 0 
15 > x ≤ 18 190 5 1 0 0 0 0 0 0 0 
18 > x ≤ 21 184 0 4 2 1 0 0 0 0 0 
21 > x ≤ 24 177 1 1 1 0 0 0 0 0 0 
Total  80 25 8 11 4 4 2 3 5 
Number of patients who discontinued clozapine by three monthly intervals for each overall reason for discontinuation. N taking clozapine is the 
number of patients still taking clozapine at the beginning of that time period 
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Appendix 5: Timing of clinician-led discontinuations 
Month N taking clozapine ADR 
Inadequate 
response 
Blood 
monitoring 
Anticipated 
non-
adherence 
Other 
x ≤ 3 316 36 0 1 0 2 
3 > x ≤ 6 252 6 0 0 0 2 
6 > x ≤ 9 232 3 1 0 2 1 
9 > x ≤ 12 210 5 0 0 0 0 
12 > x ≤ 15 197 1 0 0 0 0 
15 > x ≤ 18 190 3 0 0 0 0 
18 > x ≤ 21 184 0 1 0 0 0 
21 > x ≤ 24 177 0 1 0 0 0 
Total  54 3 1 2 5 
Timing of clinician-led discontinuations. Number of patients who discontinued clozapine 
from a clinician-led decision for each reason by three monthly intervals from initiation. N 
taking clozapine is the number of patients still taking clozapine at the beginning of that 
time period.  
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Appendix 6: Timing of discontinuations due to a patient decision 
Month N taking clozapine ADR 
Inadequate 
response 
Blood 
monitoring 
Belief 
medication not 
required 
Delusional 
belief 
Non-
adherence 
NOS 
x ≤ 3 316 8 1 3 2 2 8 
3 > x ≤ 6 252 5 2 0 1 0 4 
6 > x ≤ 9 232 5 1 4 1 0 2 
9 > x ≤ 12 210 2 0 1 0 2 4 
12 > x ≤ 15 197 3 0 1 0 0 1 
15 > x ≤ 18 190 2 0 0 0 0 1 
18 > x ≤ 21 184 0 1 1 0 0 4 
21 > x ≤ 24 177 1 0 0 0 0 1 
Total  26 5 10 4 4 25 
Timing of discontinuations due to a patient decision. Number of patients who discontinued clozapine from a patient decision by three monthly 
intervals from initiation. N taking clozapine is the number of patients still taking clozapine at the beginning of that time period. 
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Appendix 7: Specific ADRs cited as a reason for discontinuation 
ADR 
Clinician-led  
decision  
N 
Patient  
decision 
N 
Overall  
N 
Sedation 13 15 28 
Neutropenia 15 0 15 
Tachycardia 12 1 13 
Dizziness 8 2 10 
Nausea & vomiting 4 6 10 
Weight gain 5 4 9 
Fever 7 1 8 
Hypersalivation 4 4 8 
Flu type symptoms 6 0 6 
ECG abnormalities 5 0 5 
Constipation 3 1 4 
Hypertension 3 0 3 
Chest pain 2 0 2 
Hypotension 2 0 2 
Hyperglycaemia 1 1 2 
Pneumonia 1 0 1 
Pulmonary embolism 1 0 1 
Diabetes mellitus 1 0 1 
Metabolic Syndrome 1 0 1 
Headaches 0 1 1 
Adverse drug reactions (ADRs) cited as a reason for discontinuation of clozapine for 80 
patients (130 ADRs). ADRs are not exclusive and differentiated by whether the 
discontinuation was a clinician-led decision or patient decision. 
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Appendix 8: Data for Figure 5.1. 
 
CGI-I of 1  
(very much improved) 
 
CGI-I score of 2  
(much improved) 
 
CGI-I score of 3 or 4  
(minimally improved or no change) 
Time N Mean SE L95% CI U95% CI  N Mean SE L95% CI U95% CI  N Mean SE L95% CI U95% CI 
0 53 5.04 0.10 4.84 5.24  162 5.19 0.05 5.09 5.29  62 5.13 0.08 4.97 5.29 
1 53 4.17 0.11 3.95 4.39  157 4.50 0.06 4.37 4.62  61 4.79 0.09 4.61 4.97 
2 51 3.76 0.10 3.57 3.96  147 4.20 0.06 4.08 4.31  49 4.86 0.09 4.67 5.04 
3 49 3.51 0.09 3.33 3.69  149 4.11 0.06 4.00 4.22  44 4.80 0.10 4.60 4.99 
6 49 3.24 0.10 3.05 3.44  135 4.01 0.05 3.91 4.12  39 4.72 0.10 4.52 4.91 
9 46 3.35 0.10 3.14 3.56  125 3.98 0.05 3.88 4.09  34 4.62 0.08 4.45 4.79 
12 43 3.05 0.09 2.86 3.24  118 3.92 0.05 3.82 4.03  30 4.57 0.10 4.35 4.78 
18 41 2.90 0.08 2.73 3.07  118 3.82 0.05 3.72 3.92  27 4.56 0.11 4.33 4.78 
24 42 2.90 0.11 2.69 3.12  106 3.83 0.05 3.72 3.94  22 4.36 0.12 4.11 4.62 
Data for Figure 5.1: Mean CGI-Severity scores at time assessment points for patients who had an improvement score of 1 (very much improved, blue), 
2 (much improved, grey), and either 3 (minimally improved, green) or 4 (no change, orange). N = number of patients still taking clozapine at the 
beginning of that time period. SE = standard error of mean. L95% CI = lower 95% confidence interval. U95% CI = upper 95% confidence interval. 
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Appendix 9: Proportion experiencing delayed response 
Time Total N  
Absolute 
response 
(N) 
Absolute 
response 
(%) 
Relative 
response 
(N) 
Relative 
response 
(%) 
1 176 59 33.52 67 38.07 
2 109 25 22.94 41 37.61 
3 87 18 20.69 24 27.59 
6 64 9 14.06 9 14.06 
9 52 7 13.46 7 13.46 
12 41 3 7.32 5 12.20 
18 29 0 0.00 3 10.34 
Proportion experiencing delayed response. Columns represent time of assessment, total 
number of patients with a CGI-I score of 3 or 4 (minimally improved or no change) at that 
time who are still taking clozapine, number and percentage that subsequent to this time 
meet absolute response criteria, number and percentage that subsequent to this time meet 
relative response criteria. 
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